Ipilimumab Clinical Trials (2026): 791 Studies for Melanoma & Metastatic Melanoma

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

791 Ipilimumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 366 indications (including Melanoma & Metastatic Melanoma) and 123,028 total planned enrollment. 64 Phase 3 Ipilimumab trials and 344 Phase 2, 7 Phase 4 are listed. 120 Ipilimumab clinical trials are actively recruiting at 1,761 U.S. sites across 51 states. Most recent activity: NCT05732389 (Feb 2052).

Where to Participate: All Ipilimumab Trial Sites in the U.S. (1,761 sites across 51 states)

Every actively recruiting Ipilimumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALResearch SiteBirmingham35294NCT05536141Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT06364917Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT04511013Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT05112601Map
ALUniversity of Alabama at Birmingham Comprehensive Cancer CenterBirmingham35294NCT02693535Map
ALThomas HospitalFairhope36532NCT04511013Map
ALMobile Infirmary Medical CenterMobile36607NCT04511013Map
AKAlaska Breast Care and Surgery LLCAnchorage99508NCT04511013Map
AKAlaska Breast Care and Surgery LLCAnchorage99508NCT05647265Map
AKAlaska Oncology and Hematology LLCAnchorage99508NCT04511013Map
AKAlaska Oncology and Hematology LLCAnchorage99508NCT05647265Map
AKAlaska Women's Cancer CareAnchorage99508NCT04511013Map
AKAlaska Women's Cancer CareAnchorage99508NCT05647265Map
AKAnchorage Associates in Radiation MedicineAnchorage98508NCT04511013Map
AKAnchorage Associates in Radiation MedicineAnchorage98508NCT05647265Map
AKAnchorage Oncology CentreAnchorage99508NCT04511013Map
AKAnchorage Radiation Therapy CenterAnchorage99504NCT04511013Map
AKKatmai Oncology GroupAnchorage99508NCT04511013Map
AKKatmai Oncology GroupAnchorage99508NCT05647265Map
AKProvidence Alaska Medical CenterAnchorage99508NCT04511013Map
AKProvidence Alaska Medical CenterAnchorage99508NCT05647265Map
AKFairbanks Memorial HospitalFairbanks99701NCT04511013Map
AZKingman Regional Medical CenterKingman86401NCT05647265Map
AZCancer Treatment Centers of America-PhoenixPhoenix85338NCT02693535Map
AZExelixis Clinical Site #67Phoenix85054NCT05176483Map
AZMayo ClinicPhoenix85054NCT06743126Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05647265Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT03866382Map
AZHonor Health Research InstituteScottsdale85258NCT06743126Map
AZHonorHealth Research InsisuteScottsdale85258NCT06581406Map
AZMayo Clinic in ArizonaScottsdale85259NCT05647265Map
AZMayo Clinic in ArizonaScottsdale85259NCT03866382Map
AZMayo Clinic in ArizonaScottsdale85259NCT03017820Map
AZMayo Clinic in ArizonaScottsdale85259NCT06508463Map
AZExelixis Clinical Site #1Tucson85711NCT05176483Map
ARHighlands Oncology Group - FayettevilleFayetteville72703NCT07383441Map
ARMercy Hospital Fort SmithFort Smith72903NCT04511013Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT07383441Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05327686Map
ARHighlands Oncology Group - RogersRogers72758NCT07383441Map
ARHighlands Oncology GroupSpringdale72762NCT07383441Map
CAPCR OncologyArroyo Grande93420NCT05327686Map
CAPCR OncologyArroyo Grande93420NCT05647265Map
CASutter AuburnAuburn95602NCT02693535Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT07166406Map
CASutter Alta BatesBerkeley94705NCT02693535Map
CAPrecision NextGen OncologyBeverly Hills90212NCT06047379Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT04511013Map
CAProvidence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank91505NCT05647265Map
CAMills-Peninsula Medical CenterBurlingame94010NCT05327686Map
CASutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park95682NCT07166406Map
CACity of Hope Medical CenterDuarte91010NCT06399419Map
CACity of Hope Medical CenterDuarte91010NCT07128680Map
CACity of Hope National Medical CenterDuarte91010NCT05361720Map
CACity of Hope National Medical CenterDuarte91010NCT06743126Map
CAEpic Care-DublinDublin94568NCT04511013Map
CABay Area Breast Surgeons IncEmeryville94608NCT04511013Map
CAEpic Care Partners in Cancer CareEmeryville94608NCT04511013Map
CAUC San Diego Health System - EncinitasEncinitas92024NCT05327686Map
CAPalo Alto Medical Foundation-FremontFremont94538NCT07166406Map
CAOPN Healthcare, IncGlendale91203NCT06047379Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05327686Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05904080Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT07166406Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05327686Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05647265Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT05896839Map
CAUC San Diego Moores Cancer CenterLa Jolla92037NCT06581406Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT06743126Map
CACedars-Sinai Medical CenterLos Angeles90048NCT06594991Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT05896839Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT05904080Map
CAKeck Medicine of USC KoreatownLos Angeles90020NCT03866382Map
CALos Angeles General Medical CenterLos Angeles90033NCT05327686Map
CALos Angeles General Medical CenterLos Angeles90033NCT05896839Map
CALos Angeles General Medical CenterLos Angeles90033NCT05904080Map
CAThe Angeles Clinic and Research InstituteLos Angeles90025NCT05533697Map
CAThe Angeles Clinic and Research InstituteLos Angeles90025NCT06581406Map
CAThe Angeles Clinic and Research Institute, A Cedars-Sinai AffiliateLos Angeles90025NCT02693535Map
CAThe Angeles Clinic at Cedars SinaiLos Angeles90025NCT05428007Map
CAUCLA / Jonsson Comprehensive Cancer CenterLos Angeles90095NCT04511013Map
CAUCLA Hematology/OncologyLos Angeles90024NCT06743126Map
CAUniversity of California Los AngelesLos Angeles90095NCT06581406Map
CAUniversity of Southern CaliforniaLos Angeles90033NCT06047379Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05327686Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05896839Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05904080Map
CAContra Costa Regional Medical CenterMartinez94553-3156NCT04511013Map
CAMemorial Medical CenterModesto95355NCT05327686Map
CAPalo Alto Medical Foundation-Camino DivisionMountain View94040NCT07166406Map
CAProvidence Queen of The ValleyNapa94558NCT04511013Map
CAProvidence Queen of The ValleyNapa94558NCT05647265Map
CAUSC Newport BeachNewport Beach92663NCT06624644Map
CAUSC Norris Oncology/Hematology-Newport BeachNewport Beach92663NCT05904080Map
CABay Area Tumor InstituteOakland94609NCT04511013Map
CAKaiser Permanente - Oakland Medical CenterOakland94611NCT02693535Map
CAChao Family Comprehensive Cancer CenterOrange92868NCT05361720Map
CAChao Family Comprehensive Cancer Center, University of California, IrvineOrange92868NCT04472767Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05327686Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05904080Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT07166406Map
CAExelixis Clinical Site #123Palo Alto94304NCT05176483Map
CAPalo Alto Medical Foundation Health CarePalo Alto94301NCT07166406Map
CAStanford Cancer InstitutePalo Alto94304NCT06581406Map
CAStanford Cancer Institute Palo AltoPalo Alto94304NCT05904080Map
CAStanford UniversityPalo Alto94304NCT06712927Map
CASutter Palo Alto Medical Foundation: Palo AltoPalo Alto94301NCT02693535Map
CAKaiser Permanente - Roseville Medical CenterRoseville95661NCT02693535Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT05327686Map
CASutter Cancer Centers Radiation Oncology Services-RosevilleRoseville95661NCT07166406Map
CASutter RosevilleRoseville95661NCT02693535Map
CASutter Roseville Medical CenterRoseville95661NCT05327686Map
CASutter Roseville Medical CenterRoseville95661NCT07166406Map
CAKaiser Permanente - Sacramento Medical CenterSacramento95814NCT02693535Map
CASutter Medical Center SacramentoSacramento95816NCT05327686Map
CASutter Medical Center SacramentoSacramento95816NCT07166406Map
CASutter SacramentoSacramento95816NCT02693535Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT03816345Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT07166406Map
CAResearch SiteSan Diego92093NCT05536141Map
CASharp Memorial HospitalSan Diego92123NCT04511013Map
CAUC San Diego Medical Center - HillcrestSan Diego92103NCT05327686Map
CACalifornia Pacific Medical Center Research InstituteSan Francisco94115NCT02693535Map
CACalifornia Pacific Medical Center-Pacific CampusSan Francisco94115NCT07166406Map
CAKaiser Permanente - San Francisco Medical CenterSan Francisco94115NCT02693535Map
CAKaiser Permanente - South San Francisco Medical CenterSan Francisco94080NCT02693535Map
CASutter Cancer Research ConsortiumSan Francisco94115NCT02693535Map
CAUCSFSan Francisco94143NCT06624644Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT05533697Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94158NCT04665206Map
CAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco94143NCT06743126Map
CAUCSF Medical Center-Mission BaySan Francisco94158NCT05327686Map
CAKaiser Permanente - San Jose Medical CenterSan Jose95119NCT02693535Map
CAKaiser Permanente - San Leandro Medical CenterSan Leandro94577NCT02693535Map
CAMills Health CenterSan Mateo94401NCT05327686Map
CAExelixis Clinical Site #59Santa Barbara93463NCT05176483Map
CARidley-Tree Cancer CenterSanta Barbara93105NCT05327686Map
CASutter Sansum ClinicSanta Barbara93105NCT02693535Map
CAKaiser Permanente - Santa Clara Medical CenterSanta Clara95051NCT02693535Map
CASutter Palo Alto Medical Foundation: FremontSanta Cruz994538NCT02693535Map
CASutter Palo Alto Medical Foundation: Santa CruzSanta Cruz95065NCT02693535Map
CAResearch SiteSanta Monica90404NCT05536141Map
CASarcoma Oncology Research CenterSanta Monica90403NCT03138161Map
CAProvidence Medical Foundation - Santa RosaSanta Rosa95403NCT04511013Map
CAProvidence Medical Foundation - Santa RosaSanta Rosa95403NCT05647265Map
CAProvidence Santa Rosa Memorial HospitalSanta Rosa95405NCT04511013Map
CAProvidence Santa Rosa Memorial HospitalSanta Rosa95405NCT05647265Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT05327686Map
CASutter Pacific Medical FoundationSanta Rosa95403NCT07166406Map
CAStanfordStanford94305NCT06624644Map
CAStanford Cancer CenterStanford94305NCT06743126Map
CAStanford University (Data Collection Only)Stanford94305NCT06594991Map
CAPalo Alto Medical Foundation-SunnyvaleSunnyvale94086NCT07166406Map
CASutter Palo Alto Medical Foundation: SunnyvaleSunnyvale94086NCT02693535Map
CAKaiser Permanente - Vallejo Medical CenterVallejo94589NCT02693535Map
CAEpic Care Cyberknife CenterWalnut Creek94597NCT04511013Map
CAKaiser Permanente - Walnut Creek Medical CenterWalnut Creek94596NCT02693535Map
CORocky Mountain Cancer Centers-AuroraAurora80012NCT04511013Map
COUCHealth University of Colorado HospitalAurora80045NCT05327686Map
COUniversity of Colorado AnschutzAurora80045NCT06624644Map
COUniversity of Colorado Cancer CenterAurora80045NCT05533697Map
COUniversity of Colorado Cancer CenterAurora84005NCT06362369Map
COUniversity of Colorado HospitalAurora80045NCT04511013Map
COUniversity of Colorado Hospital - Anschutz Cancer Pavilion(ACP)Aurora80045NCT06581406Map
COUniversity of Colorado, Anschutz Medical CampusAurora80045NCT06743126Map
COBoulder Community Foothills HospitalBoulder80303NCT04511013Map
CORocky Mountain Cancer Centers-BoulderBoulder80304NCT04511013Map
CORocky Mountain Cancer Centers - CentennialCentennial80112NCT04511013Map
COColorado Blood Cancer InstituteDenver80218NCT04511013Map
COPresbyterian - Saint Lukes Medical Center - Health OneDenver80218NCT04511013Map
CORocky Mountain Cancer Centers-MidtownDenver80218NCT04511013Map
CORocky Mountain Cancer Centers-RoseDenver80220NCT04511013Map
COThe Women's Imaging CenterDenver80209NCT04511013Map
COUCHealth - Cherry CreekDenver80206NCT05327686Map
COUniversity of ColoradoDenver80204NCT06624644Map
COMountain Blue Cancer Care Center - SwedishEnglewood80113NCT04511013Map
CORocky Mountain Cancer Centers - SwedishEnglewood80113NCT04511013Map
COSwedish Medical CenterEnglewood80113NCT04511013Map
COThe Melanoma & Skin Cancer InstituteEnglewood80113NCT06581406Map
COThe Melanoma and Skin Cancer InstituteEnglewood80113NCT04511013Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT05327686Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT07166406Map
COPoudre Valley HospitalFort Collins80524NCT05327686Map
COPoudre Valley HospitalFort Collins80524NCT07166406Map
COSaint Mary's Hospital and Regional Medical CenterGrand Junction81501NCT07166406Map
COUCHealth Greeley HospitalGreeley80631NCT05327686Map
COUCHealth Greeley HospitalGreeley80631NCT07166406Map
COUCHealth Highlands Ranch HospitalHighlands Ranch80129NCT05327686Map
CORocky Mountain Cancer Centers-LakewoodLakewood80228NCT04511013Map
COExelixis Clinical Site #87Littleton80124NCT05176483Map
CORocky Mountain Cancer Centers-LittletonLittleton80120NCT04511013Map
CORocky Mountain Cancer Centers-Sky RidgeLone Tree80124NCT04511013Map
COUCHealth Lone Tree Health CenterLone Tree80124NCT05327686Map
COMedical Center of the RockiesLoveland80538NCT05327686Map
COMedical Center of the RockiesLoveland80538NCT07166406Map
CORocky Mountain Cancer Centers-ThorntonThornton80260NCT04511013Map
CTSaint Vincent's Medical Center (SVMC)Bridgeport06606NCT02693535Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT07166406Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT07166406Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT07166406Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT07166406Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT07166406Map
CTSmilow Cancer Hospital-Hamden Care CenterHamden06518NCT07166406Map
CTHartford Healthcare Alliance (Data Collection Only)Hartford06102NCT06594991Map
CTHartford HospitalHartford06102NCT02693535Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT07166406Map
CTMidstate Medical Center (MSMC)Meriden06451NCT02693535Map
CTThe Hospital of Central Connecticut (HOCC) Cancer CenterNew Britain06053NCT02693535Map
CTExelixis Clinical Site #62New Haven06510NCT05176483Map
CTSmilow Cancer Center/Yale-New Haven HospitalNew Haven06510NCT03816345Map
CTSmilow Cancer Center/Yale-New Haven HospitalNew Haven06510NCT07166406Map
CTYale Cancer CenterNew Haven06510NCT06743126Map
CTYale UniversityNew Haven06520NCT03816345Map
CTYale UniversityNew Haven06520NCT07166406Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT07166406Map
CTWilliam W. Backus HospitalNorwich06360NCT02693535Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT07166406Map
CTCharlotte HungerfordTorrington06790NCT02693535Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT07166406Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT07166406Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT07166406Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT07166406Map
CTWindham Hospital (WH)Willimantic06226NCT02693535Map
DEBeebe Medical CenterLewes19958NCT05327686Map
DEBeebe South Coastal Health CampusMillville19967NCT05327686Map
DEChristiana Care Health System- Site Number : 8400011Newark19713-2072NCT05584670Map
DEChristiana Care Health System-Christiana HospitalNewark19718NCT05327686Map
DEHelen F Graham Cancer CenterNewark19713NCT05327686Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05327686Map
DEBeebe Health CampusRehoboth Beach19971NCT05327686Map
DEChristiana Care Health System-Wilmington HospitalWilmington19801NCT05327686Map
DCGeorge Washington UniversityWashington D.C.20037NCT05533697Map
DCGeorgetown University Medical CenterWashington D.C.20007NCT06581406Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT03816345Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT03866382Map
DCSibley Memorial HospitalWashington D.C.20016NCT05896839Map
DCSibley Memorial HospitalWashington D.C.20016NCT07293351Map
FLMount Sinai Comprehensive Cancer Center at AventuraAventura33180NCT05327686Map
FLUM Sylvester Comprehensive Cancer Center at AventuraAventura33180NCT05896839Map
FLUniversity of Miami/Sylvester Cancer Institute - AventuraAventura33180NCT02693535Map
FLExelixis Clinical Site #48Celebration34747NCT05176483Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT05896839Map
FLUniversity of Miami/Sylvester Cancer Institute - LennarCoral Gables33146NCT02693535Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT05896839Map
FLUniversity of Miami/Sylvester Cancer Institute - Deerfield BeachDeerfield Beach33442NCT02693535Map
FLHoly Cross HospitalFort Lauderdale33308NCT02693535Map
FLHoly Cross HospitalFort Lauderdale33308NCT03866382Map
FLExelixis Clinical Site #11Gainesville32610NCT05176483Map
FLUniversity of Florida HealthGainesville32610NCT02693535Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT05327686Map
FLExelixis Clinical Site #78Jacksonville32224NCT05176483Map
FLMayo Clinic - Jacksonville FLJacksonville32224NCT06581406Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05327686Map
FLMoffitt Cancer Center at SperosLand O' Lakes34638NCT07227012Map
FLExelixis Clinical Site #47Miami33136NCT05176483Map
FLMiami Cancer InstituteMiami33176NCT05327686Map
FLResearch SiteMiami33136NCT05536141Map
FLSylvester Comprehensive Cancer CenterMiami33136NCT06581406Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT05896839Map
FLUniversity of MiamiMiami33136NCT06889493Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenteMiami33136NCT06743126Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT05896839Map
FLUniversity of Miami Sylvester Comprehensive Cancer CenterMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Alex's PlaceMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Griffin Cancer Research BuildingMiami33136NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - KendallMiami33176NCT02693535Map
FLUniversity of Miami/Sylvester Cancer Institute - Sole MiaMiami33181NCT02693535Map
FLMount Sinai Medical CenterMiami Beach33140NCT05327686Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT05896839Map
FLOrlando Health Cancer InstituteOrlando32806NCT04511013Map
FLOrlando Health Cancer InstituteOrlando32806NCT03866382Map
FLOrlando Health UF Health Cancer CenterOrlando32806NCT05533697Map
FLMemorial Hospital WestPembroke Pines33028NCT05327686Map
FLExelixis Clinical Site #61Plantation33322NCT05176483Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT05896839Map
FLUniversity of Miami/Sylvester Cancer Institute - PlantationPlantation33324NCT02693535Map
FLMoffitt Cancer Center at SouthShoreRuskin33570NCT07227012Map
FLExelixis Clinical Site #8Tampa33612NCT05176483Map
FLMoffitt Cancer CenterTampa33612NCT04996823Map
FLMoffitt Cancer CenterTampa33612NCT04511013Map
FLMoffitt Cancer CenterTampa33612NCT04562129Map
FLMoffitt Cancer CenterTampa33612NCT06295159Map
FLMoffitt Cancer CenterTampa87535NCT06624644Map
FLMoffitt Cancer CenterTampa33612NCT06743126Map
FLMoffitt Cancer CenterTampa33612NCT07227012Map
FLMoffitt Cancer Center - International PlazaTampa33607NCT07227012Map
FLMoffitt Cancer Center - McKinley CampusTampa33612NCT04511013Map
FLMoffitt Cancer Center - McKinley CampusTampa33612NCT07227012Map
FLMoffitt Cancer Center-International PlazaTampa33607NCT04511013Map
FLMoffitt McKinley HospitalTampa33612NCT07227012Map
FLMoffitt Cancer Center at Wesley ChapelWesley Chapel33544NCT07227012Map
GAUniversity Cancer and Blood Center LLCAthens30607NCT05112601Map
GACancer Treatment Centers of America - AtlantaAtlanta30265NCT02693535Map
GAEmory Proton Therapy CenterAtlanta30308NCT07166406Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06324240Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT07166406Map
GAEmory University Hospital MidtownAtlanta30308NCT05904080Map
GAEmory University Hospital MidtownAtlanta30308NCT03690986Map
GAEmory University Hospital MidtownAtlanta30308NCT03866382Map
GAEmory University Hospital MidtownAtlanta30308NCT06324240Map
GAEmory University Hospital MidtownAtlanta30308NCT07166406Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT03866382Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06324240Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT07155317Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT07166406Map
GAEmory University Winship Cancer InstituteAtlanta30322NCT02693535Map
GAEmory Winship Cancer InstituteAtlanta30322NCT06581406Map
GAGrady Health SystemAtlanta30303NCT06324240Map
GAGrady Health SystemAtlanta30303NCT07166406Map
GAResearch SiteAtlanta30322-1013NCT05536141Map
GAAugusta University Medical CenterAugusta30912NCT05112601Map
GAGynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research PavilionSavannah31405NCT02693535Map
GALewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma InstituteSavannah31405NCT02693535Map
GASummit Cancer CareSavannah31405NCT02693535Map
HIThe Queen's Medical Center - West Oahu‘Ewa Beach96706NCT02693535Map
HIThe Queen's Medical CenterHonolulu96813NCT07075120Map
HIThe Queen's Medical Center - KuakiniHonolulu96817NCT02693535Map
HIThe Queen's Medical Center - POB IHonolulu96813NCT02693535Map
HIThe Queen's Medical Center - PunchbowlHonolulu96813NCT02693535Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05327686Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT04511013Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT03866382Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT04511013Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05647265Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05112601Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05327686Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT04511013Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT03866382Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT04511013Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05904080Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT03866382Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05112601Map
IDWalter Knox Memorial HospitalEmmett83617NCT04511013Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT04511013Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05647265Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05112601Map
IDIdaho Urologic Institute-MeridianMeridian83642NCT04511013Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT04511013Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05647265Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05112601Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05327686Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04511013Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT03866382Map
IDSaint Luke's Cancer Institute - NampaNampa83686NCT04511013Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05647265Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05112601Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT04511013Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05904080Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT03866382Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05112601Map
IDKootenai Cancer ClinicSandpoint83864NCT04511013Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05904080Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT03866382Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05112601Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT04511013Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT05647265Map
ILSaint Anthony's HealthAlton62002NCT04511013Map
ILRush - Copley Medical CenterAurora60504NCT04511013Map
ILRush-Copley Medical CenterAurora60504NCT05647265Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT04511013Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT07383441Map
ILIllinois CancerCare-CantonCanton61520NCT04511013Map
ILIllinois CancerCare-CantonCanton61520NCT07383441Map
ILMemorial Hospital of CarbondaleCarbondale62902NCT04511013Map
ILSIH Cancer InstituteCarterville62918NCT04511013Map
ILIllinois CancerCare-CarthageCarthage62321NCT04511013Map
ILIllinois CancerCare-CarthageCarthage62321NCT07383441Map
ILCentralia Oncology ClinicCentralia62801NCT05327686Map
ILCentralia Oncology ClinicCentralia62801NCT04511013Map
ILSaint Mary's HospitalCentralia62801NCT04511013Map
ILCancer Treatment Centers of America-ChicagoChicago60099NCT02693535Map
ILExelixis Clinical Site #26Chicago60612NCT05176483Map
ILNorthwestern Memorial HospitalChicago60611NCT06581406Map
ILNorthwestern UniversityChicago60611NCT05327686Map
ILNorthwestern UniversityChicago60611NCT05647265Map
ILNorthwestern UniversityChicago60611NCT05896839Map
ILNorthwestern UniversityChicago60611NCT05904080Map
ILRush MD Anderson Cancer CenterChicago60612NCT03866382Map
ILThe University of Chicago MedicineChicago60637NCT05533697Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05327686Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05647265Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05904080Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT03866382Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT07166406Map
ILUniversity of Chicago Medical CenterChicago60637NCT04665206Map
ILUniversity of Chicago Medical CenterChicago60637NCT06581406Map
ILUniversity of Chicago Medical CenterChicago60637NCT06743126Map
ILUniversity of IllinoisChicago60612NCT05904080Map
ILCarle at The RiverfrontDanville61832NCT05327686Map
ILCarle at The RiverfrontDanville61832NCT04511013Map
ILCarle at The RiverfrontDanville61832NCT05647265Map
ILCarle at The RiverfrontDanville61832NCT05904080Map
ILCarle at The RiverfrontDanville61832NCT05112601Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05327686Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT04511013Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT03866382Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT07383441Map
ILDecatur Memorial HospitalDecatur62526NCT05327686Map
ILDecatur Memorial HospitalDecatur62526NCT04511013Map
ILDecatur Memorial HospitalDecatur62526NCT07383441Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05327686Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05647265Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05904080Map
ILIllinois CancerCare-DixonDixon61021NCT04511013Map
ILCarle Physician Group-EffinghamEffingham62401NCT05327686Map
ILCarle Physician Group-EffinghamEffingham62401NCT04511013Map
ILCarle Physician Group-EffinghamEffingham62401NCT05647265Map
ILCarle Physician Group-EffinghamEffingham62401NCT05904080Map
ILCarle Physician Group-EffinghamEffingham62401NCT05112601Map
ILCrossroads Cancer CenterEffingham62401NCT05327686Map
ILCrossroads Cancer CenterEffingham62401NCT04511013Map
ILCrossroads Cancer CenterEffingham62401NCT03866382Map
ILIllinois CancerCare-EurekaEureka61530NCT04511013Map
ILIllinois CancerCare-EurekaEureka61530NCT07383441Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05904080Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT04511013Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT07383441Map
ILWestern Illinois Cancer Treatment CenterGalesburg61401NCT04511013Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05327686Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05647265Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05904080Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05904080Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05327686Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05647265Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05904080Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05327686Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05647265Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05904080Map
ILIngalls Memorial HospitalHarvey60426NCT05327686Map
ILIngalls Memorial HospitalHarvey60426NCT05904080Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05904080Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT04511013Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT07383441Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05327686Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05647265Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05904080Map
ILIllinois CancerCare-MacombMacomb61455NCT04511013Map
ILIllinois CancerCare-MacombMacomb61455NCT07383441Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05327686Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05647265Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05904080Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05112601Map
ILLoyola University Medical CenterMaywood60153NCT03866382Map
ILGood Samaritan Regional Health CenterMount Vernon62864NCT04511013Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05327686Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05904080Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT07166406Map
ILCarle BroMenn Medical CenterNormal61761NCT05112601Map
ILCarle Cancer Institute NormalNormal61761NCT05112601Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05327686Map
ILCancer Care Center of O'FallonO'Fallon62269NCT04511013Map
ILHSHS Saint Elizabeth's HospitalO'Fallon62269NCT05327686Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT05327686Map
ILRush MD Anderson Cancer Center at Rush Oak ParkOak Park60304NCT03866382Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05327686Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05647265Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05904080Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05327686Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05904080Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT07166406Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT04511013Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT07383441Map
ILIllinois CancerCare-PekinPekin61554NCT04511013Map
ILIllinois CancerCare-PekinPekin61554NCT07383441Map
ILIllinois CancerCare-PeoriaPeoria61615NCT04511013Map
ILIllinois CancerCare-PeoriaPeoria61615NCT07383441Map
ILMethodist Medical Center of IllinoisPeoria61636NCT04511013Map
ILIllinois CancerCare-PeruPeru61354NCT04511013Map
ILIllinois CancerCare-PeruPeru61354NCT07383441Map
ILValley Radiation OncologyPeru61354NCT04511013Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT04511013Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT07383441Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT05327686Map
ILMemorial Hospital EastShiloh62269NCT05896839Map
ILMemorial Hospital EastShiloh62269NCT03866382Map
ILMemorial Hospital EastShiloh62269NCT07166406Map
ILMemorial Medical CenterSpringfield62781NCT04511013Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05327686Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT04511013Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT03866382Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT07383441Map
ILSpringfield ClinicSpringfield62702NCT05327686Map
ILSpringfield ClinicSpringfield62702NCT04511013Map
ILSpringfield ClinicSpringfield62702NCT03866382Map
ILSpringfield Memorial HospitalSpringfield62781NCT05327686Map
ILSpringfield Memorial HospitalSpringfield62781NCT03866382Map
ILCarle Cancer CenterUrbana61801NCT05327686Map
ILCarle Cancer CenterUrbana61801NCT04511013Map
ILCarle Cancer CenterUrbana61801NCT05647265Map
ILCarle Cancer CenterUrbana61801NCT05904080Map
ILCarle Cancer CenterUrbana61801NCT05112601Map
ILThe Carle Foundation HospitalUrbana61801NCT05327686Map
ILThe Carle Foundation HospitalUrbana61801NCT04511013Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05327686Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05647265Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05904080Map
ILIllinois CancerCare - WashingtonWashington61571NCT04511013Map
ILIllinois CancerCare - WashingtonWashington61571NCT07383441Map
ILRush-Copley Healthcare CenterYorkville60560NCT04511013Map
ILRush-Copley Healthcare CenterYorkville60560NCT05647265Map
INIU Health North HospitalCarmel46032NCT05112601Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05327686Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT07166406Map
INNorthwest Cancer Center - HobartHobart46342NCT05112601Map
INCommunity Health Network (The University of Texas MD Anderson Cancer Center)Indianapolis46250NCT02693535Map
INExelixis Clinical Site #4Indianapolis46250NCT05176483Map
INFranciscan Health IndianapolisIndianapolis46237NCT05327686Map
INFranciscan Health MooresvilleMooresville46158NCT05327686Map
INReid HealthRichmond47374NCT04511013Map
IAMary Greeley Medical CenterAmes50010NCT05327686Map
IAMary Greeley Medical CenterAmes50010NCT04511013Map
IAMary Greeley Medical CenterAmes50010NCT03866382Map
IAMcFarland Clinic - AmesAmes50010NCT05327686Map
IAMcFarland Clinic - AmesAmes50010NCT04511013Map
IAMcFarland Clinic - AmesAmes50010NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05904080Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT07166406Map
IAUniversity of Iowa Healthcare Cancer Services Quad CitiesBettendorf52722NCT03866382Map
IAMcFarland Clinic - BooneBoone50036NCT04511013Map
IASaint Anthony Regional HospitalCarroll51401NCT04511013Map
IAMercy HospitalCedar Rapids52403NCT07383441Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT07383441Map
IAMercy Cancer Center-West LakesClive50325NCT05904080Map
IAMercy Cancer Center-West LakesClive50325NCT07166406Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05327686Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05904080Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT03866382Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT07166406Map
IAMethodist Jennie Edmundson HospitalCouncil Bluffs51503NCT05904080Map
IAGreater Regional Medical CenterCreston50801NCT07166406Map
IABroadlawns Medical CenterDes Moines50314NCT04511013Map
IAIowa Lutheran HospitalDes Moines50316NCT04511013Map
IAIowa Methodist Medical CenterDes Moines50309NCT05327686Map
IAIowa Methodist Medical CenterDes Moines50309NCT04511013Map
IAIowa Methodist Medical CenterDes Moines50309NCT05904080Map
IAIowa Methodist Medical CenterDes Moines50309NCT03866382Map
IAIowa Methodist Medical CenterDes Moines50309NCT07166406Map
IAMedical Oncology and Hematology Associates-Des MoinesDes Moines50309NCT04511013Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05904080Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT03866382Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05904080Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT07166406Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05904080Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT07166406Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT04511013Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT03866382Map
IATrinity Regional Medical CenterFort Dodge50501NCT04511013Map
IAUniversity of IowaIowa City52242NCT06581406Map
IAUniversity of Iowa- Site Number : 8400014Iowa City52242-1009NCT05584670Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT03866382Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05112601Map
IAMcFarland Clinic - JeffersonJefferson50129NCT04511013Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT04511013Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05327686Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05904080Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT03866382Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT07166406Map
IAMercy Medical Center-West LakesWest Des Moines50266NCT07166406Map
IAMethodist West HospitalWest Des Moines50266-7700NCT04511013Map
IAThe Iowa Clinic PCWest Des Moines50266NCT07166406Map
KSUniversity of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008Fairway66205-2528NCT05584670Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT03816345Map
KSCentral Care Cancer Center - Garden CityGarden City67846NCT04511013Map
KSCentral Care Cancer Center - Great BendGreat Bend67530NCT04511013Map
KSHaysMedHays67601NCT03816345Map
KSHaysMedHays67601NCT03866382Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT03816345Map
KSLawrence Memorial HospitalLawrence66044NCT03816345Map
KSLawrence Memorial HospitalLawrence66044NCT03866382Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT03816345Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT03866382Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT03816345Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT03816345Map
KSFreeman Physician Group of PittsburgPittsburg66762NCT03866382Map
KSSalina Regional Health CenterSalina67401NCT03816345Map
KSSalina Regional Health CenterSalina67401NCT03866382Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT03816345Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT03866382Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT03816345Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT03866382Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05896839Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT03816345Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT03866382Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT07166406Map
KYExelixis Clinical Site #122Louisville40202NCT05176483Map
KYResearch SiteLouisville40202NCT05536141Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05112601Map
KYUniversity of Louisville-James Graham Brown Cancer CenterLouisville40202NCT03899155Map
KYUofL Health Medical Center NortheastLouisville40245NCT05112601Map
KYMercy Health - Paducah Medical Oncology and HematologyPaducah42003NCT04511013Map
LALouisiana Hematology Oncology Associates LLCBaton Rouge70809NCT05327686Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809NCT05327686Map
LAMary Bird Perkins Cancer Center - MetairieMetairie70002NCT05327686Map
LAResearch SiteNew Orleans70121NCT05536141Map
MEHarold Alfond Center for Cancer CareAugusta04330NCT02693535Map
MEJackson Laboratory - Maine Cancer Genomics InitiativeAugusta04330NCT02693535Map
MEWaldo County General HospitalBelfast04915NCT02693535Map
MESMHC Cancer Care and Blood Disorders -BiddefordBiddeford04005NCT02693535Map
MENorthern Light Cancer CareBrewer04412NCT02693535Map
MERaish Peavey Haskell Children's Cancer and Treatment CenterBrewer04412NCT02693535Map
MEMaineHealth Cancer Care -BrunswickBrunswick04011NCT02693535Map
MENew England Cancer SpecialistKennebunk04043NCT02693535Map
MEYork Hopsital Oncology & Infusion Care in KitteryKittery03904NCT02693535Map
MEStephens Memorial HospitalNorway04268NCT02693535Map
MEPenobscot Bay Medical CenterRockport04856NCT02693535Map
MESMHC Cancer Care and Blood Disorders -SandfordSanford04073NCT02693535Map
MEMaine Children's Cancer ProgramScarborough04074NCT02693535Map
MEMaine Medical Partner's Women's HealthScarborough04074NCT02693535Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05112601Map
MENew England Cancer SpecialistScarborough04074NCT02693535Map
MEMaineHealth Cancer Care -South PortlandSouth Portland04106NCT02693535Map
MENew England Cancer SpecialistTopsham04086NCT02693535Map
MEYork Hospital Oncology & Infusion Care in WellsWells04090NCT02693535Map
MEYork Hospital Oncology & Infusion Care in YorkYork Village03909NCT02693535Map
MDExelixis Clinical Site #14Baltimore21201NCT05176483Map
MDJohns Hopkins HospitalBaltimore21231NCT03521830Map
MDJohns Hopkins HospitalBaltimore21287NCT07293351Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05896839Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT03816345Map
MDResearch SiteBaltimore21287NCT05536141Map
MDSidney Kimmel Comprehensive Cancer CenterBaltimore21231NCT04248569Map
MDSidney Kimmel Comprehensive Cancer CenterBaltimore21231NCT06941857Map
MDUniversity of MD Greenebaum Comprehensive Cancer CenterBaltimore21201NCT06743126Map
MDNational Cancer Institute Developmental Therapeutics ClinicBethesda20892NCT03816345Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03866382Map
MDFMH James M Stockman Cancer InstituteFrederick21702NCT03866382Map
MABeverly HospitalBeverly01915NCT05327686Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06708949Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06743126Map
MABrigham and Women's HospitalBoston02115NCT05327686Map
MADana FarberBoston02215NCT06624644Map
MADana Farber Cancer InstituteBoston02215NCT05428007Map
MADana Farber Cancer InstituteBoston02215NCT05533697Map
MADana_Farber Cancer Institute (DFCI)Boston02215NCT03899155Map
MADana-Farber Cancer InstituteBoston02215NCT05327686Map
MADana-Farber Cancer InstituteBoston02215NCT04665206Map
MADana-Farber Cancer InstituteBoston02215NCT03816345Map
MAExelixis Clinical Site #7Boston02215NCT05176483Map
MAMassachusetts General HospitalBoston02114NCT05428007Map
MAMassachusetts General HospitalBoston02114NCT05533697Map
MAMassachusetts General HospitalBoston02114NCT04665206Map
MAMassachusetts General HospitalBoston02114NCT06581406Map
MAMassachusetts General HospitalBoston02114NCT06743126Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT05327686Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT05779423Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT03816345Map
MAResearch SiteBoston02215NCT05536141Map
MATufts Medical CenterBoston02111NCT05904080Map
MALahey Hospital and Medical CenterBurlington01805NCT05327686Map
MALahey Hospital and Medical CenterBurlington01805NCT03866382Map
MALahey Hospital and Medical CenterBurlington01805NCT07383441Map
MAAddison Gilbert HospitalGloucester01930NCT05327686Map
MALahey Medical Center-PeabodyPeabody01960NCT05327686Map
MALahey Medical Center-PeabodyPeabody01960NCT03866382Map
MALahey Medical Center-PeabodyPeabody01960NCT07383441Map
MITrinity Health Ann Arbor HospitalAnn Arbor48106NCT02693535Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05327686Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT03866382Map
MIUniversity of MichiganAnn Arbor48109NCT06743126Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT04511013Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT06866262Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT05327686Map
MIBronson Battle CreekBattle Creek49017NCT04511013Map
MIBronson Battle CreekBattle Creek49017NCT05112601Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT07383441Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05327686Map
MITrinity Health Medical Center - BrightonBrighton48114NCT03866382Map
MIUniversity of Michigan - Brighton Center for Specialty CareBrighton48116NCT04511013Map
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT03866382
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT07166406
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT07383441Map
MITrinity Health Medical Center - CantonCanton48188NCT05327686Map
MITrinity Health Medical Center - CantonCanton48188NCT03866382Map
MIChelsea HospitalChelsea48118NCT05327686Map
MIChelsea HospitalChelsea48118NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT07383441Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT03866382Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT03866382Map
MICorewell Health Dearborn HospitalDearborn48124NCT05327686Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT03866382Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT07166406Map
MIBarbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006Detroit48201NCT05584670Map
MIExelixis Clinical Site #13Detroit48202NCT05176483Map
MIExelixis Clinical Site #65Detroit48201NCT05176483Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT02693535Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT03866382Map
MIHenry Ford HospitalDetroit48202NCT05533697Map
MIHenry Ford HospitalDetroit48202NCT03866382Map
MIHenry Ford HospitalDetroit48202NCT07166406Map
MIResearch SiteDetroit48201NCT05536141Map
MIResearch SiteDetroit48202NCT05536141Map
MIHenry Ford River District HospitalEast China Township48054NCT03866382
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05327686Map
MICancer Hematology Centers - FlintFlint48503NCT03866382Map
MIGenesys Hurley Cancer InstituteFlint48503NCT02693535Map
MIGenesys Hurley Cancer InstituteFlint48503NCT03866382Map
MIHurley Medical CenterFlint48503NCT03866382Map
MICancer Research Consortium of West MichiganGrand Rapids49503NCT02693535Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT05112601Map
MIHelen DeVos Children's Hospital at Spectrum HealthGrand Rapids49503NCT04511013Map
MISpectrum Health at Butterworth CampusGrand Rapids49503NCT04511013Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT04511013Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT05112601Map
MIHenry Ford Saint John Hospital - AcademicGrosse Pointe Woods48236NCT03866382Map
MIHenry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods48236NCT03866382Map
MIAllegiance HealthJackson49201NCT03866382Map
MIAllegiance HealthJackson49201NCT07166406Map
MIAscension Borgess Cancer CenterKalamazoo49009NCT04511013Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT05112601Map
MIBorgess Medical CenterKalamazoo49048NCT04511013Map
MIBronson Methodist HospitalKalamazoo49007NCT04511013Map
MIBronson Methodist HospitalKalamazoo49007NCT05112601Map
MIWest Michigan Cancer CenterKalamazoo49007NCT04511013Map
MIWest Michigan Cancer CenterKalamazoo49007NCT05112601Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT02693535Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05327686Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT03866382Map
MITrinity Health Livonia HospitalLivonia48154NCT02693535Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05327686Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT03866382Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT07383441Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT03866382Map
MITrinity Health Muskegon HospitalMuskegon49444NCT04511013Map
MITrinity Health Muskegon HospitalMuskegon49444NCT05112601Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT05112601Map
MILakeland Hospital NilesNiles49120NCT04511013Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT04511013Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT05112601Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT03866382Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT07166406Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT03866382Map
MINewland Medical Associates-PontiacPontiac48341NCT03866382Map
MITrinity Health Oakland HospitalPontiac48341NCT02693535Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT03866382Map
MICorewell Health Reed City HospitalReed City49677NCT05112601Map
MISpectrum Health Reed City HospitalReed City49677NCT04511013Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05327686Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT02693535Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT03866382Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT05112601Map
MICorewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph49085NCT05112601Map
MILakeland Medical Center Saint JosephSaint Joseph49085NCT04511013Map
MIMarie Yeager Cancer CenterSaint Joseph49085NCT04511013Map
MIMyMichigan Medical Center TawasTawas City48764NCT03866382Map
MIMichigan Cancer Research ConsortiumTraverse City48341NCT02693535Map
MIMunson Medical CenterTraverse City49684NCT04511013Map
MIMunson Medical CenterTraverse City49684NCT05112601Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05327686Map
MIHenry Ford Health Warren HospitalWarren48093NCT02693535Map
MIHenry Ford Health Warren HospitalWarren48093NCT03866382Map
MIHenry Ford Warren Hospital - GLCMSWarren48093NCT03866382Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT03866382Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT07166406Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT03866382Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT07166406Map
MIUniversity of Michigan Health - WestWyoming49519NCT04511013Map
MIUniversity of Michigan Health - WestWyoming49519NCT05112601Map
MIHuron Gastroenterology PCYpsilanti48106NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05327686Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT03866382Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT07383441Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05327686Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05904080Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT05327686Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT07166406Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT04511013Map
MNCambridge Medical CenterCambridge55008NCT04511013Map
MNAllina Health Cancer Institute - Mercy HospitalCoon Rapids55433NCT07227012Map
MNMercy HospitalCoon Rapids55433NCT04511013Map
MNMercy HospitalCoon Rapids55433NCT05112601Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05327686Map
MNEssentia Health - Deer River ClinicDeer River56636NCT03866382Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05112601Map
MNEssentia Health - Deer River ClinicDeer River56636NCT07166406Map
MNEssentia Health Cancer CenterDuluth55805NCT05327686Map
MNEssentia Health Cancer CenterDuluth55805NCT03866382Map
MNEssentia Health Cancer CenterDuluth55805NCT05112601Map
MNEssentia Health Cancer CenterDuluth55805NCT07166406Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT05327686Map
MNEssentia Health Saint Mary's Medical CenterDuluth55805NCT07166406Map
MNMiller-Dwan HospitalDuluth55805NCT05327686Map
MNMiller-Dwan HospitalDuluth55805NCT05112601Map
MNMiller-Dwan HospitalDuluth55805NCT07166406Map
MNFairview Southdale HospitalEdina55435NCT05327686Map
MNFairview Southdale HospitalEdina55435NCT04511013Map
MNFairview Southdale HospitalEdina55435NCT03866382Map
MNFairview Southdale HospitalEdina55435NCT05112601Map
MNUnity HospitalFridley55432NCT04511013Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05327686Map
MNEssentia Health Hibbing ClinicHibbing55746NCT03866382Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05112601Map
MNEssentia Health Hibbing ClinicHibbing55746NCT07166406Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT05327686Map
MNFairview Clinics and Surgery Center Maple GroveMaple Grove55369NCT04511013Map
MNMinnesota Oncology Hematology PA-MaplewoodMaplewood55109NCT04511013Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT04511013Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05327686Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT04511013Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05112601Map
MNAllina Health Cancer Institute - Abbott Northwestern HospitalMinneapolis55407NCT07227012Map
MNHealth Partners IncMinneapolis55454NCT04511013Map
MNHennepin County Medical CenterMinneapolis55415NCT05327686Map
MNHennepin County Medical CenterMinneapolis55415NCT04511013Map
MNHennepin County Medical CenterMinneapolis55415NCT03866382Map
MNM Health Fairview University of Minnesota Medical CenterMinneapolis55455NCT04665206Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT05327686Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT05647265Map
MNMonticello Cancer CenterMonticello55362NCT04511013Map
MNNew Ulm Medical CenterNew Ulm56073NCT04511013Map
MNFairview Northland Medical CenterPrinceton55371NCT04511013Map
MNNorth Memorial Medical Health CenterRobbinsdale55422NCT04511013Map
MNExelixis Clinical Site #68Rochester55905NCT05176483Map
MNMayo Clinic in RochesterRochester55905NCT05327686Map
MNMayo Clinic in RochesterRochester55905NCT05647265Map
MNMayo Clinic in RochesterRochester55905NCT03866382Map
MNMayo Clinic in RochesterRochester55905NCT03017820Map
MNMayo Clinic in RochesterRochester55905NCT06508463Map
MNMayo Clinic in RochesterRochester55905NCT07510334Map
MNMayo Clinic RochesterRochester55905NCT06581406Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04511013Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05112601Map
MNAllina Health Cancer Institute - United HospitalSaint Paul55102NCT07227012Map
MNRegions HospitalSaint Paul55101NCT05327686Map
MNRegions HospitalSaint Paul55101NCT04511013Map
MNRegions HospitalSaint Paul55101NCT03866382Map
MNRegions HospitalSaint Paul55101NCT05112601Map
MNUnited HospitalSaint Paul55102NCT04511013Map
MNUnited HospitalSaint Paul55102NCT05112601Map
MNEssentia Health SandstoneSandstone55072NCT05327686Map
MNEssentia Health SandstoneSandstone55072NCT03866382Map
MNEssentia Health SandstoneSandstone55072NCT05112601Map
MNEssentia Health SandstoneSandstone55072NCT07166406Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05327686Map
MNSaint Francis Regional Medical CenterShakopee55379NCT04511013Map
MNSaint Francis Regional Medical CenterShakopee55379NCT05112601Map
MNLakeview HospitalStillwater55082NCT05327686Map
MNLakeview HospitalStillwater55082NCT04511013Map
MNLakeview HospitalStillwater55082NCT03866382Map
MNEssentia Health Virginia ClinicVirginia55792NCT05327686Map
MNEssentia Health Virginia ClinicVirginia55792NCT03866382Map
MNEssentia Health Virginia ClinicVirginia55792NCT05112601Map
MNEssentia Health Virginia ClinicVirginia55792NCT07166406Map
MNRidgeview Medical CenterWaconia55387NCT05327686Map
MNRidgeview Medical CenterWaconia55387NCT04511013Map
MNRidgeview Medical CenterWaconia55387NCT03866382Map
MNRice Memorial HospitalWillmar56201NCT04511013Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT04511013Map
MNFairview Lakes Medical CenterWyoming55092NCT04511013Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT07383441Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT07383441Map
MSUniversity of Mississippi Medical CenterJackson39216NCT03866382Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT07383441Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT07383441Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT07383441Map
MOSaint Louis Cancer and Breast Institute-BallwinBallwin63011NCT04511013Map
MOCentral Care Cancer Center - BolivarBolivar65613NCT04511013Map
MOCox Cancer Center BransonBranson65616NCT04511013Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05327686Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04511013Map
MOSaint Francis Medical CenterCape Girardeau63703NCT03866382Map
MOSaint Francis Medical CenterCape Girardeau63703NCT07383441Map
MOSoutheast Cancer CenterCape Girardeau63703NCT04511013Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05896839Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT03816345Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT03866382Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT07166406Map
MOMU Health - University Hospital/Ellis Fischel Cancer CenterColumbia65212NCT05327686Map
MOMU Health - University Hospital/Ellis Fischel Cancer CenterColumbia65212NCT05112601Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05896839Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT03816345Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT03866382Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT07166406Map
MOParkland Health Center - FarmingtonFarmington63640NCT04511013Map
MOParkland Health Center - FarmingtonFarmington63640NCT03866382Map
MOParkland Health Center - FarmingtonFarmington63640NCT07383441Map
MOCapital Region Southwest CampusJefferson City65109NCT04511013Map
MOFreeman Health SystemJoplin64804NCT04511013Map
MOMercy Hospital JoplinJoplin64804NCT04511013Map
MOUniversity Health Truman Medical CenterKansas City64108NCT03816345Map
MOUniversity Health Truman Medical CenterKansas City64108NCT03866382Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT03816345Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT03816345Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT03866382Map
MOUniversity of Kansas Cancer Center at North Kansas City HospitalNorth Kansas City64116NCT03816345Map
MODelbert Day Cancer Institute at PCRMCRolla65401NCT04511013Map
MOMercy Clinic-Rolla-Cancer and HematologyRolla65401NCT04511013Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT04511013Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT04511013Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT03866382Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT07383441Map
MOCoxHealth South HospitalSpringfield65807NCT04511013Map
MOMercy Hospital SpringfieldSpringfield65804NCT05327686Map
MOMercy Hospital SpringfieldSpringfield65804NCT04511013Map
MOMercy Hospital Saint LouisSt Louis63141NCT05327686Map
MOMercy Hospital Saint LouisSt Louis63141NCT04511013Map
MOMercy Hospital Saint LouisSt Louis63141NCT03866382Map
MOMercy Hospital SouthSt Louis63128NCT05327686Map
MOMercy Hospital SouthSt Louis63128NCT04511013Map
MOMercy Hospital SouthSt Louis63128NCT05904080Map
MOMercy Hospital SouthSt Louis63128NCT03866382Map
MOMissouri Baptist Medical CenterSt Louis63131NCT04511013Map
MOMissouri Baptist Medical CenterSt Louis63131NCT03866382Map
MOMissouri Baptist Medical CenterSt Louis63131NCT07383441Map
MOSaint Louis Cancer and Breast Institute-South CitySt Louis63109NCT04511013Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05896839Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT03816345Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT03866382Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT07166406Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05896839Map
MOSiteman Cancer Center-South CountySt Louis63129NCT03816345Map
MOSiteman Cancer Center-South CountySt Louis63129NCT03866382Map
MOSiteman Cancer Center-South CountySt Louis63129NCT07166406Map
MOWashington UniversitySt Louis63110NCT05533697Map
MOWashington University School of MedicineSt Louis63110NCT05896839Map
MOWashington University School of MedicineSt Louis63110NCT03816345Map
MOWashington University School of MedicineSt Louis63110NCT03866382Map
MOWashington University School of MedicineSt Louis63110NCT05112601Map
MOWashington University School of MedicineSt Louis63110NCT06968988Map
MOWashington University School of MedicineSt Louis63110NCT07166406Map
MOWashington University School of MedicineSt Louis63110NCT07293351Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT04511013Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT03866382Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT07383441Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT03866382Map
MOMissouri Baptist Outpatient Center-Sunset HillsSunset Hills63127NCT04511013Map
MOMercy Hospital WashingtonWashington63090NCT04511013Map
MTCommunity Hospital of AnacondaAnaconda59711NCT04511013Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05904080Map
MTCommunity Hospital of AnacondaAnaconda59711NCT03866382Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05112601Map
MTBillings Clinic Cancer CenterBillings59101NCT04511013Map
MTBillings Clinic Cancer CenterBillings59101NCT05904080Map
MTBillings Clinic Cancer CenterBillings59101NCT03866382Map
MTBillings Clinic Cancer CenterBillings59101NCT05112601Map
MTIntermountain Health West End ClinicBillings59106NCT05112601Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT05112601Map
MTBozeman Deaconess HospitalBozeman59715NCT04511013Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05904080Map
MTBozeman Health Deaconess HospitalBozeman59715NCT03866382Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05112601Map
MTBenefis Healthcare- Sletten Cancer InstituteGreat Falls59405NCT04511013Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05904080Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT03866382Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05112601Map
MTGreat Falls ClinicGreat Falls59405NCT04511013Map
MTKalispell Regional Medical CenterKalispell59901NCT04511013Map
MTLogan Health Medical CenterKalispell59901NCT05904080Map
MTLogan Health Medical CenterKalispell59901NCT03866382Map
MTLogan Health Medical CenterKalispell59901NCT05112601Map
MTCommunity Medical CenterMissoula59804NCT05904080Map
MTCommunity Medical CenterMissoula59804NCT03866382Map
MTCommunity Medical CenterMissoula59804NCT05112601Map
MTCommunity Medical HospitalMissoula59804NCT04511013Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT04511013Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT05647265Map
NENebraska Medicine-BellevueBellevue68123NCT05327686Map
NENebraska Medicine-BellevueBellevue68123NCT03866382Map
NECancer Partners of Nebraska - Pine LakeLincoln68516NCT04511013Map
NESoutheast Nebraska Cancer Center - 68th Street PlaceLincoln68516NCT04511013Map
NEExelixis Clinical Site #2Omaha68130NCT05176483Map
NENebraska Cancer Specialists/Oncology Hematology West PC - MECCOmaha68114NCT05904080Map
NENebraska Medicine-Village PointeOmaha68118NCT05327686Map
NENebraska Medicine-Village PointeOmaha68118NCT03866382Map
NENebraska Methodist HospitalOmaha68114NCT05904080Map
NENebraska Methodist HospitalOmaha68114NCT05112601Map
NEResearch SiteOmaha68124NCT05536141Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT02693535Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05327686Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT03866382Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06743126Map
NVCarson Tahoe Regional Medical CenterCarson City89703NCT05647265Map
NVCancer and Blood Specialists-HendersonHenderson89052NCT05647265Map
NVComprehensive Cancer Centers of Nevada - HendersonHenderson89052NCT05647265Map
NVComprehensive Cancer Centers of Nevada-Horizon RidgeHenderson89052NCT05647265Map
NVComprehensive Cancer Centers of Nevada-Southeast HendersonHenderson89074NCT05647265Map
NVLas Vegas Urology - Green ValleyHenderson89074NCT05647265Map
NVLas Vegas Urology - PebbleHenderson89074NCT05647265Map
NVOncology Las Vegas - HendersonHenderson89074NCT05647265Map
NVUrology Specialists of Nevada - Green ValleyHenderson89074NCT05647265Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT05647265Map
NVComprehensive Cancer Centers of NevadaLas Vegas89148NCT05647265Map
NVComprehensive Cancer Centers of Nevada - Central ValleyLas Vegas89169NCT05647265Map
NVComprehensive Cancer Centers of Nevada - NorthwestLas Vegas89128NCT05647265Map
NVComprehensive Cancer Centers of Nevada - Town CenterLas Vegas89144NCT05647265Map
NVComprehensive Cancer Centers of Nevada-SummerlinLas Vegas89144NCT05647265Map
NVExelixis Clinical Site #55Las Vegas89052NCT05176483Map
NVHope Cancer Care of NevadaLas Vegas89103NCT05647265Map
NVLas Vegas Prostate Cancer CenterLas Vegas89113NCT05647265Map
NVLas Vegas Urology - Cathedral RockLas Vegas89128NCT05647265Map
NVLas Vegas Urology - PecosLas Vegas89074NCT05647265Map
NVLas Vegas Urology - Smoke RanchLas Vegas89128NCT05647265Map
NVLas Vegas Urology - SunsetLas Vegas89113NCT05647265Map
NVOncology Las Vegas - TenayaLas Vegas89128NCT05647265Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05647265Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT03866382Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05647265Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT03866382Map
NVOptumCare Cancer Care at MountainViewLas Vegas89128NCT05647265Map
NVRadiation Oncology Centers of Nevada CentralLas Vegas89106NCT05647265Map
NVRadiation Oncology Centers of Nevada SoutheastLas Vegas89119NCT05647265Map
NVSummerlin Hospital Medical CenterLas Vegas89144NCT05647265Map
NVSunrise Hospital and Medical CenterLas Vegas89109NCT05647265Map
NVUniversity Cancer CenterLas Vegas89169NCT05647265Map
NVUniversity Medical Center of Southern NevadaLas Vegas89102NCT05647265Map
NVUrology Specialists of Nevada - CentralLas Vegas89106NCT05647265Map
NVUrology Specialists of Nevada - NorthwestLas Vegas89128NCT05647265Map
NVUrology Specialists of Nevada - SouthwestLas Vegas89113NCT05647265Map
NVWomen's Cancer Center of NevadaLas Vegas89106NCT05112601Map
NVHope Cancer Care of Nevada-PahrumpPahrump89048NCT05647265Map
NVRadiation Oncology AssociatesReno89509NCT05647265Map
NVRenown Health Medical OncologyReno89502NCT07227012Map
NVRenown Office of Clinical ResearchReno89502NCT07227012Map
NVRenown Regional Medical CenterReno89502NCT05647265Map
NVRenown Regional Medical CenterReno89502NCT07227012Map
NVSaint Mary's Regional Medical CenterReno89503NCT05647265Map
NHNH Oncology - Hematology, PAConcord03103NCT02693535Map
NHDartmouth HitchcockLebanon03756NCT06362369Map
NHSolinsky Center for Cancer CareManchester03103NCT02693535Map
NHNew England Cancer SpecialistPortsmouth03801NCT02693535Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05327686Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05904080Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT03866382Map
NJMemorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge07920NCT06594991Map
NJMemorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge07920NCT07532902Map
NJCooper Hospital University Medical CenterCamden08103NCT05327686Map
NJExelixis Clinical Site #88East Brunswick08816NCT05176483Map
NJExelixis Clinical Site #105Hackensack07601NCT05176483Map
NJHackensack Meridian Health (Data Collection Only)Hackensack07601NCT06594991Map
NJJohn Theurer Cancer CenterHackensack07601NCT05533697Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601-2191NCT07291076Map
NJJohn Theurer Cancer Center Site Number : 8400001Hackensack07601NCT05584670Map
NJJohn Theurer Cancer Center, Hackensack Meridian HealthHackensack07410NCT05715229Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05327686Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05904080Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT03866382Map
NJMemorial Sloan Kettering Monmouth (All Protocol Activities)Middletown07748NCT06594991Map
NJMemorial Sloan Kettering Monmouth (All Protocol Activities)Middletown07748NCT07532902Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05327686Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05904080Map
NJMemorial Sloan Kettering BergenMontvale07645NCT03866382Map
NJMemorial Sloan Kettering Bergen (All Protocol Activities)Montvale07645NCT07532902Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06594991Map
NJAtlantic Health System/Morristown Medical CenterMorristown07960NCT06743126Map
NJCooper CyberKnife CenterMount Laurel08054NCT05327686Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT03816345Map
NMLovelace Medical Center - Saint Joseph SquareAlbuquerque87102NCT02693535Map
NMLovelace Medical Center-Saint Joseph SquareAlbuquerque87102NCT05327686Map
NMLovelace Radiation OncologyAlbuquerque87109NCT05327686Map
NMPresbyterian Kaseman HospitalAlbuquerque87110NCT02693535Map
NMThe University of New Mexico Comprehensive Cancer CenterAlbuquerque87131NCT02693535Map
NMUniversity of New MexicoAlbuquerque87106NCT06624644Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05112601Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT07166406Map
NMMemorial Medical CenterLas Cruces88011NCT02693535Map
NMPresbyterian Rust Medical CenterRio Rancho87124NCT02693535Map
NYNorthwell Health Imbert Cancer CenterBay Shore11706NCT05327686Map
NYRoswell Park Cancer InstituteBuffalo14263NCT03899155Map
NYMemorial Sloan Kettering CommackCommack11725NCT05327686Map
NYMemorial Sloan Kettering CommackCommack11725NCT05904080Map
NYMemorial Sloan Kettering CommackCommack11725NCT03866382Map
NYMemorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack11725NCT07532902Map
NYMemorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack11725NCT06594991Map
NYMemorial Sloan Kettering WestchesterEast White Plains10604NCT05327686Map
NYGlens Falls HospitalGlens Falls12801NCT05327686Map
NYNorthwell Health Cancer Institute at HuntingtonGreenlawn11740NCT05327686Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05384496Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05904080Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT03866382Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT06594991Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT07532902Map
NYNorthwell Health Monter Cancer CenterLake Success11042NCT02693535Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT05327686Map
NYNYU Langone Hematology Oncology Associates-MineolaMineola11501NCT03899155Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05896839Map
NYNYU Langone Hospital - Long IslandMineola11501NCT03816345Map
NYNYU Langone Hospital - Long IslandMineola11501NCT03866382Map
NYNorthern Westchester HospitalMount Kisco10549NCT02693535Map
NYNorthern Westchester HospitalMount Kisco10549NCT05327686Map
NYCohen Children's Medical CenterNew Hyde Park11040NCT02693535Map
NYExelixis Clinical Site #6New York10065NCT05176483Map
NYExelixis Clinical Site #60New York10032NCT05176483Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT05188118Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05327686Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05896839Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT03816345Map
NYLaura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York10016NCT06743126Map
NYLenox Hill HospitalNew York10075NCT05327686Map
NYManhattan Eye Ear and Throat HospitalNew York10065NCT05327686Map
NYManhattan Eye, Ear, and Throat HospitalNew York10065NCT02693535Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05327686Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05384496Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04665206Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05904080Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03866382Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06581406Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06743126Map
NYMemorial Sloan Kettering Cancer Center - Melanoma & ImmunotherapeuticsNew York10065NCT05533697Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT06594991Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT07532902Map
NYMount Sinai HospitalNew York10029NCT07166406Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT03816345Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT03866382Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT03816345Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT03866382Map
NYNYU Langone HealthNew York10016NCT05428007Map
NYNYU Langone HealthNew York10016NCT07504796Map
NYNYU Langone Health-Perlmutter Cancer CenterNew York10016NCT05533697Map
NYNYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013New York10016-6402NCT05584670Map
NYResearch SiteNew York10029NCT05536141Map
NYResearch SiteNew York10065NCT05536141Map
NYStaten Island University HospitalNew York10305NCT02693535Map
NYQueens Cancer CenterRego Park11374NCT02693535Map
NYUniversity of RochesterRochester14642NCT05112601Map
NYUniversity of RochesterRochester14642NCT06743126Map
NYPhelps HospitalSleepy Hollow10591NCT02693535Map
NYPhelps Memorial Hospital CenterSleepy Hollow10591NCT05327686Map
NYExelixis Clinical Site #76Syracuse13210NCT05176483Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT05112601Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT07166406Map
NYMontefiore Medical Center-Einstein CampusThe Bronx10461NCT07166406Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05327686Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05904080Map
NYMemorial Sloan Kettering NassauUniondale11553NCT03866382Map
NYMemorial Sloan Kettering Nassau (All Protocol Activities)Uniondale11553NCT07532902Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT06594991Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05112601Map
NCDuke Cancer Center CaryCary27518NCT05327686Map
NCLineberger Comprehensive Cancer CenterChapel Hill27599NCT02693535Map
NCUNC Hospitals, The University of North Carolina at Chapel HillChapel Hill27599NCT06743126Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05327686Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05904080Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT03866382Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT05327686Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT05327686Map
NCAtrium Health's Levine Cancer InstituteCharlotte28277NCT02693535Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05327686Map
NCLevine Cancer Institute-BallantyneCharlotte28277NCT05327686Map
NCNovant Health Presbyterian Medical CenterCharlotte28204NCT05904080Map
NCWake Forest University at ClemmonsClemmons27012NCT05327686Map
NCWake Forest University at ClemmonsClemmons27012NCT04511013Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT04511013Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT05327686Map
NCDuke Cancer Center SouthpointDurham27713NCT05647265Map
NCDuke University Medical CenterDurham27710NCT05327686Map
NCDuke University Medical CenterDurham27710NCT05647265Map
NCDuke University Medical CenterDurham27710NCT05112601Map
NCDuke University Medical CenterDurham27710NCT06581406Map
NCDuke University Medical CenterDurham27710NCT06708949Map
NCExelixis Clinical Site #12Durham27710NCT05176483Map
NCLevine Cancer Institute-GastonGastonia28054NCT05327686Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT04511013Map
NCMargaret R Pardee Memorial HospitalHendersonville28791NCT03866382Map
NCHayworth Cancer CenterHigh Point27262NCT05327686Map
NCNovant Health Cancer Institute - HuntersvilleHuntersville28078NCT05904080Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT04511013Map
NCNovant Health Cancer Institute - MatthewsMatthews28105NCT05904080Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT05327686Map
NCNovant Health Cancer Institute - MooresvilleMooresville28117NCT05904080Map
NCDuke Cancer Center RaleighRaleigh27609NCT05327686Map
NCDuke Cancer Center RaleighRaleigh27609NCT05647265Map
NCDuke Women's Cancer Care RaleighRaleigh27607NCT05112601Map
NCWake Forest Baptist Health - Hematology Oncology - StatesvilleStatesville28677NCT04511013Map
NCWake Forest Baptist Health - Wilkes Medical CenterWilkesboro28659NCT05327686Map
NCWake Forest Baptist Health - Wilkes Medical CenterWilkesboro28659NCT04511013Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05327686Map
NCWake Forest University Health SciencesWinston-Salem27157NCT04511013Map
NDSanford Bismarck Medical CenterBismarck58501NCT05327686Map
NDSanford Bismarck Medical CenterBismarck58501NCT05904080Map
NDSanford Health- BismarckBismarck58501NCT02693535Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT05112601Map
NDSanford Broadway Medical CenterFargo58122NCT05327686Map
NDSanford Broadway Medical CenterFargo58122NCT05904080Map
NDSanford Health- FargoFargo58122NCT02693535Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05327686Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05904080Map
OHUH Seidman Cancer Center at UH Avon Health CenterAvon44011NCT05327686Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT05327686Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT04511013Map
OHUHHS-Chagrin Highlands Medical CenterBeachwood44122NCT05112601Map
OHIndu and Raj Soin Medical CenterBeavercreek45431NCT04511013Map
OHStrecker Cancer Center-BelpreBelpre45714NCT04511013Map
OHStrecker Cancer Center-BelpreBelpre45714NCT03866382Map
OHSaint Elizabeth Boardman HospitalBoardman44512NCT04511013Map
OHDayton Physicians LLC-Miami Valley SouthCenterville45459NCT04511013Map
OHMiami Valley Hospital SouthCenterville45459NCT05327686Map
OHMiami Valley Hospital SouthCenterville45459NCT05112601Map
OHGeauga HospitalChardon44024NCT04511013Map
OHGeauga HospitalChardon44024NCT05112601Map
OHAdena Regional Medical CenterChillicothe45601NCT04511013Map
OHAdena Regional Medical CenterChillicothe45601NCT03866382Map
OHGood Samaritan Hospital - CincinnatiCincinnati45220NCT05112601Map
OHOncology Hematology CareCincinnati45242NCT03899155Map
OHOncology Hematology Care Inc-KenwoodCincinnati45236NCT04511013Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT05327686Map
OHUniversity of Cincinnati Medical CenterCincinnati45219NCT02693535Map
OHCase Western Reserve UniversityCleveland44106NCT05327686Map
OHCase Western Reserve UniversityCleveland44106NCT04511013Map
OHCase Western Reserve UniversityCleveland44106NCT05112601Map
OHCleveland ClinicCleveland44195NCT05361720Map
OHCleveland Clinic Cancer Center/Fairview HospitalCleveland44111NCT05112601Map
OHCleveland Clinic FoundationCleveland44195NCT05112601Map
OHCleveland Clinic, Taussig Cancer InstituteCleveland44195NCT06743126Map
OHExelixis Clinical Site #10Cleveland44106NCT05176483Map
OHResearch SiteCleveland44106NCT05536141Map
OHResearch SiteCleveland44195NCT05536141Map
OHUniversity Hospitals Seidman Cancer CenterCleveland44106NCT05361720Map
OHColumbus Oncology and Hematology Associates IncColumbus43214NCT04511013Map
OHColumbus Oncology and Hematology Associates IncColumbus43214NCT03866382Map
OHDoctors HospitalColumbus43228NCT04511013Map
OHDoctors HospitalColumbus43228NCT03866382Map
OHGrant Medical CenterColumbus43215NCT04511013Map
OHGrant Medical CenterColumbus43215NCT03866382Map
OHMount Carmel East HospitalColumbus43213NCT04511013Map
OHMount Carmel East HospitalColumbus43213NCT03866382Map
OHMount Carmel Health Center WestColumbus43222NCT04511013Map
OHMount Carmel Health Center WestColumbus43222NCT03866382Map
OHOhio State UniversityColumbus43210NCT06743126Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05327686Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04697576Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04511013Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03816345Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03866382Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05112601Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT07166406Map
OHRiverside Methodist HospitalColumbus43214NCT04511013Map
OHRiverside Methodist HospitalColumbus43214NCT03866382Map
OHThe Mark H Zangmeister CenterColumbus43219NCT04511013Map
OHThe Mark H Zangmeister CenterColumbus43219NCT03866382Map
OHThe Ohio State UniversityColumbus43210NCT06581406Map
OHThe Ohio UniversityColumbus43210NCT03899155Map
OHDayton Physician LLC-Miami Valley Hospital NorthDayton45415NCT04511013Map
OHMiami Valley HospitalDayton45409NCT05327686Map
OHMiami Valley Hospital NorthDayton45415NCT05327686Map
OHPremier Blood and Cancer CenterDayton45409NCT05327686Map
OHDelaware Health Center-Grady Cancer CenterDelaware43015NCT04511013Map
OHDelaware Health Center-Grady Cancer CenterDelaware43015NCT03866382Map
OHGrady Memorial HospitalDelaware43015NCT04511013Map
OHGrady Memorial HospitalDelaware43015NCT03866382Map
OHColumbus Oncology and Hematology AssociatesDublin43016NCT04511013Map
OHDublin Methodist HospitalDublin43016NCT04511013Map
OHArmes Family Cancer CenterFindlay45840NCT04511013Map
OHBlanchard Valley HospitalFindlay45840NCT04511013Map
OHOrion Cancer CareFindlay45840NCT04511013Map
OHAtrium Medical Center-Middletown Regional HospitalFranklin45005-1066NCT05327686Map
OHDayton Physicians LLC-AtriumFranklin45005NCT04511013Map
OHCentral Ohio Breast and Endocrine SurgeryGahanna43230NCT04511013Map
OHDayton Physicians LLC-WayneGreenville45331NCT04511013Map
OHMiami Valley Cancer Care and InfusionGreenville45331NCT05327686Map
OHWayne HospitalGreenville45331NCT04511013Map
OHMount Carmel Grove City HospitalGrove City43123NCT04511013Map
OHZangmeister Center Grove CityGrove City43123NCT04511013Map
OHGreater Dayton Cancer CenterKettering45409NCT04511013Map
OHKettering HealthKettering45429NCT02693535Map
OHKettering Medical CenterKettering45429NCT04511013Map
OHKettering Medical CenterKettering45429NCT03866382Map
OHFairfield Medical CenterLancaster43130NCT04511013Map
OHFairfield Medical CenterLancaster43130NCT03866382Map
OHSaint Rita's Medical CenterLima45801NCT04511013Map
OHOhioHealth Mansfield HospitalMansfield44903NCT04511013Map
OHOhioHealth Mansfield HospitalMansfield44903NCT03866382Map
OHMarietta Memorial HospitalMarietta45750NCT04511013Map
OHMarietta Memorial HospitalMarietta45750NCT03866382Map
OHOhioHealth Marion General HospitalMarion43302NCT04511013Map
OHOhioHealth Marion General HospitalMarion43302NCT03866382Map
OHMemorial HospitalMarysville43040NCT03866382Map
OHHillcrest Hospital Cancer CenterMayfield Heights44124NCT05112601Map
OHUH Seidman Cancer Center at Lake Health Mentor CampusMentor44060NCT05327686Map
OHUH Seidman Cancer Center at Lake Health Mentor CampusMentor44060NCT05112601Map
OHUH Seidman Cancer Center at Southwest General HospitalMiddleburg Heights44130NCT04511013Map
OHKnox Community HospitalMount Vernon43050NCT04511013Map
OHKnox Community HospitalMount Vernon43050NCT03866382Map
OHMount Carmel New Albany Surgical HospitalNew Albany43054NCT04511013Map
OHLicking Memorial HospitalNewark43055NCT04511013Map
OHLicking Memorial HospitalNewark43055NCT03866382Map
OHNewark Radiation OncologyNewark43055NCT04511013Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT05327686Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT04511013Map
OHUniversity Hospitals Parma Medical CenterParma44129NCT05112601Map
OHMercy Health Perrysburg Cancer CenterPerrysburg43551NCT04511013Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT04511013Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT03866382Map
OHUniversity Hospitals Portage Medical CenterRavenna44266NCT05327686Map
OHUniversity Hospitals Portage Medical CenterRavenna44266NCT04511013Map
OHUH Seidman Cancer Center at Firelands Regional Medical CenterSandusky44870NCT04511013Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT04511013Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT03866382Map
OHSpringfield Regional Medical CenterSpringfield45505NCT04511013Map
OHMercy Health - Saint Anne HospitalToledo43623NCT04511013Map
OHSaint Vincent Mercy Medical CenterToledo43608NCT04511013Map
OHDayton Physicians LLC - TroyTroy45373NCT04511013Map
OHUpper Valley Medical CenterTroy45373NCT05327686Map
OHUniversity Hospitals Sharon Health CenterWadsworth44281NCT04511013Map
OHSaint Joseph Warren HospitalWarren44484NCT04511013Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT05327686Map
OHWest Chester HospitalWest Chester45069NCT02693535Map
OHSaint Ann's HospitalWesterville43081NCT04511013Map
OHSaint Ann's HospitalWesterville43081NCT03866382Map
OHUH Seidman Cancer Center at Saint John Medical CenterWestlake44145NCT04511013Map
OHUH Seidman Cancer Center at Saint John Medical CenterWestlake44145NCT05112601Map
OHSaint Elizabeth Youngstown HospitalYoungstown44501NCT04511013Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT04511013Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT03866382Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT05904080Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT03866382Map
OKMercy Hospital Oklahoma CityOklahoma City73120NCT04511013Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05327686Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04511013Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05904080Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT03866382Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05112601Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT05327686Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT05112601Map
ORSaint Alphonsus Medical Center-Baker CityBaker City97814NCT04511013Map
ORSaint Charles Health SystemBend97701NCT04511013Map
ORSaint Charles Health SystemBend97701NCT05647265Map
ORClackamas Radiation Oncology CenterClackamas97015NCT04511013Map
ORClackamas Radiation Oncology CenterClackamas97015NCT05647265Map
ORClackamas Radiation Oncology CenterClackamas97015NCT07166406Map
ORProvidence Cancer Institute Clackamas ClinicClackamas97015NCT04511013Map
ORBay Area HospitalCoos Bay97420NCT04511013Map
ORBay Area HospitalCoos Bay97420NCT05647265Map
ORProvidence Hood River Memorial HospitalHood River97031NCT05647265Map
ORProvidence Newberg Medical CenterNewberg97132NCT04511013Map
ORProvidence Newberg Medical CenterNewberg97132NCT05647265Map
ORProvidence Newberg Medical CenterNewberg97132NCT03866382Map
ORProvidence Newberg Medical CenterNewberg97132NCT07166406Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT03866382Map
ORSaint Alphonsus Medical Center-OntarioOntario97914NCT04511013Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT04511013Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05647265Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT03866382Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT07166406Map
ORExelixis Clinical Site #51Portland97239NCT05176483Map
OROregon Health and Science UniversityPortland97239NCT05904080Map
OROregon Health and Science UniversityPortland97239NCT03866382Map
ORProvidence Cancer Institute Franz ClinicPortland97213NCT06743126Map
ORProvidence Health & ServicesPortland97213NCT02693535Map
ORProvidence Portland Medical CenterPortland97213NCT04511013Map
ORProvidence Portland Medical CenterPortland97213NCT05647265Map
ORProvidence Portland Medical CenterPortland97213NCT03866382Map
ORProvidence Portland Medical CenterPortland97213NCT05112601Map
ORProvidence Portland Medical CenterPortland97213NCT07166406Map
ORProvidence Portland Medical CenterPortland97213NCT07291076Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04511013Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05647265Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT03866382Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05112601Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT07166406Map
ORProvidence St. Vincent Medical CenterPortland97225NCT07291076Map
ORSaint Charles Health System-RedmondRedmond97756NCT04511013Map
ORSaint Charles Health System-RedmondRedmond97756NCT05647265Map
PALehigh Valley Hospital - Cedar CrestAllentown18103NCT02693535Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05327686Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT03866382Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT05327686Map
PAUPMC-Heritage Valley Health System BeaverBeaver15009NCT05112601Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT05327686Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT03866382Map
PALehigh Valley Hospital- MuhlenbergBethlehem18017NCT02693535Map
PAUPMC Hillman Cancer Center at Butler Health SystemButler16001NCT05112601Map
PACarlisle Regional Cancer CenterCarlisle17015NCT05327686Map
PAChristiana Care Health System-Concord Health CenterChadds Ford19317NCT05327686Map
PAUPMC Hillman Cancer Center - Passavant - CranberryCranberry Township16066NCT05112601Map
PAGeisinger Medical CenterDanville17822NCT05327686Map
PAGeisinger Medical CenterDanville17822NCT07166406Map
PAPocono Medical CenterEast Stroudsburg18301NCT02693535Map
PAPocono Medical CenterEast Stroudsburg18301NCT03866382Map
PASaint Vincent HospitalErie16544NCT05327686Map
PAUPMC Hillman Cancer Center ErieErie16505NCT05327686Map
PAUPMC Hillman Cancer Center ErieErie16505NCT03866382Map
PAUPMC Hillman Cancer Center ErieErie16505NCT05112601Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT05327686Map
PAUPMC Cancer Center at UPMC HorizonFarrell16121NCT05112601Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT05327686Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT03866382Map
PAUPMC Cancer Centers - Arnold Palmer PavilionGreensburg15601NCT05112601Map
PAUPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg17109NCT05327686Map
PAGeisinger Medical Center-Cancer Center HazletonHazleton18201NCT05327686Map
PALehigh Valley Hospital-HazletonHazleton18201NCT02693535Map
PALehigh Valley Hospital-HazletonHazleton18201NCT03866382Map
PAExelixis Clinical Site #104Hershey17033NCT05176483Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT05327686Map
PAIRMC Cancer CenterIndiana15701NCT05327686Map
PAIRMC Cancer CenterIndiana15701NCT05112601Map
PAJefferson HospitalJefferson Hills15025NCT05327686Map
PAUPMC-Johnstown/John P. Murtha Regional Cancer CenterJohnstown15901NCT05112601Map
PALancaster General HealthLancaster17601NCT03899155Map
PALancaster General HospitalLancaster17601NCT03646617Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT05327686Map
PAGeisinger Medical Oncology-LewisburgLewisburg17837NCT07166406Map
PAUPMC Cancer Center at UPMC McKeesportMcKeesport15132NCT05112601Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT05327686Map
PAUPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg17050NCT05112601Map
PAForbes HospitalMonroeville15146NCT05327686Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT03866382Map
PAUPMC Hillman Cancer Center - MonroevilleMonroeville15146NCT05112601Map
PAUPMC Hillman Cancer Center in CoraopolisMoon Township15108NCT05112601Map
PAUPMC Hillman Cancer Center - Part of Frick HospitalMount Pleasant15666NCT05112601Map
PAArnold Palmer Cancer Center Medical Oncology NorwinN. Huntingdon15642NCT03866382
PAArnold Palmer Cancer Center Medical Oncology NorwinN. Huntingdon15642NCT05112601
PAUPMC Cancer Center-Natrona HeightsNatrona Heights15065NCT05112601Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT05327686Map
PAUPMC Hillman Cancer Center - New CastleNew Castle16105NCT05112601Map
PAAbramson Cancer CenterPhiladelphia19104NCT03646617Map
PAAbramson Cancer Center at University of PennsylvaniaPhiladelphia19104NCT04464759Map
PAExelixis Clinical Site #98Philadelphia19104NCT05176483Map
PAFox Chase Cancer CenterPhiladelphia19111NCT02693535Map
PAFox Chase Cancer CenterPhiladelphia19111NCT05498792Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06743126Map
PAPenn Medicine Abramson Cancer CenterPhiladelphia19104NCT06708949Map
PAThomas Jeffersion University, Sidney Kimmel Cancer CenterPhiladelphia19107NCT06743126Map
PAThomas Jefferson UniversityPhiladelphia19107NCT06581406Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT06743126Map
PAUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphia19104NCT06747845Map
PAUPennPhiladelphia19107NCT06624644Map
PAAllegheny General HospitalPittsburgh15212NCT05327686Map
PAExelixis Clinical Site #24Pittsburgh15232NCT05176483Map
PAExelixis Clinical Site #32Pittsburgh15212NCT05176483Map
PAResearch SitePittsburgh15232NCT05536141Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05327686Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT04511013Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05896839Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT03816345Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT03866382Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05112601Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06581406Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT06743126Map
PAUPMC-Magee Womens HospitalPittsburgh15213NCT05327686Map
PAUPMC-Magee Womens HospitalPittsburgh15213NCT05112601Map
PAUPMC-Mercy HospitalPittsburgh15219NCT05112601Map
PAUPMC-Passavant HospitalPittsburgh15237NCT05327686Map
PAUPMC-Passavant HospitalPittsburgh15237NCT03866382Map
PAUPMC-Passavant HospitalPittsburgh15237NCT05112601Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT05327686Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT03866382Map
PAUPMC-Saint Clair Hospital Cancer CenterPittsburgh15243NCT05112601Map
PAUPMC-Saint MargaretPittsburgh15215NCT05327686Map
PAUPMC-Saint MargaretPittsburgh15215NCT05112601Map
PAUPMC-Shadyside HospitalPittsburgh15232NCT05327686Map
PAWest Penn HospitalPittsburgh15224NCT05327686Map
PAGeisinger Cancer Services-PottsvillePottsville17901NCT05327686Map
PACommunity Medical CenterScranton18510NCT05327686Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT05327686Map
PAUPMC Cancer Center at UPMC NorthwestSeneca16346NCT05112601Map
PAUPMC Cancer Center-WashingtonWashington15301NCT05112601Map
PAUPMC West Mifflin-Cancer Center JeffersonWest Mifflin15122NCT05112601Map
PAReading HospitalWest Reading19611NCT05327686Map
PAWexford Health and Wellness PavilionWexford15090NCT05327686Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05327686Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT07166406Map
PADivine Providence HospitalWilliamsport17754NCT05327686Map
PAUPMC MemorialYork17408NCT05327686Map
RIBrown University Health Cancer InstituteProvidence02906NCT06362369Map
RIRhode Island HospitalProvidence02903NCT04933903Map
RIRhode Island Hospital Site Number : 8400004Providence02903NCT05584670Map
RIWomen and Infants HospitalProvidence02905NCT05112601Map
SCSC Cancer Specialists at St. Joseph's/Candler BlufftonBluffton29910NCT02693535Map
SCSt. Joseph's/Candler SmithBluffton29910NCT02693535Map
SCSummit Cancer Care at St. Josph's/Candler BlufftonBluffton29910NCT02693535Map
SCMedical University of South CarolinaCharleston29425NCT05327686Map
SCMedical University of South CarolinaCharleston29425NCT05904080Map
SCMedical University of South CarolinaCharleston29425NCT03866382Map
SCMUSC Hollings Cancer CenterCharleston29425NCT07293351Map
SCSelf Regional HealthcareGreenwood29646NCT05327686Map
SCSouth Carolina Cancer SpecialistsHilton Head Island29926NCT02693535Map
SCCarolina Urologic Research Center, LLCMyrtle Beach29572NCT07293351Map
SCExelixis Clinical Site #9Myrtle Beach29572NCT05176483Map
SDAvera Cancer InstituteSioux Falls57105NCT06743126Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05327686Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05904080Map
SDSanford Cancer Center Oncology Clinic and PharmacySioux Falls57104NCT02693535Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05327686Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05904080Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT07383441Map
TNThe West Clinic, PLLC dba West Cancer CenterGermantown38138NCT06581406Map
TNUniversity of Tennessee Medical CenterKnoxville37920NCT06581406Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT07383441Map
TNExelixis Clinical Site #3Nashville37203NCT05176483Map
TNResearch SiteNashville37203NCT05536141Map
TNResearch SiteNashville37240NCT05536141Map
TNSara Cannon Research Institute TennesseeNashville37203NCT05533697Map
TNSarah Cannon Research InstituteNashville37203NCT06581406Map
TNSCRI Oncology PartnersNashville37203NCT06743126Map
TNTennesse OncologyNashville37203NCT03899155Map
TNTennessee OncologyNashville37203NCT07291076Map
TNTennessee Oncology - Nashville / Sarah Cannon Research InstituteNashville37203NCT02693535Map
TNVanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic)Nashville37232NCT06581406Map
TNVanderbilt University Medical CenterNashville37232NCT06047379Map
TNVanderbilt University Medical CenterNashville37232NCT06708949Map
TNVanderbilt University Medical CenterNashville37232NCT07291076Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05361720Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05501665Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT05904080Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT03866382Map
TNVanderbilt-Ingram Cancer CenterNashville37232NCT07188896Map
TXExelixis Clinical Site #46Austin78705NCT05176483Map
TXBaylor UniversityDallas75246NCT06743126Map
TXBaylor, Scott and White Research InstituteDallas75246NCT06047379Map
TXExelixis Clinical Site #111Dallas75246NCT05176483Map
TXExelixis Clinical Site #89Dallas75246NCT05176483Map
TXParkland Memorial HospitalDallas75235NCT05327686Map
TXParkland Memorial HospitalDallas75235NCT05112601Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06708949Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06743126Map
TXUniversity of Texas, Southwestern Medical CenterDallas75390NCT05361720Map
TXUT Southwestern Medical CenterDallas75390NCT06581406Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05327686Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT05647265Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT03816345Map
TXUT Southwestern Simmons Cancer Center - RedBirdDallas75237NCT03866382Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05327686Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05647265Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT03816345Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT03866382Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT05112601Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05327686Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05647265Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT03816345Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT03866382Map
TXUT Southwestern/Simmons Cancer Center-Fort WorthFort Worth76104NCT05112601Map
TXM D Anderson Cancer CenterHouston77030NCT03816345Map
TXM D Anderson Cancer CenterHouston77030NCT05048212Map
TXMD Anderson Cancer CenterHouston77030NCT04665206Map
TXMD Anderson Cancer CenterHouston77030NCT06362369Map
TXMD Anderson Cancer CenterHouston77030NCT07401875Map
TXThe University of Texas M. D. Anderson Cancer CenterHouston77030NCT06708949Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT02693535Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT06743126Map
TXThe University Of Texas Md Anderson Cancer CenterHouston77030NCT06581406Map
TXUniversity of Texas MD Anderson Cancer Center Site Number : 8400005Houston77030-4000NCT05584670Map
TXExelixis Clinical Site #73Irving75063NCT05176483Map
TXNEXT OncologyIrving75039NCT07563738Map
TXExelixis Clinical Site #50Plano75075NCT05176483Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05327686Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05647265Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT03816345Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT03866382Map
TXUT Southwestern Clinical Center at Richardson/PlanoRichardson75080NCT05112601Map
TXNEXT OncologySan Antonio78229NCT04665206Map
TXResearch SiteSan Antonio78229NCT05536141Map
TXScott and White Memorial HospitalTemple76508NCT05327686Map
TXExelixis Clinical Site #70Tyler75601NCT05176483Map
UTCedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer CenterCedar City84720NCT02693535Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT06365619Map
UTHuntsman Cancer Institute at the University of UtahSalt Lake City84112NCT03646617Map
UTHuntsman Cancer Institute, University of UtahSalt Lake City84112NCT06743126Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT04511013Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05896839Map
UTIntermountain HealthcareSalt Lake City84107NCT02693535Map
UTDixie Regional Medical Center-River Road CampusSt. George84770NCT02693535Map
VTCentral Vermont Medical Center/National Life Cancer TreatmentBerlin Corners05602NCT05327686Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05327686Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05327686Map
VAInova Alexandria HospitalAlexandria22304NCT05327686Map
VAInova Alexandria HospitalAlexandria22304NCT07166406Map
VAVirginia Cancer Specialists, PCArlington22201NCT04665206Map
VAExelixis Clinical Site #66Charlottesville22903NCT05176483Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05112601Map
VAInova Fair Oaks HospitalFairfax22033NCT05327686Map
VAInova Fair Oaks HospitalFairfax22033NCT07166406Map
VAInova Schar Cancer InstituteFairfax22042NCT02693535Map
VAInova Schar Cancer InstituteFairfax22031NCT05327686Map
VAInova Schar Cancer InstituteFairfax22031NCT07166406Map
VANEXT Oncology VirginiaFairfax22031NCT07563738Map
VAInova Fairfax HospitalFalls Church22042NCT07166406Map
VAInova Loudoun HospitalLeesburg20176NCT07166406Map
VABon Secours Saint Francis Medical CenterMidlothian23114NCT05327686Map
VABon Secours Cancer Institute at Reynolds CrossingRichmond23230NCT05327686Map
VAHenrico Doctor's HospitalRichmond23229NCT05112601Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT05904080Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05904080Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT03816345Map
VAVirginia Commonwealth UniversityRichmond23219NCT06743126Map
WAProvidence Regional Cancer System-AberdeenAberdeen98520NCT04511013Map
WAProvidence Regional Cancer System-AberdeenAberdeen98520NCT05647265Map
WAPeaceHealth Saint Joseph Medical CenterBellingham98225NCT04511013Map
WAPeaceHealth Saint Joseph Medical CenterBellingham98225NCT05647265Map
WANorthwest Medical SpecialtiesBonney Lake98391NCT02693535Map
WAProvidence Regional Cancer System-CentraliaCentralia98531NCT04511013Map
WAProvidence Regional Cancer System-CentraliaCentralia98531NCT05647265Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT04511013Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05647265Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05112601Map
WAProvidence Regional Cancer PartnershipEverett98201NCT04511013Map
WAProvidence Regional Cancer PartnershipEverett98201NCT05647265Map
WANorthwest Medical SpecialtiesFederal Way98003NCT02693535Map
WANorthwest Medical SpecialtiesGig Harbor98332NCT02693535Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT04511013Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05647265Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05112601Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT04511013Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT05647265Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT03866382Map
WAProvidence Regional Cancer System-LaceyLacey98503NCT04511013Map
WAProvidence Regional Cancer System-LaceyLacey98503NCT05647265Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT04511013Map
WAPeaceHealth Saint John Medical CenterLongview98632NCT05647265Map
WASkagit Regional Health Cancer Care CenterMount Vernon98274NCT05647265Map
WANorthwest Medical SpecialtiesOlympia98502NCT02693535Map
WAJefferson HealthcarePort Townsend98368NCT04511013Map
WANorthwest Medical SpecialtiesPuyallup98373NCT02693535Map
WAValley Medical CenterRenton98055NCT05647265Map
WAValley Medical CenterRenton98055NCT03866382Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06581406Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06743126Map
WAFred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010Seattle98109-4405NCT05584670Map
WASwedish Cancer InstituteSeattle98104NCT02693535Map
WASwedish Medical Center-Ballard CampusSeattle98107NCT04511013Map
WASwedish Medical Center-Ballard CampusSeattle98107NCT05647265Map
WASwedish Medical Center-Cherry HillSeattle98122-5711NCT04511013Map
WASwedish Medical Center-Cherry HillSeattle98122-5711NCT05647265Map
WASwedish Medical Center-First HillSeattle98122NCT04511013Map
WASwedish Medical Center-First HillSeattle98122NCT05647265Map
WASwedish Medical Center-First HillSeattle98122NCT05112601Map
WAVirginia Mason Medical CenterSeattle98101NCT05327686Map
WAPeaceHealth United General Medical CenterSedro-Woolley98284NCT04511013Map
WAPeaceHealth United General Medical CenterSedro-Woolley98284NCT05647265Map
WAProvidence Regional Cancer System-SheltonShelton98584NCT04511013Map
WACancer Care Northwest - Spokane SouthSpokane99202NCT05647265Map
WACancer Care Northwest-North SpokaneSpokane99218NCT05647265Map
WACancer Care Northwest-ValleySpokane99216NCT05647265Map
WANorthwest Medical SpecialtiesTacoma98405NCT02693535Map
WANorthwest Medical SpecialtiesTacoma98405NCT06047379Map
WAPeaceHealth Southwest Medical CenterVancouver98664NCT04511013Map
WAPeaceHealth Southwest Medical CenterVancouver98664NCT05647265Map
WAProvidence Saint Mary Regional Cancer CenterWalla Walla99362NCT04511013Map
WAProvidence Saint Mary Regional Cancer CenterWalla Walla99362NCT05647265Map
WANorth Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima98902NCT05647265Map
WAProvidence Regional Cancer System-YelmYelm98597NCT04511013Map
WVEdwards Comprehensive Cancer CenterHuntington25701NCT05327686Map
WVWest Virginia University HealthcareMorgantown26506NCT05904080Map
WVCamden Clark Medical CenterParkersburg26101NCT05904080Map
WILanglade Hospital and Cancer CenterAntigo54409NCT05327686Map
WILanglade Hospital and Cancer CenterAntigo54409NCT04511013Map
WIDuluth Clinic AshlandAshland54806NCT05327686Map
WIDuluth Clinic AshlandAshland54806NCT03866382Map
WIDuluth Clinic AshlandAshland54806NCT05112601Map
WIDuluth Clinic AshlandAshland54806NCT07166406Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT05327686Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT05112601Map
WINorthwest Wisconsin Cancer CenterAshland54806NCT07166406Map
WIAurora Cancer Care - BurlingtonBurlington53105NCT02693535Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT03866382Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05327686Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04511013Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05904080Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT03866382Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT07166406Map
WIMayo Clinic Health System-Eau Claire ClinicEau Claire54701NCT03866382Map
WIAurora Health Care - Germantown Health CenterGermantown53022NCT02693535Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT03866382Map
WIAurora Cancer Care - GraftonGrafton53024NCT02693535Map
WIAurora Cancer Care-GraftonGrafton53024NCT03866382Map
WIAurora BayCare Medical CenterGreen Bay54311NCT02693535Map
WIAurora BayCare Medical CenterGreen Bay54311NCT03866382Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05327686Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05327686Map
WIEssentia Health-Hayward ClinicHayward54843NCT05327686Map
WIEssentia Health-Hayward ClinicHayward54843NCT07166406Map
WIAurora Cancer Care - Kenosha SouthKenosha53142NCT02693535Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT03866382Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04511013Map
WIUniversity of Wisconsin Carbone Cancer CenterMadison53792NCT04511013Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05327686Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05327686Map
WIUniversity Of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT06581406Map
WIAurora Bay Area Medical CenterMarinette54143NCT02693535Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT03866382Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05327686Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04511013Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05904080Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT03866382Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT07166406Map
WIAspirus Medford HospitalMedford54451NCT04511013Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT05327686Map
WIAurora Cancer Care MilwaukeeMilwaukee53209NCT02693535Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT03866382Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT03866382Map
WIAurora Sinai Medical CenterMilwaukee53223NCT02693535Map
WIAurora Sinai Medical CenterMilwaukee53233NCT03866382Map
WIAurora St. Luke's Medical CenterMilwaukee53215NCT02693535Map
WIAurora West Allis Medical CenterMilwaukee53227NCT02693535Map
WIExelixis Clinical Site #33Milwaukee53226NCT05176483Map
WIMedical College of WisconsinMilwaukee53226NCT05327686Map
WIMarshfield Clinic-Minocqua CenterMinocqua54548NCT04511013Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05327686Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05904080Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT03866382Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05327686Map
WIProHealth D N Greenwald CenterMukwonago53149NCT03866382Map
WIProHealth D N Greenwald CenterMukwonago53149NCT07166406Map
WICancer Center of Western WisconsinNew Richmond54017NCT05327686Map
WICancer Center of Western WisconsinNew Richmond54017NCT04511013Map
WIDrexel Town Square Health CenterOak Creek53154NCT05327686Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05327686Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT03866382Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT07166406Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT02693535Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT03866382Map
WIAurora Cancer Care - RacineRacine53406NCT02693535Map
WIAurora Cancer Care-RacineRacine53406NCT03866382Map
WIAspirus Cancer Care - James Beck Cancer CenterRhinelander54501NCT05327686Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05327686Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT04511013Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05904080Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT03866382Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT07166406Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05327686Map
WIVince Lombardi Cancer CenterSheboygan53081NCT02693535Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT03866382Map
WIEssentia Health-Spooner ClinicSpooner54801NCT05327686Map
WIEssentia Health-Spooner ClinicSpooner54801NCT07166406Map
WIAscension Saint Michael's HospitalStevens Point54481NCT04511013Map
WIAspirus Cancer Care - Stevens PointStevens Point54481NCT05327686Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05327686Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04511013Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05904080Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT03866382Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT07166406Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05327686Map
WIAurora Medical Center in SummitSummit53066NCT02693535
WIAurora Medical Center in SummitSummit53066NCT03866382
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT05327686Map
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT07166406Map
WIVince Lombardi Cancer Clinic - Two RiversTwo Rivers54241NCT02693535Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT03866382Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT03866382Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05327686Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT03866382Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT07166406Map
WIAspirus Regional Cancer CenterWausau54401NCT05327686Map
WIAspirus Regional Cancer CenterWausau54401NCT04511013Map
WIAurora Cancer Care - Milwaukee WestWauwatosa53226NCT02693535Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT03866382Map
WIAurora West Allis Medical CenterWest Allis53227NCT03866382Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT05327686Map
WIMarshfield Medical Center - WestonWeston54476NCT05327686Map
WIMarshfield Medical Center - WestonWeston54476NCT04511013Map
WIMarshfield Medical Center - WestonWeston54476NCT05904080Map
WIMarshfield Medical Center - WestonWeston54476NCT03866382Map
WIMarshfield Medical Center - WestonWeston54476NCT07166406Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT05327686Map
WIAspirus Cancer Care - Wisconsin RapidsWisconsin Rapids54494NCT04511013Map
WYCheyenne Regional Medical Center-WestCheyenne82001NCT04511013Map
WYBillings Clinic-CodyCody82414NCT04511013Map
WYWelch Cancer CenterSheridan82801NCT04511013Map

Ipilimumab clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedterminatedwithdrawnsuspendednot yet recruitingunknownno longer availableTotal
Early P12242111
P11926904010148198
P1/P220174923814122
P2526513747141523344
P2/P32332111
P361635211364
P421317
N/A541912334

Recruiting Ipilimumab clinical trials (120)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT05732389RESET-RImmunotherapy in Patients With Early dMMR Rectal CancerP2Cancer of Rectum39Feb 2023
NCT02498756Cytokine-induced Killer Study for Patients With Stage II MelanomaP2Melanoma300Aug 2015
NCT06999980Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)P2Cutaneous Melanoma494Feb 2026
NCT06492421Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.P2Lung Cancer90Jul 2024
NCT06482801Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITP2Liver Cancer90Jun 2024
NCT05187338Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsP1/P2Lung Cancer100Nov 2021
NCT07403877TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerP2Colorectal Cancer (MSI-H)114Feb 2026
NCT06240143MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaP1/P2Melanoma96Mar 2024
NCT04248569DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaP1Fibrolamellar Hepatocellular Carcinoma (FLC)56Apr 2020
NCT07383441Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerP3Advanced Clear Cell Renal Cell Carcinoma718Jun 2026
NCT07444619A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasP1Soft Tissue Sarcomas18Aug 2026
NCT07230613NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized MelanomaP2Cutaneous Melanoma, Stage III50Jan 2026
NCT06492408Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.P2Hepatic Cancer90Jul 2024
NCT06483347Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via ITP2Lung Cancer90Apr 2024
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaP2Advanced Clear Cell Renal Cell Carcinoma18Apr 2026
NCT03815890BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IOP2Breast Cancer80Oct 2019
NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.P3Advanced Kidney Cancer142Apr 2026
NCT06683755TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)P1/P2Melanoma30May 2025
NCT03521830Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaP2Basal Cell Carcinoma57Nov 2018
NCT05112601Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaP2Endometrial Adenocarcinoma81Jun 2022
NCT07355205FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerP2Non-small Cell Lung Cancer Stage IV26Jun 2026
NCT06364631CARE1CARE1 Pragmatic Clinical TrialP3Metastatic Kidney Cancer1,250Apr 2024
NCT06794775SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaP3Malignant Melanoma Stage III128Jul 2025
NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaP1Peripheral T Cell Lymphoma21Jan 2024
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaP1B-Cell Non-Hodgkin Lymphoma99Apr 2017
NCT03026140NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerP2Colon Carcinoma353Mar 2017
NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsP1/P2Advanced Solid Tumors361Sep 2022
NCT07293351RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)P1/P2Advanced Renal Cell Carcinoma (RCC)254Mar 2026
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3Melanoma, Cutaneous Malignant360Jan 2025
NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaP2/P3Metastatic Uveal Melanoma280Dec 2024
NCT07291076HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)P1/P2Hepatocellular Carcinoma (HCC)198Mar 2026
NCT06866262Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialP1/P2Locally Advanced Clear Cell Renal Cell Carcinoma55Aug 2025
NCT06968988Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaP1Metastatic Soft-tissue Sarcoma18Jan 2026
NCT03138161SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaP1/P2Advanced Soft Tissue Sarcoma250Apr 2017
NCT07061379PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenPROMs144Jul 2025
NCT07504796ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabP4Metastatic Melanoma90Apr 2026
NCT07587827ODI-2001-01Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerP1Metastatic Colorectal Cancer (CRC)77Nov 2026
NCT06624644A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaP2/P3Melanoma (Skin Cancer)135Aug 2025
NCT07188896RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)P2Advanced Renal Cell Carcinoma (aRCC)120Apr 2026
NCT06926790GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)P2Lung Cancer - Non Small Cell69Feb 2025
NCT07430202FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)P1Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))27Aug 2026
NCT06365619NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaP2Melanoma25Jun 2026
NCT05176483STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsP1Renal Cell Carcinoma (RCC)1,314Dec 2021
NCT06889493NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)P1Neuroendocrine Carcinoma36May 2025
NCT06342037TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialP2Metastatic Breast Cancer60Jun 2024
NCT04665206Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsP1/P2Solid Tumor, Adult434Mar 2021
NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesP2Melanoma60Aug 2025
NCT07401875SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)P1Phase 1b35Mar 2026
NCT04562129IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsP2Melanoma Stage III29Sep 2020
NCT07563738TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212P1/P2Mesothelioma229Mar 2026
NCT03340129ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)P2Melanoma Stage Iv218Aug 2019
NCT03899155Pan Tumor Rollover StudyP2Cancer1,500Aug 2019
NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerP1Diffuse Pleural Mesothelioma60Apr 2026
NCT07501117Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaP1Uveal Melanoma15May 2026
NCT07422753A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCP2Hepatocellular Carcinoma (HCC)36Mar 2026
NCT05536141ARC-20A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsP1Clear Cell Renal Cell Carcinoma362Oct 2022
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3Advanced Hepatocellular Carcinoma226Feb 2026
NCT07233668IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCN/AMetastatic Renal Cell Carcinoma ( mRCC)172Dec 2025
NCT06747845ParpVax2Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyP2Pancreatic Adenocarcinoma Metastatic68May 2025
NCT06941857NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerP2Pancreatic Cancer20Sep 2025
NCT06362369A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyP1/P2Advanced Cancer126Aug 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4Oncology776Sep 2023
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2Lymphoma, Non-Hodgkin4,200Mar 2016
NCT06708949RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)P2Renal Cell Carcinoma, Clear Cell15Mar 2025
NCT06295159Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaP2Melanoma Stage III90May 2024
NCT07227012Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.P1/P2Carcinoma, Hepatocellular138Dec 2025
NCT07147101HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentAdvanced Hepatocellular Carcinoma (HCC)150Sep 2025
NCT06490536The Sagittarius TrialP3Colon Cancer Stage II700Oct 2024
NCT07128680EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerP1Advanced Clear Cell Renal Cell Carcinoma33Mar 2026
NCT07506109A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerP2BRAF V600E49Mar 2026
NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaP1/P2Unresectable Hepatocellular Carcinoma33Feb 2026
NCT06514651MAQ-001 in Patients With Advanced Solid TumorsP1Advanced Solid Tumor30Jun 2024
NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsP1/P2Solid Tumor542Nov 2022
NCT05904080Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerP2Metastatic Nasopharyngeal Carcinoma50Feb 2024
NCT05327686SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialP2Metastatic Renal Cell Carcinoma240Feb 2023
NCT03563729MEMBRAINSMelanoma Metastasized to the Brain and SteroidsP2Malignant Melanoma80Jun 2018
NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaP2HCC - Hepatocellular Carcinoma43Mar 2026
NCT05492123Nivolumab-ipilimumab and Chemoradiation for Cervical CancerP2Uterine Cervical Neoplasms112Aug 2022
NCT07422779MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaN/AMetastatic Melanoma100Mar 2022
NCT03816345Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOP1Autoimmune Disease300Jul 2019
NCT07487662ACTION-001TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskP2Hepato Cellular Carcinoma (HCC)105Mar 2026
NCT07394062ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)Nonsmall Cell Lung Cancer, Stage IV400Feb 2026
NCT05428007Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaP2Melanoma105Feb 2023
NCT07134842WinGlio-ipiA Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.P1Glioblastoma16Jul 2025
NCT05779423Cryoablation+Ipilimumab+Nivolumab in MelanomaP2Metastatic Melanoma37Sep 2023
NCT07075120Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerP1Hepatocellular Carcinoma (HCC)15Apr 2026
NCT07155317Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialP2Advanced Acral Melanoma99Oct 2025
NCT05048212A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesP2Brain Metastases20Sep 2022
NCT04697576Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaP1Clinical Stage I Cutaneous Melanoma AJCC v836Oct 2021
NCT03646617RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaP2Metastatic Melanoma54Nov 2018
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2Cancer1,550Aug 2016
NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerP1Squamous Cell Carcinoma of the Head and Neck50Nov 2018
NCT03406247ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaP2Head and Neck Squamous Cell Carcinoma140Feb 2018
NCT06364917DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCP2Non Small Cell Lung Cancer24May 2025
NCT06594991A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaP2Advanced Melanoma88Sep 2024
NCT05310643NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCP2Metastatic Colorectal Cancer30May 2022
NCT05498792Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaEarly P1Locally Advanced or Metastatic Melanoma12Nov 2022
NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaP2Hepatocellular Carcinoma35Aug 2020
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisP1/P2Diffuse Astrocytoma, IDH-Mutant134Nov 2023
NCT05361720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyP2Advanced Clear Cell Renal Cell Carcinoma54Dec 2022
NCT04511013A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesP2Acral Lentiginous Melanoma112Jan 2021
NCT05384496Axitinib and Nivolumab for the Treatment of Mucosal MelanomaP2Mucosal Melanoma20May 2022
NCT05715229G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyP2Carcinoma, Non-Small-Cell Lung108Sep 2023
NCT05597800LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeP2NSCLC Stage IV105Feb 2023
NCT04996823Axitinib + Ipilimumab in Advanced MelanomaP2Melanoma25Aug 2021
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsP2Bladder Adenocarcinoma314May 2019
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2Lung Non-Small Cell Carcinoma25May 2023
NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerP1/P2Clinical Stage III Cutaneous Melanoma AJCC v816Jul 2024
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2Lymphoma, Non-Hodgkin720Mar 2018
NCT04464759LIMITA Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaP1/P2Melanoma94Oct 2020
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerP1Anatomic Stage I Breast Cancer AJCC v818Dec 2025
NCT06353646XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerN/APancreatic Cancer28Mar 2024
NCT05188118Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell CarcinomaEarly P1Renal Cell Carcinoma20Feb 2023
NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaP2Pleural Biphasic Mesothelioma26Nov 2024
NCT06399419CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerP1Advanced Clear Cell Renal Cell Carcinoma28Jun 2024
NCT04933903LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabP2Non Small Cell Lung Cancer25Oct 2021
NCT03844256CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyP1/P2Urinary Bladder Cancer50Jan 2019
NCT06163820BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesP1/P2Melanoma Brain Metastases46May 2025
NCT03707808myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabP1/P2Solid Tumor18Jan 2018
NCT04823403HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaP1Hepatocellular Carcinoma27Nov 2020

Ipilimumab clinical trials by indication

Melanoma (94)

NCTAcronymPhaseStatusTitle
NCT02498756P2not yet recruitingCytokine-induced Killer Study for Patients With Stage II Melanoma
NCT04196452DMTRN/Aactive not recruitingA Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
NCT06240143MARIANEP1/P2recruitingIntradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
NCT06683755TRINITYP1/P2not yet recruitingPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
NCT06365619NeoRelapseP2recruitingNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
NCT03999749P2active not recruitingA Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT06712927P2recruitingTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
NCT02374242ABCP2active not recruitingAnti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
+ 86 more, see All trials below.

Metastatic Melanoma (39)

NCTAcronymPhaseStatusTitle
NCT07504796P4recruitingctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NCT07422779MAKN/ArecruitingImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
NCT05779423P2recruitingCryoablation+Ipilimumab+Nivolumab in Melanoma
NCT03646617RadVaxP2recruitingIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT03122522P2active not recruitingA Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
NCT03645928P2terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT01701674N/AcompletedIpilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
NCT05704933Early P1completedPilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
+ 31 more, see All trials below.

Renal Cell Carcinoma (16)

NCTAcronymPhaseStatusTitle
NCT05148546NESCIOP2active not recruitingNeoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
NCT03873402P3active not recruitingA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03937219COSMIC-313P3active not recruitingStudy of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT05188118Early P1recruitingRapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
NCT05501054P1/P2active not recruitingPhase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
NCT03141177CheckMate 9ERP3active not recruitingA Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT04074967P1/P2active not recruitingStudy of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
NCT03297593P2completedNivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
+ 8 more, see All trials below.

Prostate Cancer (15)

NCTAcronymPhaseStatusTitle
NCT03061539P2active not recruitingNivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
NCT01688492P1/P2active not recruitingCombining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
NCT02985957CheckMate 650P2completedA Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
NCT02601014STARVE-PCP2completedBiomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
NCT01804465CTLA-4P2completedSipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
NCT02113657Early P1completedT-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
NCT02423928CryoITP1completedPhase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
NCT01530984P2withdrawnIpilimumab and GMCSF Immunotherapy for Prostate Cancer
+ 7 more, see All trials below.

Malignant Melanoma (14)

NCTAcronymPhaseStatusTitle
NCT03563729MEMBRAINSP2recruitingMelanoma Metastasized to the Brain and Steroids
NCT02068196Ipi4P4active not recruitingA National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
NCT04223648MEDI4736Early P1withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
NCT04382664P2completedUV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT02523313P2completedImmunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
NCT02275416P1/P2completedSafety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
NCT01024231MDX-1106P1completedDose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT02272855P2completedA Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
+ 6 more, see All trials below.

Advanced Cancer (12)

NCTAcronymPhaseStatusTitle
NCT06362369P1/P2recruitingA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT03459222P1/P2completedAn Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
NCT03369223P1/P2completedA Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
NCT03110107P1/P2terminatedFirst-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
NCT04270864PRIMOP1terminatedIntratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
NCT03444753P1terminatedAn Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
NCT02996110FRACTION-RCCP2completedA Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
NCT02658890P1/P2completedAn Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
+ 4 more, see All trials below.

Non-Small Cell Lung Cancer (11)

NCTAcronymPhaseStatusTitle
NCT06946797CheckMate-1533P2active not recruitingA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT02259621NA_00092076P2active not recruitingNeoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT07526961N/AcompletedReal-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
NCT02477826CheckMate 227P3completedAn Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT03215706CheckMate 9LAP3completedA Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03001882CheckMate 592P2completedAn Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT03953235P1/P2completedA Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
NCT05005273P2completedA Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
+ 3 more, see All trials below.

Pancreatic Cancer (11)

NCTAcronymPhaseStatusTitle
NCT06941857P2recruitingNC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT06353646N/ArecruitingXH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NCT05721846CheckVACP1active not recruitingNivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
NCT04361162P2active not recruitingNivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
NCT05014776P2completedStudy of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
NCT05116917INFLUENCEP2terminatedImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
NCT03190265P2completedStudy of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
NCT04258150TRIPPLE-RP2terminatedIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
+ 3 more, see All trials below.

Non Small Cell Lung Cancer (11)

NCTAcronymPhaseStatusTitle
NCT05012254NIVIPI-BrainP2active not recruitingNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
NCT06364917DISCERNP2recruitingDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
NCT04933903LOWP2recruitingBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
NCT03377023P1/P2active not recruitingPhase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
NCT03520686P3terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT04966676ATLASP2terminatedStudy of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
NCT02998528CheckMate 816P3completedA Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
NCT04571632LuscidP2unknownClinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
+ 3 more, see All trials below.

Cancer (11)

NCTAcronymPhaseStatusTitle
NCT03899155P2recruitingPan Tumor Rollover Study
NCT02925234DRUPP2recruitingThe Drug Rediscovery Protocol (DRUP Trial)
NCT04300244NIPUP2active not recruitingNivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
NCT03400332P1/P2completedA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
NCT04319224JTX-2011P1/P2terminatedVopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
NCT03989362EMERGEP2completedVopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
NCT03251924P1/P2terminatedA Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
NCT02467361P1completedA Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
+ 3 more, see All trials below.

Advanced Melanoma (10)

NCTAcronymPhaseStatusTitle
NCT04462406P2active not recruitingUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT06594991P2recruitingA Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
NCT01134614P2active not recruitingIpilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT04495257RCCP1completedA Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT07079644N/AcompletedOutcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
NCT04894994P2terminatedFLX475 in Combination With Ipilimumab in Advanced Melanoma
NCT01621490PD-1P1completedPH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT02224768N/AcompletedYERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
+ 2 more, see All trials below.

Solid Tumor (9)

NCTAcronymPhaseStatusTitle
NCT05584670P1/P2recruitingA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
NCT03707808myDAvIpNiP1/P2recruitingIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
NCT05284214SALIENTP2withdrawnSargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
NCT03647163P1/P2active not recruitingPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
NCT03195478P1/P2completedA Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
NCT03865082ILLUMINATE-206P2active not recruitingStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
NCT03013491PROCLAIM-CX-072P1/P2terminatedPROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
NCT03993379PROCLAIMP2terminatedPROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
+ 1 more, see All trials below.

Breast Cancer (9)

NCTAcronymPhaseStatusTitle
NCT03815890BELLINIP2recruitingPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
NCT03546686P2active not recruitingPeri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT03789110NIMBUSP2active not recruitingNIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT04591431ROMEP2unknownThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
NCT02833233N/AcompletedA Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
NCT03818685BreastImmune03P2unknownEvaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
NCT04132817P1completedA Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
NCT03409198ICONP2completedPhase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer
+ 1 more, see All trials below.

Mesothelioma (8)

NCTAcronymPhaseStatusTitle
NCT07563738TEADCOP1/P2recruitingA 2-part Phase 1/2 Open-label Trial on ODM-212
NCT03907852TC-210P1/P2active not recruitingPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
NCT03918252P2active not recruitingNeoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT04334759DREAM3RP3completedDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT02899299CheckMate743P3completedStudy of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
NCT05041062P2completedA Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
NCT04840615P1terminatedIntratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
NCT02716272MAPS2P2completedNivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Glioblastoma (8)

NCTAcronymPhaseStatusTitle
NCT07134842WinGlio-ipiP1recruitingA Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
NCT04606316P1active not recruitingSurgical Nivolumab And Ipilimumab For Recurrent GBM
NCT03233152GlitIpNiP1/P2active not recruitingA Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
NCT04817254ICIP2completedAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
NCT05074992NeAT GlioP2terminatedA Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
NCT03422094P1terminatedNeoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT03707457P1terminatedBiomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
NCT03460782N/Ano longer availableAn Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Lung Cancer (8)

NCTAcronymPhaseStatusTitle
NCT06492421P2recruitingNeoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT05187338P1/P2recruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT06483347P2recruitingCheckpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT03575793P1/P2completedA Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
NCT02869789P4completedAn Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02538666CheckMate 451P3completedAn Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
NCT03256136P2completedNivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT00527735NSCLCP2completedPhase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (8)

NCTAcronymPhaseStatusTitle
NCT04472767P2recruitingCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04039607CheckMate 9DWP3active not recruitingA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT04823403HIPANIVP1recruitingHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
NCT01658878CheckMate040P1/P2completedAn Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
NCT05220722P1/P2terminatedPressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
NCT03682276PRIME-HCCP1/P2unknownSafety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma
NCT03222076P2completedNivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
NCT03203304SBRTP1terminatedStereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

Uveal Melanoma (7)

NCTAcronymPhaseStatusTitle
NCT07501117P1not yet recruitingNeoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
NCT03070392P2completedSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT04463368SCANDIUM IIP1completedIsolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
NCT02913417P1/P2unknownYttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
NCT03922880P1completedStudy of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
NCT02626962GEM1402P2completedTrial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
NCT03408587CLEVERP1completedCAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Clinical Stage III Cutaneous Melanoma AJCC v8 (7)

NCTAcronymPhaseStatusTitle
NCT04940299P2active not recruitingTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT05896839P1/P2recruitingImmunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT02506153P3active not recruitingPhysician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02224781P3active not recruitingDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT03816332P1active not recruitingTacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
NCT04967196P1terminatedIpilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
NCT03033576P2completedTesting Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Advanced Clear Cell Renal Cell Carcinoma (6)

NCTAcronymPhaseStatusTitle
NCT07383441P3recruitingAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
NCT07510334P2recruitingVSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT07000149eVOLVE-RCC02P3active not recruitingA Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
NCT07128680EXL01P1recruitingImmunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
NCT05361720P2recruitingGenetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
NCT06399419P1recruitingCBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Carcinoma, Non-Small-Cell Lung (6)

NCTAcronymPhaseStatusTitle
NCT05715229G360-IITP2recruitingImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT05401786RAD-IOP2active not recruitingAnti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
NCT03083691BIOLUMAP2completedBIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
NCT03302234NSCLCP3completedStudy of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
NCT03262779P2completedIpilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
NCT03663166NSCLCP1/P2terminatedRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Advanced Malignant Solid Neoplasm (6)

NCTAcronymPhaseStatusTitle
NCT04317105P1/P2active not recruitingTesting the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04021043BMS-986156P1/P2completedBMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
NCT02419495KPT-330P1terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02408861P1terminatedNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01738139P1completedIpilimumab and Imatinib Mesylate in Advanced Cancer
NCT03326258P1/P2withdrawnGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Non-small Cell Lung Cancer (6)

NCTAcronymPhaseStatusTitle
NCT03285321NSCLCP2completedUnresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
NCT03573947TOP1705P2completedPhase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
NCT03425331P2terminatedBiomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NCT01454102BMS-936558P1completedStudy of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT03509584P1terminatedPhase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
NCT01998126P1completedCombination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Malignant Melanoma Stage III (5)

NCTAcronymPhaseStatusTitle
NCT06794775SWE-NEOP3recruitingSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
NCT04949113NADINAP3active not recruitingNeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT02977052OpACIN-neoP2unknownOptimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
NCT04133948DONIMIP1/P2completedMulticenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
NCT01302496TriMix-IpiP2completedAutologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma (Skin) (5)

NCTAcronymPhaseStatusTitle
NCT06377111P1active not recruitingA Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
NCT01176474P1completedVaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
NCT03949153CRIRINP1/P2completedCryotherapy With in Situ Immunotherapy in Melanoma Metastasis
NCT00077532P2completedMonoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
NCT00357461P2withdrawnIpilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma Stage III (5)

NCTAcronymPhaseStatusTitle
NCT04562129P2recruitingIL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT06295159P2recruitingNeoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT04013854P2active not recruitingAdjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04007588BMS-986205P2withdrawnA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT03153085HF10P2completedA Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

Clear Cell Renal Cell Carcinoma (5)

NCTAcronymPhaseStatusTitle
NCT05536141ARC-20P1recruitingA Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT03793166P3active not recruitingImmunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT02210117Early P1active not recruitingNivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
NCT06049576P1active not recruitingNivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT03149159P2withdrawnInvestigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Advanced Renal Cell Carcinoma (5)

NCTAcronymPhaseStatusTitle
NCT05928806ARCITECTP2suspendedAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT02231749P3completedNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT03117309P2completedStudy of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03829111CBM588P1completedCBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
NCT04203901P2terminatedDendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Recurrent Melanoma (5)

NCTAcronymPhaseStatusTitle
NCT01708941P2active not recruitingIpilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT02203604P2terminatedHigh-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
NCT01970527P2terminatedPhase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
NCT01703507P1completedPhase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
NCT00871481P1/P2completedLaboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Hepatocellular Carcinoma (HCC) (4)

NCTAcronymPhaseStatusTitle
NCT07291076HCCP1/P2recruitingA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07422753P2recruitingA Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
NCT07075120P1recruitingIpilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
NCT03510871HCCP2completedNivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Metastatic Renal Cell Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT05327686SAMURAIP2recruitingTesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT04090710CYTOSHRINKP2active not recruitingSBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
NCT03075423P2completedRandomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
NCT03126331P2completedIntermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Advanced Solid Tumors (4)

NCTAcronymPhaseStatusTitle
NCT05533697P1/P2recruitingStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05407675P1/P2completedA Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
NCT03461952NIMBLeP2terminatedNivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
NCT03525795P1completedORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Urothelial Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT05200988Indi-BladeP2active not recruitingCheckpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
NCT03387761NABUCCOP1completedNeo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
NCT01524991P2completedFirst-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
NCT00362713P1completedStudy of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

Gastric Cancer (4)

NCTAcronymPhaseStatusTitle
NCT05144854P3active not recruitingA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT02872116CheckMate649P3completedEfficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT03784040da VINciP1unknownNivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
NCT03409848INTEGAP2completedIpilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Squamous Cell Carcinoma of the Head and Neck (4)

NCTAcronymPhaseStatusTitle
NCT03690986P1recruitingVX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
NCT02812524P1active not recruitingIpilimumab for Head and Neck Cancer Patients
NCT04290546P1completedCIML NK Cell in Head & Neck Cancer
NCT04326257P2completedPersonalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Small Cell Lung Cancer (4)

NCTAcronymPhaseStatusTitle
NCT03670056P2active not recruitingIpilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
NCT03043599P1/P2completedIpilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
NCT03406715SCLCP2terminatedCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
NCT03026166P1/P2terminatedA Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Head and Neck Cancer (4)

NCTAcronymPhaseStatusTitle
NCT02919683P2active not recruitingWindow Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
NCT03700905IMSTAR-HNP3unknownStudy of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
NCT02741570CheckMate 651P3completedStudy of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02823574CheckMate 714P2completedStudy of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Intraocular Melanoma (4)

NCTAcronymPhaseStatusTitle
NCT00084656P2completedMonoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
NCT00058279P1/P2completedMonoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00032045P2completedVaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00025181P1completedMonoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Cutaneous Melanoma (3)

NCTAcronymPhaseStatusTitle
NCT06999980Neo IRENIEP2recruitingNeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
NCT03929029P1active not recruitingNeoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
NCT02519322P2completedNeoadjuvant and Adjuvant Checkpoint Blockade

Colorectal Cancer (3)

NCTAcronymPhaseStatusTitle
NCT04117087P1active not recruitingPooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT06410534P2withdrawnA Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
NCT03377361CheckMate 9N9P1/P2completedAn Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Metastatic Uveal Melanoma (3)

NCTAcronymPhaseStatusTitle
NCT06581406P2/P3recruitingA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT05987332P2/P3active not recruitingIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT01585194P2completedNivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Non-small Cell Lung Cancer (NSCLC) (3)

NCTAcronymPhaseStatusTitle
NCT06487156FINNN/Aactive not recruitingA Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07215962N/Aactive not recruitingLong-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
NCT02221739NSCLCP1/P2completedStudy of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Advanced Solid Tumor (3)

NCTAcronymPhaseStatusTitle
NCT06514651P1recruitingMAQ-001 in Patients With Advanced Solid Tumors
NCT05933265P1/P2active not recruitingStudy of LP-184 in Patients With Advanced Solid Tumors
NCT04855929ANV419-001P1completedA Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Brain Metastases (3)

NCTAcronymPhaseStatusTitle
NCT05048212P2recruitingA Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT03458455TREATMENTN/AunknownImproved Therapy Response Assessment in Metastatic Brain Tumors
NCT02460068NIBIT-M2P3unknownA Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Metastatic Colorectal Cancer (3)

NCTAcronymPhaseStatusTitle
NCT05310643NIPIRESCUEP2recruitingNivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NCT04008030CheckMate 8HWP3active not recruitingA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT03832621MAYAP2completedNIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer

Colorectal Cancer Metastatic (3)

NCTAcronymPhaseStatusTitle
NCT04730544NIPISAFEP2active not recruitingTwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
NCT04721301P1completedIpilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
NCT03982121ISILIP1withdrawnStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Sarcoma (3)

NCTAcronymPhaseStatusTitle
NCT03463408Early P1active not recruitingImmunotherapy + Radiation in Resectable Soft Tissue Sarcoma
NCT04741438RAR-ImmuneP3unknownEfficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
NCT01445379P1completedPhase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Recurrent Glioblastoma (3)

NCTAcronymPhaseStatusTitle
NCT04003649P1active not recruitingIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
NCT02017717CheckMate 143P3completedA Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
NCT03430791P2terminatedTrial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Merkel Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT03071406P2active not recruitingRandomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
NCT03798639P1completedNivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
NCT01913691P2withdrawnStudy of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Metastatic Cancer (3)

NCTAcronymPhaseStatusTitle
NCT03693014P2active not recruitingA Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
NCT03453892ST-ICIN/AcompletedInvestigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
NCT03009058MODULATEP1/P2terminatedStudy of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Advanced Malignancies (3)

NCTAcronymPhaseStatusTitle
NCT03233139P1active not recruitingSafety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
NCT03126110P1/P2completedPhase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT03241173P1/P2completedA Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Various Advanced Cancer (3)

NCTAcronymPhaseStatusTitle
NCT03143153CheckMate 648P3completedA Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
NCT02488759CheckMate358P1/P2completedAn Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
NCT03130959CheckMate 908P2completedA Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

Advanced Renal Cell Carcinoma (aRCC) (2)

NCTAcronymPhaseStatusTitle
NCT07188896RCCP2recruitingA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT06345183N/AcompletedReal-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

HCC - Hepatocellular Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT07560488P2recruitingIpilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT05665348TRIPLETP2/P3completedStudy Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Cutaneous Melanoma, Stage III (2)

NCTAcronymPhaseStatusTitle
NCT07230613NEOREM-NEO-1P2recruitingNeo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT03719131P2active not recruitingRituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Metastatic Soft-tissue Sarcoma (2)

NCTAcronymPhaseStatusTitle
NCT06968988P1recruitingZanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
NCT04551430P2active not recruitingCabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Neuroendocrine Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT06889493NECP1recruitingSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
NCT03591731NIPINECP2completedNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Lung Cancer - Non Small Cell (2)

NCTAcronymPhaseStatusTitle
NCT06926790GALAXY 3P2recruitingNeoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
NCT01471197P2terminatedSafety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Liver Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06482801P2recruitingCheckpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
NCT02239900SBRTP1completedIpilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

Cancer of Rectum (2)

NCTAcronymPhaseStatusTitle
NCT05732389RESET-RP2recruitingImmunotherapy in Patients With Early dMMR Rectal Cancer
NCT02948348P1/P2unknownStudy to Nivolumab Following Preoperative Chemoradiotherapy

Clinical Stage IV Cutaneous Melanoma AJCC v8 (2)

NCTAcronymPhaseStatusTitle
NCT03873818P2completedLow Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT05341349P1terminatedStereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Lung Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04929041P2/P3suspendedTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT03391869P3active not recruitingNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Urothelial Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03036098CheckMate901P3active not recruitingStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT05219435VEXILLUMP2completedStudy of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Mucosal Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT05384496P2recruitingAxitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT03241186P2active not recruitingIpilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Prostatic Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT05150236ANZUP2001P2unknownEVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
NCT02506114P2terminatedNeoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Adult Solid Tumor (2)

NCTAcronymPhaseStatusTitle
NCT04892043P1terminatedStudy of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
NCT04084951P1completedStudy of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Metastatic Pancreatic Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT04787991REVOLUTIONP1completedExploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT01896869P2completedFOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Metastatic Ovarian Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04611126P1/P2terminatedT-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
NCT03287674P1/P2completedTIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Solid Tumor, Adult (2)

NCTAcronymPhaseStatusTitle
NCT04665206P1/P2recruitingStudy to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT03728179RACINP1completedRACIN in Patients With Advanced TIL-negative Solid Tumors

Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT03739710NSCLCP2completedPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT06790303NSCLCP2terminatedPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Acral Lentiginous Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT04511013P2recruitingA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT02978443P2terminatedA Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Gliosarcoma (2)

NCTAcronymPhaseStatusTitle
NCT04396860P2/P3completedTesting the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT02311920P1completedIpilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Pancreatic Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT03816358P1active not recruitingTesting the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
NCT03404960ParpvaxP1/P2completedNiraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

Soft Tissue Sarcoma (2)

NCTAcronymPhaseStatusTitle
NCT04118166P2completedIpilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
NCT02982486P2unknownA Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Melanoma Stage Iv (2)

NCTAcronymPhaseStatusTitle
NCT03340129ABC-XP2recruitingAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
NCT03161756CHARLIP1/P2unknownEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Kidney Cancer (2)

NCTAcronymPhaseStatusTitle
NCT02950766P1active not recruitingNeoVax Plus Ipilimumab in Renal Cell Carcinoma
NCT00057889P2completedMonoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03502733P1active not recruitingTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
NCT00047164P1completedMonoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Metastatic Malignant Neoplasm in the Liver (2)

NCTAcronymPhaseStatusTitle
NCT03068624P1unknownAutologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
NCT03472586P2completedIpilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Bladder Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03520491P2active not recruitingA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
NCT02553642CA209-260P2completedRelationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Lymphoma, Non-Hodgkin (2)

NCTAcronymPhaseStatusTitle
NCT02693535TAPURP2recruitingTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT03297606CAPTURP2recruitingCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Carcinoma, Renal Cell (2)

NCTAcronymPhaseStatusTitle
NCT03138512CheckMate 914P3completedA Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
NCT02917772TITAN-RCCP2completedTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

B-Cell Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03017820P1recruitingA Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT01919619P2completedLenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Gastrointestinal Stromal Tumor (2)

NCTAcronymPhaseStatusTitle
NCT02880020P2completedNivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
NCT01643278P1completedDasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Advanced Cancers (2)

NCTAcronymPhaseStatusTitle
NCT02668770P1terminatedIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT01750983P1completedIpilimumab and Lenalidomide in Advanced Cancer

Recurrent Squamous Cell Lung Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT02785952P3active not recruitingLung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02154490N/AcompletedLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Unresectable Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT01927419CheckMate 069P2completedStudy of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT02115243P1completedTrial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Unresectable or Metastatic Melanoma (2)

NCTAcronymPhaseStatusTitle
NCT01844505P3completedPhase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
NCT01810016P1terminatedNY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Cervical Adenocarcinoma (2)

NCTAcronymPhaseStatusTitle
NCT01693783P2completedIpilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
NCT01711515P1completedChemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (2)

NCTAcronymPhaseStatusTitle
NCT00039091P1terminatedMonoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
NCT00060372P1completedIpilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Metastatic Colorectal Cancer (CRC) (1)

NCTAcronymPhaseStatusTitle
NCT07587827ODI-2001-01P1not yet recruitingStudy Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

Soft Tissue Sarcomas (1)

NCTAcronymPhaseStatusTitle
NCT07444619P1not yet recruitingA Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1)

NCTAcronymPhaseStatusTitle
NCT07430202FLCP1not yet recruitingA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Advanced Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07338981P3not yet recruitingThe Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Diffuse Pleural Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT07532902P1recruitingA Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Non-small Cell Lung Cancer Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT07355205FLINNP2not yet recruitingFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Advanced Renal Cell Carcinoma (RCC) (1)

NCTAcronymPhaseStatusTitle
NCT07293351RCCP1/P2recruitingA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1b (1)

NCTAcronymPhaseStatusTitle
NCT07401875SHARKP1recruitingA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Hepato Cellular Carcinoma (HCC) (1)

NCTAcronymPhaseStatusTitle
NCT07487662ACTION-001P2not yet recruitingTACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

BRAF V600E (1)

NCTAcronymPhaseStatusTitle
NCT07506109P2recruitingA Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Unresectable Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07482059P1/P2recruitingA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT07166406P3recruitingTesting Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Colorectal Cancer (MSI-H) (1)

NCTAcronymPhaseStatusTitle
NCT07403877TORCH-OPTIMAP2not yet recruitingNeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Nonsmall Cell Lung Cancer, Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT07394062ALCG-01N/ArecruitingReal-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Anatomic Stage I Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT06324240P1recruitingPersonalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Metastatic Renal Cell Carcinoma ( mRCC) (1)

NCTAcronymPhaseStatusTitle
NCT07233668IVE in mRCCN/Anot yet recruitingImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Carcinoma, Hepatocellular (1)

NCTAcronymPhaseStatusTitle
NCT07227012P1/P2recruitingSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Advanced Acral Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT07155317P2recruitingTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Advanced Hepatocellular Carcinoma (HCC) (1)

NCTAcronymPhaseStatusTitle
NCT07147101HCC-IM-1N/ArecruitingDifferent First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Very High Risk Prostate Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06388369NEPIP1/P2terminatedNeoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Locally Advanced Clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06866262P1/P2recruitingInulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Melanoma (Skin Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT06624644P2/P3recruitingA Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

PROMs (1)

NCTAcronymPhaseStatusTitle
NCT07061379PROMOTINGN/ArecruitingPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen

Melanoma Brain Metastases (1)

NCTAcronymPhaseStatusTitle
NCT06163820BETTERP1/P2recruitingBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Pancreatic Adenocarcinoma Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT06747845ParpVax2P2recruitingMaintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Renal Cell Carcinoma, Clear Cell (1)

NCTAcronymPhaseStatusTitle
NCT06708949RCCP2recruitingA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Melanoma, Cutaneous Malignant (1)

NCTAcronymPhaseStatusTitle
NCT06743126SUPRAMEP3recruitingSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Melanoma Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT06784648P1/P2active not recruitingDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Diffuse Hemispheric Glioma, H3 G34-Mutant (1)

NCTAcronymPhaseStatusTitle
NCT05457959P1withdrawnPeptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Pleural Biphasic Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT05647265P2recruitingTesting the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Metastatic Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07024862N/Aactive not recruitingLong-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Colon Cancer Stage II (1)

NCTAcronymPhaseStatusTitle
NCT06490536P3recruitingThe Sagittarius Trial

Hepatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06492408P2recruitingNeoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06342037TONIC-3P2recruitingNOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Metastatic Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06364631CARE1P3recruitingCARE1 Pragmatic Clinical Trial

ICB-refractory Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT06250335ICBP2active not recruitingImpact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

Metastatic Nasopharyngeal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05904080P2recruitingTesting Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Peripheral T Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06508463P1recruitingIntravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Healthy Male Volunteers (1)

NCTAcronymPhaseStatusTitle
NCT06159101P1unknownA Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Unresectable Pleural Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT06097728eVOLVE-MesoP3active not recruitingMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases (1)

NCTAcronymPhaseStatusTitle
NCT05504642CERAD-IMMUNEP2withdrawnChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

Diffuse Astrocytoma, IDH-Mutant (1)

NCTAcronymPhaseStatusTitle
NCT06047379P1/P2recruitingSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Locally Advanced Extraskeletal Myxoid Chondrosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05836571P2active not recruitingTesting Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

IDH1-mutant Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05921760P1/P2terminatedIvosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Oncology (1)

NCTAcronymPhaseStatusTitle
NCT06031233MINUTEP4recruitingEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Atypical Teratoid Rhabdoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05407441P1/P2active not recruitingTazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Lung Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05501665P1/P2recruitingSplit Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

NSCLC Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT05597800LUNGVIRP2not yet recruitingNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

BCLC Stage B Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05199285P2terminatedA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Gastroenteropancreatic Neuroendocrine Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05262556P1active not recruitingNP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Locally Advanced or Metastatic Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05498792Early P1recruitingStudy of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Leptomeningeal Metastasis (1)

NCTAcronymPhaseStatusTitle
NCT05598853IT-IOP1active not recruitingIntrathecal Double Checkpoint Inhibition

Uterine Cervical Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05492123P2recruitingNivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Melanoma, Ocular (1)

NCTAcronymPhaseStatusTitle
NCT05169957HAMMER IP1completedHepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Myeloproliferative Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05444530P1completedA Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04781855P1withdrawnIpilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Refractory Cutaneous Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT05200143P2terminatedStudy of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Endometrial Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT05112601P2recruitingTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Colonic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05456165P2withdrawnStudy of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05144529TOP2101P2terminatedA Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Osteosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT05302921P2completedNeoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Colorectal Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05141721P2/P3active not recruitingA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Locally Advanced Rectal Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04751370P2active not recruitingTesting Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Metastatic Malignant Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04840589P1suspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Mesothelioma, Malignant (1)

NCTAcronymPhaseStatusTitle
NCT05136677CheckMate 6DWP2completedA Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Stage IV Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05088889P1unknownMaintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Renal Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05215470CLARAP2active not recruitingCLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Renal Cell Carcinoma (RCC) (1)

NCTAcronymPhaseStatusTitle
NCT05176483STELLAR-002P1recruitingStudy of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Clinical Stage I Cutaneous Melanoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT04697576P1recruitingIntralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Advanced Biliary Tract Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04969887MOST-CIRCUITP2active not recruitingCombination Immunotherapy in Rare Cancers Under InvesTigation

Metastatic Uveal Melanoma in the Liver (1)

NCTAcronymPhaseStatusTitle
NCT04935229PERIOP1terminatedIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Advanced or Metastatic Solid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04887870P2/P3completedStudy of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Nerve Sheath Tumors (1)

NCTAcronymPhaseStatusTitle
NCT04465643P1completedNeoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Metastatic Prostate Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04709276CHAMPP2active not recruitingA Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04938232P2active not recruitingIpilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Healthy Subjects (1)

NCTAcronymPhaseStatusTitle
NCT04868760P1completedA Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male Volunteers

Metastatic Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04863885P1/P2active not recruitingCombination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Carcinoma, Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04151563CheckMate 79XP1/P2withdrawnA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Advance Solid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04850755P1completedA Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Carcinosarcoma of Ovary (1)

NCTAcronymPhaseStatusTitle
NCT04149275P2withdrawnCabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Constitutional Mismatch Repair Deficiency Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT04500548P1withdrawnTesting the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Prostatic Neoplasms, Castration-Resistant (1)

NCTAcronymPhaseStatusTitle
NCT04717154INSPIREP2completedIpilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

Astrocytoma, IDH-Mutant, Grade 4 (1)

NCTAcronymPhaseStatusTitle
NCT04145115P2active not recruitingA Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Kidney Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT04513522CheckMate 7C9P4completedA Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

Undifferentiated Pleomorphic Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT04480502ENVASARCP2unknownENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04610658P1terminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Papillary Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04413123P2active not recruitingCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Brain Metastases, Adult (1)

NCTAcronymPhaseStatusTitle
NCT04434560P2terminatedNeoadjuvant Immunotherapy in Brain Metastases

Metastatic Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04315155BENEFITP1withdrawnEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Metastatic Microsatellite Stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04575922P2unknownNivolumab+Ipilimumab+RT in MSS mCRC

Cancer, Hepatocellular (1)

NCTAcronymPhaseStatusTitle
NCT04340193CheckMate 74WP3completedA Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) (1)

NCTAcronymPhaseStatusTitle
NCT04141644Osi+IpiP1active not recruitingSafety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Aggressive Variant Prostate Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04388852P1active not recruitingDS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Malignant Rhabdoid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04416568P2active not recruitingStudy of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Cutaneous Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04620200MATISSEP2completedNeo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Clear-Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04518046P1completedStudy of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Metastatic Large Cell Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04079712P2active not recruitingTesting the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Cervix Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04256213COLIBRIN/AcompletedCOL Immunotherapy Before Radiochimio + Ipilimumab

Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04311710CheckMate 76UP1terminatedA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04247165LAPTOPP1/P2completedNivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Rectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04124601CHINORECP2completedNeoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

Advanced Colon Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04362839P1completedRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Fibrolamellar Hepatocellular Carcinoma (FLC) (1)

NCTAcronymPhaseStatusTitle
NCT04248569P1recruitingDNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03878524SMMARTP1terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Differentiated Thyroid Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03914300P2active not recruitingTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Neuroblastoma (1)

NCTAcronymPhaseStatusTitle
NCT04239040P1terminatedGVAX Plus Checkpoint Blockade in Neuroblastoma

Relapsed/Refractory Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT04635735P1/P2terminatedStudy of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Head and Neck Squamous Cell Carcinoma (HNSCC) (1)

NCTAcronymPhaseStatusTitle
NCT04080804P2active not recruitingStudy of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Cancer of Unknown Primary Site (1)

NCTAcronymPhaseStatusTitle
NCT04131621CheCUPP2unknownNivolumab/Ipilimumab in Second Line CUP-syndrome

Uveal Melanoma, Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT04283890CHOPINP1/P2active not recruitingPHP and Immunotherapy in Metastasized UM

Prostate Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT05655715CheckPROP2completedCheckpoint Inhibitors and SBRT for MCRPC

Localized Oesogastric Adenocarcimona (1)

NCTAcronymPhaseStatusTitle
NCT04006262NEONIPIGAP2active not recruitingPre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Melanoma With Brain Metastasis (1)

NCTAcronymPhaseStatusTitle
NCT03903640P2terminatedOptune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Non-Small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT04026412CheckMate73LP3completedA Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

ALK Gene Rearrangement (1)

NCTAcronymPhaseStatusTitle
NCT04013542P1active not recruitingIpilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Advanced NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT04043195NSCLCP1/P2active not recruitingNivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Pituitary (1)

NCTAcronymPhaseStatusTitle
NCT04042753P2completedNivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Basal Cell Nevus Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT03767439P2withdrawnNivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03799445P2terminatedIpilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Gastric and Esophagogastric Junction Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03443856VESTIGEP2active not recruitingPostoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Autoimmune Disease (1)

NCTAcronymPhaseStatusTitle
NCT03816345P1recruitingTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03912064P1active not recruitingA Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Anatomic Stage 0 Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT04185311P1terminatedIpilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Grade 2 Meningioma (1)

NCTAcronymPhaseStatusTitle
NCT03604978P1/P2active not recruitingNivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Bladder Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03866382P2recruitingTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03604991P2/P3suspendedNivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Melanoma (Excluding Uveal Melanoma) (1)

NCTAcronymPhaseStatusTitle
NCT03752398DUET-3P1completedA Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Breast Neoplasm Female (1)

NCTAcronymPhaseStatusTitle
NCT03650894HERP2active not recruitingNivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Advanced Solid Cancers (1)

NCTAcronymPhaseStatusTitle
NCT03956680P1completedAn Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Acute Myeloid Leukemia and Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT02846376CPIT-002P1terminatedSingle Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Mucinous Adenocarcinoma of the Colon (1)

NCTAcronymPhaseStatusTitle
NCT03693846P2terminatedNivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Metastatic Hormone-sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03879122P2/P3unknownA Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Inoperable œsophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03437200CRUCIALP2terminatedCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer

Metastatic Malignant Neoplasm in the Bone (1)

NCTAcronymPhaseStatusTitle
NCT03749460P1/P2completedNivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Urinary Bladder Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03844256CRIMIP1/P2recruitingA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Clinical Stage 0 Gastric Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03776487P2active not recruitingNivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Stage III Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03477864P1withdrawnStereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Colorectal Neoplasms Malignant (1)

NCTAcronymPhaseStatusTitle
NCT03507699P1completedCombined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Metastatic Castration Resistant Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03570619IMPACTP2completedImmunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT03769155P1active not recruitingVX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Basal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03521830P2recruitingNivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Adenocarcinoma of the Stomach (1)

NCTAcronymPhaseStatusTitle
NCT03647969P2completedModified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Pan Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03668119CheckMate 848P2completedA Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Unresectable Stage III Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT03235245EBINP2active not recruitingImmunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Advanced Metastatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03651271P2completedNivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Allogeneic Hematopoietic Stem Cell Transplantation Recipient (1)

NCTAcronymPhaseStatusTitle
NCT03600155P1completedNivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Malignant Peritoneal Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT03508570P1completedNivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Metastatic Hormone-Sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03532217P1completedNeoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT03620123OPTIMP2completedA Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Relapsed Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03305445P1completedNivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03468985P2completedNivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03469960DICIPLEP3completedDouble Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Ovarian Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03355976P2active not recruitingBrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Bone Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03449108TNBCP2active not recruitingLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Stage III Cutaneous Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT03396952P2completedProstaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Classic Kaposi Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03219671CKSP2unknownNivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03347123ECHO-208P1/P2terminatedA Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Colon Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03442569P2completedPhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Neuroendocrine Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03420521P2terminatedNivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Newly Diagnosed High Grade Glioma (1)

NCTAcronymPhaseStatusTitle
NCT03425292P1completedA Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Esophageal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03416244RAMONAP2completedA Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Advanced Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03351361eNERGYP3completedNivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

Leptomeningeal Carcinomatosis (1)

NCTAcronymPhaseStatusTitle
NCT02939300P2completedIpilimumab and Nivolumab in Leptomeningeal Metastases

Breast Cancer Female (1)

NCTAcronymPhaseStatusTitle
NCT03342417P2terminatedCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Head and Neck Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03406247ADJORL1P2recruitingAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

MGMT-unmethylated Glioblastoma (GBM) (1)

NCTAcronymPhaseStatusTitle
NCT03367715P2completedNivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT03388632P1completedRecombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Genitourinary Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03333616P2active not recruitingNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Colon Carcinoma Metastatic in the Liver (1)

NCTAcronymPhaseStatusTitle
NCT03373188P1completedVX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Kidney Medullary Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03274258P2terminatedPhase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Metastatic Cancer Colorectal (1)

NCTAcronymPhaseStatusTitle
NCT03350126NIPICOLP2active not recruitingiRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Cervical Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03220009P2withdrawnNivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)

NCTAcronymPhaseStatusTitle
NCT03283046P1withdrawnStudy of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Renal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03203473P2active not recruitingStudy of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Recurrent B Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02879695P1active not recruitingBlinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

MSS (1)

NCTAcronymPhaseStatusTitle
NCT03271047MSSP2completedStudy of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Non Small Cell Lung Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03168464P1/P2terminatedRadiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Dedifferentiated Liposarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03307616P2active not recruitingNivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Thyroid Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03246958P2completedNivolumab Plus Ipilimumab in Thyroid Cancer

HER2/Neu Negative (1)

NCTAcronymPhaseStatusTitle
NCT02892734P2terminatedIpilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Squamous-Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03823625SQUINTP2unknownAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)

Biliary Tract Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT03101566P2completedStudy of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Stage IV Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03223155COSINRP1active not recruitingConcurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

Previously Treated Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT02890329P1active not recruitingIpilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Gastrointestinal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02923934P2completedA Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

High Grade Serous Ovarian (1)

NCTAcronymPhaseStatusTitle
NCT03245892P1completedA Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Transitional Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03219775TITAN-TCCP2unknownTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Stage I Lung Non-Small Cell Cancer AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT03158129P2completedNivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Malignant Melanoma Stage IV (1)

NCTAcronymPhaseStatusTitle
NCT03166397P2unknownAdoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Clear Cell Metastatic Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02960906BIONIKKP2completedA BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Salivary Gland Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03172624P2completedStudy of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Major Salivary Gland Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03146650P2unknownNivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Larynx (1)

NCTAcronymPhaseStatusTitle
NCT03162731Early P1completedNivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Microsatellite Stable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03104439P2active not recruitingNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Advanced Soft Tissue Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT03138161SAINTP1/P2recruitingSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Nasopharyngeal Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03097939P2unknownPhase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Colon Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03026140NICHEP2recruitingNeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Non-Small-Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02864251CheckMate722P3completedA Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Kidney Cancer Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03065179RADVAXP2completedSBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

Immunotherapy (1)

NCTAcronymPhaseStatusTitle
NCT03003637IMCISIONP1/P2completedImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

Cancer Treated With Immune-checkpoint Inhibitors (1)

NCTAcronymPhaseStatusTitle
NCT03963518SURROGATE-ICIN/AcompletedImmune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Acinar Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02834013P2active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare Tumors

Metastatic Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02977156ISI-JXP1completedImmunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.

Metastatic Malignant Neoplasm in the Brain (1)

NCTAcronymPhaseStatusTitle
NCT02696993P1/P2active not recruitingNivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Stage III/IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02857569NIVIPITP1/P2completedA Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

Broad Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02913313P1/P2completedA Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Metastatic Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02866383CheckPACP2completedImmune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

Advanced Gastric Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02935634FRACTION-GCP2completedA Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Stage III Skin Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02437279OpACINP1unknownStudy to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

Endometrial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02922764P1completedA Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Malignant Pleural Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT03048474INITIATEP2completedIpilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Malignant Glioma (1)

NCTAcronymPhaseStatusTitle
NCT02829931P1completedHypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT02681302CPIT001P1/P2terminatedCheck Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

Castration Levels of Testosterone (1)

NCTAcronymPhaseStatusTitle
NCT02703623P2active not recruitingAbiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Advanced/Metastatic Solid Tumors or Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT02675439ADU-S100P1terminatedSafety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Stage IIIC Skin Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02941744ipnivP1/P2completedA Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

Meningiomas (1)

NCTAcronymPhaseStatusTitle
NCT02648997P2active not recruitingAn Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Non-Small-Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02659059CheckMate 568P2completedNivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Anatomic Stage III Breast Cancer AJCC v8 (1)

NCTAcronymPhaseStatusTitle
NCT02453620P1active not recruitingEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Limited Stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02046733STIMULIP2completedSmall Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Stage III Cutaneous Melanoma AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT02339571P2/P3active not recruitingA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02530463P2active not recruitingNivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Locally Advanced Bone Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT02500797P2completedNivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Recurrent Fallopian Tube Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02498600P2completedNivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Bladder Small Cell Neuroendocrine Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02496208P1active not recruitingCabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Metastatic Leiomyosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT02428192P2completedNivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Anal Canal Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02314169P2active not recruitingNivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Unresectable Stage III or Stage IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02413827P1/P2terminatedA Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Acute Bilineal Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02397720P2completedNivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Stage III or IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02200562P1terminatedIpilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT02279732P3completedPhase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (1)

NCTAcronymPhaseStatusTitle
NCT02254772P1/P2completedA Phase I/II Study of Intratumoral Injection of SD-101

Liver Metastases (1)

NCTAcronymPhaseStatusTitle
NCT02107755P2completedStereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Solid Cancers (1)

NCTAcronymPhaseStatusTitle
NCT02174172P1completedA Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Stage IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT02054520P2terminatedImmunotherapy Study for Patients With Stage IV Melanoma

In-transit Metastases Melanoma Stage IIIB and IIIC (1)

NCTAcronymPhaseStatusTitle
NCT02094391ILP+/-IPIP2completedTrial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma

Microsatellite Unstable Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02060188CheckMate142P2completedA Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Recurrent Classic Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01896999P1/P2active not recruitingBrentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Non-small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02039674MK-3475P1/P2completedA Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Stage IIIC Cutaneous Melanoma AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT01950390P2completedIpilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Castration Sensitive Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02020070P2active not recruitingCombining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response (1)

NCTAcronymPhaseStatusTitle
NCT01988077P2terminatedClinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

Advanced or Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT01928394P1/P2completedA Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Newly Diagnosed Melanoma Metastases in the Brain and Spine (1)

NCTAcronymPhaseStatusTitle
NCT01950195P1terminatedSRS (Stereotactic Radiosurgery) Plus Ipilimumab

BRAF V600E Mutation Present (1)

NCTAcronymPhaseStatusTitle
NCT01940809P1terminatedIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)

NCTAcronymPhaseStatusTitle
NCT01822509P1completedIpilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Advanced or Metastatic Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01783938P2completedStudy of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT01935921P1completedIpilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Adult Nasal Type Extranodal NK/T-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01769222P1terminatedIpilimumab and Local Radiation for Selected Solid Tumors

Solid Tumours (1)

NCTAcronymPhaseStatusTitle
NCT01767454P1completedStudy of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

CANCER, NOS (1)

NCTAcronymPhaseStatusTitle
NCT01750580P1completedSafety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Ciliary Body and Choroid Melanoma, Medium/Large Size (1)

NCTAcronymPhaseStatusTitle
NCT01730157Early P1terminatedRadioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT01757639P1completedIpilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Untreated Stage III Melanoma or Stage IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01676649P2unknownIpilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

CD20 Positive (1)

NCTAcronymPhaseStatusTitle
NCT01729806P1completedIpilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01715077N/AcompletedStudy of Ipilimumab in the Immune System

CANCER,NOS (1)

NCTAcronymPhaseStatusTitle
NCT01714739P1/P2completedA Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line (1)

NCTAcronymPhaseStatusTitle
NCT01611558P2completedPhase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01592370P1/P2completedAn Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction (1)

NCTAcronymPhaseStatusTitle
NCT01585987P2completedAn Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Duct Cell Adenocarcinoma of the Pancreas (1)

NCTAcronymPhaseStatusTitle
NCT01473940P1completedIpilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Adenocarcinoma of the Prostate (1)

NCTAcronymPhaseStatusTitle
NCT01498978P2completedIpilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01450761ED-SCLCP3completedTrial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Ocular Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01355120DeCOGP2completedTHE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease

Extensive Stage Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01331525ICEP2completedThe Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer

Melanoma of Unknown Primary (1)

NCTAcronymPhaseStatusTitle
NCT01274338P3active not recruitingIpilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Malignant Melanoma, Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT01363206GIPIP2completedGranulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

Lung Cancer - Non Small Cell Squamous (1)

NCTAcronymPhaseStatusTitle
NCT01285609P3completedPhase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Metastatic Malignant Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01654692NIBIT-M1P2completedA Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

Leukemia, Myeloid, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT00732186P1withdrawnStudy of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00586391CRETI-NHP1active not recruitingCD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

High Risk Stage III Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT00636168P3completedEfficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Unresectable Stage III or IV Malignant Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT00261365MDX-010P1/P2completedPhase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Synovial Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT00140855P2terminatedA Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Adult Grade III Lymphomatoid Granulomatosis (1)

NCTAcronymPhaseStatusTitle
NCT00089076P1/P2terminatedMDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Prostate Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00170157P2completedHormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Recurrent Prostate Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00064129P1completedIpilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Ipilimumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
MINUTENCT06031233P4recruitingOncology776
Ipi4NCT02068196P4active not recruitingMalignant Melanoma150PMID 30821848
CheckMate 7C9NCT04513522P4completedKidney Neoplasms101
CHECKMATE 920NCT02982954P4completedRenal Cell Carcinoma211PMID 35210307
PROCLIVITY02NCT01856023P4terminatedMetastatic Melanoma29
eVOLVE-RCC02NCT07000149P3active not recruitingAdvanced Clear Cell Renal Cell Carcinoma1,116
CARE1NCT06364631P3recruitingMetastatic Kidney Cancer1,250
SWE-NEONCT06794775P3recruitingMalignant Melanoma Stage III128
SUPRAMENCT06743126P3recruitingMelanoma, Cutaneous Malignant360
NADINANCT04949113P3active not recruitingMalignant Melanoma Stage III423PMID 37104746
eVOLVE-MesoNCT06097728P3active not recruitingUnresectable Pleural Mesothelioma861
COSMIC-313NCT03937219P3active not recruitingRenal Cell Carcinoma855PMID 34550754
CheckMate 9DWNCT04039607P3active not recruitingHepatocellular Carcinoma732PMID 40349714
CheckMate 8HWNCT04008030P3active not recruitingMetastatic Colorectal Cancer839PMID 39602630
CheckMate901NCT03036098P3active not recruitingUrothelial Cancer1,314PMID 37870949
CheckMate 9ERNCT03141177P3active not recruitingRenal Cell Carcinoma701PMID 41617395
DICIPLENCT03469960P3completedNon-Small Cell Lung Cancer Metastatic265
RAR-ImmuneNCT04741438P3unknownSarcoma96
DREAM3RNCT04334759P3completedMesothelioma214PMID 33358660
CheckMate 648NCT03143153P3completedVarious Advanced Cancer970PMID 37139963
CheckMate 816NCT02998528P3completedNon Small Cell Lung Cancer505PMID 40454642
CheckMate73LNCT04026412P3completedNon-Small Cell Lung Cancer (NSCLC)925PMID 42129521
CheckMate 227NCT02477826P3completedNon-Small Cell Lung Cancer2,747PMID 31195357
CheckMate 9LANCT03215706P3completedNon-Small Cell Lung Cancer719PMID 39270380
CheckMate 238NCT02388906P3completedMelanoma906PMID 34663559
CheckMate 143NCT02017717P3completedRecurrent Glioblastoma529PMID 32691060
CheckMate649NCT02872116P3completedGastric Cancer2,031PMID 37713657
IMSTAR-HNNCT03700905P3unknownHead and Neck Cancer276PMID 27247226
CheckMate 914NCT03138512P3completedCarcinoma, Renal Cell1,641PMID 36774933
TILNCT02278887P3completedMetastatic Melanoma168PMID 40474841
CheckMate 74WNCT04340193P3completedCancer, Hepatocellular26
CheckMate743NCT02899299P3completedMesothelioma605PMID 33206991
CheckMate722NCT02864251P3completedNon-Small-Cell Lung Carcinoma367PMID 38252907
CheckMate 651NCT02741570P3completedHead and Neck Cancer947PMID 33684371
NSCLCNCT03302234P3completedCarcinoma, Non-Small-Cell Lung568PMID 33513313
eNERGYNCT03351361P3completedAdvanced Non Small Cell Lung Cancer217PMID 39486424
CheckMate 451NCT02538666P3completedLung Cancer907PMID 33683919
CheckMate 915NCT03068455P3completedMelanoma1,844PMID 35512259
CheckMate 401NCT02599402P3completedMelanoma533PMID 37307514
NIBIT-M2NCT02460068P3unknownBrain Metastases168
CheckMate 955NCT03048136P3withdrawnNon-Small Cell Lung Cancer0
MK-3475NCT01866319P3completedMelanoma834PMID 28822576
ED-SCLCNCT01450761P3completedSmall Cell Lung Carcinoma1,351PMID 27458307
RESET-RNCT05732389P2recruitingCancer of Rectum39
Neo IRENIENCT06999980P2recruitingCutaneous Melanoma494
TORCH-OPTIMANCT07403877P2not yet recruitingColorectal Cancer (MSI-H)114
NEOREM-NEO-1NCT07230613P2recruitingCutaneous Melanoma, Stage III50
BELLININCT03815890P2recruitingBreast Cancer80PMID 39284953
FLINNNCT07355205P2not yet recruitingNon-small Cell Lung Cancer Stage IV26
NICHENCT03026140P2recruitingColon Carcinoma353PMID 34606846
RCCNCT07188896P2recruitingAdvanced Renal Cell Carcinoma (aRCC)120
GALAXY 3NCT06926790P2recruitingLung Cancer - Non Small Cell69
NeoRelapseNCT06365619P2recruitingMelanoma25PMID 29945191
TONIC-3NCT06342037P2recruitingMetastatic Breast Cancer60
ABC-XNCT03340129P2recruitingMelanoma Stage Iv218PMID 33450821
NESCIONCT05148546P2active not recruitingRenal Cell Carcinoma69
ParpVax2NCT06747845P2recruitingPancreatic Adenocarcinoma Metastatic68
ICBNCT06250335P2active not recruitingICB-refractory Melanoma4
TAPURNCT02693535P2recruitingLymphoma, Non-Hodgkin4,200PMID 36753688
ABCNCT02374242P2active not recruitingMelanoma76PMID 37132182
RCCNCT06708949P2recruitingRenal Cell Carcinoma, Clear Cell15
CheckMate-1533NCT06946797P2active not recruitingNon-Small Cell Lung Cancer76
CHAMPNCT04709276P2active not recruitingMetastatic Prostate Neuroendocrine Carcinoma41
SAMURAINCT05327686P2recruitingMetastatic Renal Cell Carcinoma240
MEMBRAINSNCT03563729P2recruitingMalignant Melanoma80
NIPISAFENCT04730544P2active not recruitingColorectal Cancer Metastatic96
ACTION-001NCT07487662P2not yet recruitingHepato Cellular Carcinoma (HCC)105PMID 41125112
RadVaxNCT03646617P2recruitingMetastatic Melanoma54
DRUPNCT02925234P2recruitingCancer1,550PMID 37424386
NIVIPI-BrainNCT05012254P2active not recruitingNon Small Cell Lung Cancer71
ADJORL1NCT03406247P2recruitingHead and Neck Squamous Cell Carcinoma140
ARCITECTNCT05928806P2suspendedAdvanced Renal Cell Carcinoma120
NA_00092076NCT02259621P2active not recruitingNon-Small Cell Lung Cancer39PMID 31754049
CheckMate 7UANCT04495010P2withdrawnMelanoma0
DISCERNNCT06364917P2recruitingNon Small Cell Lung Cancer24
NIPIRESCUENCT05310643P2recruitingMetastatic Colorectal Cancer30
Indi-BladeNCT05200988P2active not recruitingUrothelial Carcinoma50PMID 37711193
TNBCNCT03449108P2active not recruitingBone Sarcoma30
G360-IITNCT05715229P2recruitingCarcinoma, Non-Small-Cell Lung108PMID 20514052
LUNGVIRNCT05597800P2not yet recruitingNSCLC Stage IV105
NIPUNCT04300244P2active not recruitingCancer118PMID 39133306
MOST-CIRCUITNCT04969887P2active not recruitingAdvanced Biliary Tract Cancer240PMID 40608313
NIMBUSNCT03789110P2active not recruitingBreast Cancer30PMID 40360544
EBINNCT03235245P2active not recruitingUnresectable Stage III Melanoma271PMID 40449497
CAPTURNCT03297606P2recruitingLymphoma, Non-Hodgkin720
HERNCT03650894P2active not recruitingBreast Neoplasm Female30
CLARANCT05215470P2active not recruitingRenal Cancer Metastatic100
LOWNCT04933903P2recruitingNon Small Cell Lung Cancer25
CERAD-IMMUNENCT05504642P2withdrawnCervical Cancer ≥ FIGO IIB and or Lymph Node Metastases0
RAD-IONCT05401786P2active not recruitingCarcinoma, Non-Small-Cell Lung54
VESTIGENCT03443856P2active not recruitingGastric and Esophagogastric Junction Adenocarcinoma197PMID 32083013
CYTOSHRINKNCT04090710P2active not recruitingMetastatic Renal Cell Carcinoma66
ICINCT04817254P2completedGlioblastoma47
PORTSIDENCT05926960P2terminatedMelanoma38
NIPICOLNCT03350126P2active not recruitingMetastatic Cancer Colorectal57PMID 37269904
INSPIRENCT04717154P2completedProstatic Neoplasms, Castration-Resistant69
CheckMate 6DWNCT05136677P2completedMesothelioma, Malignant102
NEONIPIGANCT04006262P2active not recruitingLocalized Oesogastric Adenocarcimona32PMID 35969830
SALIENTNCT05284214P2withdrawnSolid Tumor0
VEXILLUMNCT05219435P2completedUrothelial Cancer25
ROMENCT04591431P2unknownBreast Cancer400PMID 41963505
OpACIN-neoNCT02977052P2unknownMalignant Melanoma Stage III186PMID 31160251
PICASSONCT04988841P2completedMelanoma70
NIBIT-ML1NCT04250246P2unknownMelanoma184PMID 24384533
ATLASNCT04966676P2terminatedNon Small Cell Lung Cancer5
MATISSENCT04620200P2completedCutaneous Squamous Cell Carcinoma50PMID 41062829
CheckMate 650NCT02985957P2completedProstate Cancer351PMID 32916128
ANZUP2001NCT05150236P2unknownProstatic Neoplasms93
NIPINECNCT03591731P2completedNeuroendocrine Carcinoma185PMID 41774886
ENVASARCNCT04480502P2unknownUndifferentiated Pleomorphic Sarcoma207
CheckMate142NCT02060188P2completedMicrosatellite Unstable Colorectal Cancer385PMID 28734759
TOP2101NCT05144529P2terminatedLung Cancer Metastatic19
CheckPRONCT05655715P2completedProstate Cancer Metastatic90PMID 36717150
HCCNCT03510871P2completedHepatocellular Carcinoma (HCC)43PMID 40972843
SECOMBITNCT02631447P2completedMetastatic Melanoma251PMID 39315864
NSCLCNCT03739710P2completedNeoplasms175
BreastImmune03NCT03818685P2unknownBreast Cancer95PMID 41314029
CA209-260NCT02553642P2completedBladder Cancer81PMID 29489427
IMPACTNCT03570619P2completedMetastatic Castration Resistant Prostate Cancer56
CHINORECNCT04124601P2completedRectal Cancer80PMID 40844778
NSCLCNCT03285321P2completedNon-small Cell Lung Cancer105PMID 38971369
LuscidNCT04571632P2unknownNon Small Cell Lung Cancer36PMID 38954010
BIOLUMANCT03083691P2completedCarcinoma, Non-Small-Cell Lung90
INFLUENCENCT05116917P2terminatedPancreatic Cancer19
CheckMate 848NCT03668119P2completedPan Tumor212PMID 39107131
TOP1705NCT03573947P2completedNon-small Cell Lung Cancer46
NeAT GlioNCT05074992P2terminatedGlioblastoma1
CheckMate 592NCT03001882P2completedNon-Small Cell Lung Cancer230
TITAN-TCCNCT03219775P2unknownTransitional Cell Carcinoma169PMID 38722641
CheCUPNCT04131621P2unknownCancer of Unknown Primary Site194PMID 37875494
UNISoNNCT03177239P2unknownRenal Cell Carcinoma85
CheckPACNCT02866383P2completedMetastatic Pancreatic Cancer160PMID 37744345
TITAN-RCCNCT02917772P2completedCarcinoma, Renal Cell200PMID 37844597
CRUCIALNCT03437200P2terminatedInoperable œsophageal Cancer8
CKSNCT03219671P2unknownClassic Kaposi Sarcoma20
OPTIMNCT03620123P2completedRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck54
SCLCNCT03406715P2terminatedSmall Cell Lung Cancer14
ICONNCT03409198P2completedBreast Cancer82PMID 38242720
FRACTION-GCNCT02935634P2completedAdvanced Gastric Cancer190
ILLUMINATE-206NCT03865082P2active not recruitingSolid Tumor30
CheckMate 714NCT02823574P2completedHead and Neck Cancer425PMID 37022706
EMERGENCT03989362P2completedCancer61
CheckMate 568NCT02659059P2completedNon-Small-Cell Lung Cancer324PMID 30785829
INTEGANCT03409848P2completedGastric Cancer97PMID 32487035
ZirconipiNCT03313323P2unknownMelanoma29
NIMBLeNCT03461952P2terminatedAdvanced Solid Tumors4
STIMULINCT02046733P2completedLimited Stage Small Cell Lung Cancer222
CheckMate 908NCT03130959P2completedVarious Advanced Cancer166PMID 36808285
TRIPPLE-RNCT04258150P2terminatedPancreatic Cancer26PMID 36592507
FRACTION-RCCNCT02996110P2completedAdvanced Cancer182PMID 36328377
RAMONANCT03416244P2completedEsophageal Cancer66PMID 30871493
STARVE-PCNCT02601014P2completedProstate Cancer32PMID 33636027
MAYANCT03832621P2completedMetastatic Colorectal Cancer135PMID 35258987
NSCLCNCT06790303P2terminatedNeoplasms8
GEM1402NCT02626962P2completedUveal Melanoma52PMID 33417511
SQUINTNCT03823625P2unknownSquamous-Cell Lung Cancer112PMID 39836372
CheckMate 069NCT01927419P2completedUnresectable Melanoma142PMID 25891304
MSSNCT03271047P2completedMSS75PMID 38600471
BIONIKKNCT02960906P2completedClear Cell Metastatic Renal Cell Carcinoma200PMID 35390339
RADVAXNCT03065179P2completedKidney Cancer Metastatic29
CheckMate204NCT02320058P2completedMelanoma119PMID 33880555
CTLA-4NCT01804465P2completedProstate Cancer50PMID 33986125
PROCLAIMNCT03993379P2terminatedSolid Tumor3
FRACTION-LungNCT02750514P2terminatedAdvanced Cancer295
INITIATENCT03048474P2completedMalignant Pleural Mesothelioma36PMID 33166791
BMS-986205NCT04007588P2withdrawnMelanoma Stage III0
MAPS2NCT02716272P2completedMesothelioma125PMID 30660609
HF10NCT03153085P2completedMelanoma Stage III28
GRAY-BNCT02115139P2completedMelanoma58
TOP1201 IPINCT01820754P2completedNon Small Cell Lung Cancer24PMID 29258674
SARTNCT01565837P2unknownMelanoma50
MDX-010NCT01323517P2completedMelanoma26
TriMix-IpiNCT01302496P2completedMalignant Melanoma Stage III39PMID 32114500
CTLA4 NY-ESO-1NCT01216696P2completedMetastatic Melanoma25PMID 29306769
ILP+/-IPINCT02094391P2completedIn-transit Metastases Melanoma Stage IIIB and IIIC4PMID 34132224
IPI+RTSNCT02662725P2completedMelanoma73
ICENCT01331525P2completedExtensive Stage Small Cell Lung Cancer42
GIPINCT01363206P2completedMalignant Melanoma, Metastatic29PMID 32376721
NIBIT-M1NCT01654692P2completedMetastatic Malignant Melanoma86PMID 25538176
DeCOGNCT01355120P2completedOcular Melanoma171PMID 25761109
NSCLCNCT00527735P2completedLung Cancer334
MDX-010NCT00289640P2completedMelanoma210PMID 20004617
BMS-734016NCT00135408P2completedMalignant Melanoma115

Terminated and withdrawn Ipilimumab trials (153)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Ipilimumab trials (791)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05732389RESET-RImmunotherapy in Patients With Early dMMR Rectal CancerP2recruiting39Odense University HospitalFeb 2023
NCT02498756Cytokine-induced Killer Study for Patients With Stage II MelanomaP2not yet recruiting300The First People's Hospital of ChangzhouAug 2015
NCT06999980Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)P2recruiting494Melanoma Institute AustraliaFeb 2026
NCT06492421Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.P2recruiting90Second Affiliated Hospital of Guangzhou Medical UniversityJul 2024
NCT06482801Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITP2recruiting90Second Affiliated Hospital of Guangzhou Medical UniversityJun 2024
NCT05187338Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsP1/P2recruiting100Second Affiliated Hospital of Guangzhou Medical UniversityNov 2021
NCT07403877TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerP2not yet recruiting114Fudan UniversityFeb 2026
NCT04196452DMTRA Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)active not recruiting10Bristol-Myers SquibbAug 2019
NCT06240143MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaP1/P2recruiting96The Netherlands Cancer InstituteMar 2024
NCT04248569DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaP1recruiting56Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsApr 2020
NCT07383441Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerP3recruiting718SWOG Cancer Research NetworkJun 2026
NCT07444619A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasP1not yet recruiting18M.D. Anderson Cancer CenterAug 2026
NCT07230613NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized MelanomaP2recruiting50UNICANCERJan 2026
NCT06492408Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.P2recruiting90Second Affiliated Hospital of Guangzhou Medical UniversityJul 2024
NCT06483347Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via ITP2recruiting90Second Affiliated Hospital of Guangzhou Medical UniversityApr 2024
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaP2recruiting18Mayo ClinicApr 2026
NCT02339571A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaP2/P3active not recruiting600National Cancer Institute (NCI)Nov 2015
NCT03815890BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IOP2recruiting80The Netherlands Cancer InstituteOct 2019
NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.P3not yet recruiting142Guliz OzgunApr 2026
NCT03769155VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaP1active not recruiting41Emory UniversityDec 2018
NCT06683755TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)P1/P2not yet recruiting30M.D. Anderson Cancer CenterMay 2025
NCT03521830Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaP2recruiting57Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2018
NCT05112601Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaP2recruiting81National Cancer Institute (NCI)Jun 2022
NCT07000149eVOLVE-RCC02A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCP3active not recruiting1,116AstraZenecaJul 2025
NCT07355205FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerP2not yet recruiting26Washington University School of MedicineJun 2026
NCT06364631CARE1CARE1 Pragmatic Clinical TrialP3recruiting1,250Gustave Roussy, Cancer Campus, Grand ParisApr 2024
NCT06794775SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaP3recruiting128Hildur HelgadottirJul 2025
NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaP1recruiting21Mayo ClinicJan 2024
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaP1recruiting99Mayo ClinicApr 2017
NCT03026140NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerP2recruiting353The Netherlands Cancer InstituteMar 2017
NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsP1/P2recruiting361ModernaTX, Inc.Sep 2022
NCT07293351RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)P1/P2recruiting254Bristol-Myers SquibbMar 2026
NCT06743126SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaP3recruiting360Immatics US, Inc.Jan 2025
NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaP2/P3recruiting280Replimune, Inc.Dec 2024
NCT07291076HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)P1/P2recruiting198Bristol-Myers SquibbMar 2026
NCT06866262Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialP1/P2recruiting55University of Michigan Rogel Cancer CenterAug 2025
NCT06968988Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaP1recruiting18Washington University School of MedicineJan 2026
NCT03138161SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaP1/P2recruiting250Sarcoma Oncology Research Center, LLCApr 2017
NCT07061379PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenrecruiting144IRCCS San RaffaeleJul 2025
NCT07504796ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabP4recruiting90NYU Langone HealthApr 2026
NCT07587827ODI-2001-01Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerP1not yet recruiting77Centre Georges Francois LeclercNov 2026
NCT06624644A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaP2/P3recruiting135Linnaeus Therapeutics, Inc.Aug 2025
NCT04929041Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeP2/P3suspended427National Cancer Institute (NCI)Oct 2022
NCT05457959Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantP1withdrawn0Jonsson Comprehensive Cancer CenterDec 2024
NCT07188896RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)P2recruiting120Brian RiniApr 2026
NCT06926790GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)P2recruiting69The First Affiliated Hospital of Guangzhou Medical UniversityFeb 2025
NCT06487156FINNA Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting404Bristol-Myers SquibbOct 2023
NCT04462406Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialP2active not recruiting150ECOG-ACRIN Cancer Research GroupFeb 2021
NCT07430202FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)P1not yet recruiting27Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 2026
NCT06365619NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaP2recruiting25University of UtahJun 2026
NCT05176483STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsP1recruiting1,314ExelixisDec 2021
NCT06889493NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)P1recruiting36Peter Hosein, MDMay 2025
NCT02950766NeoVax Plus Ipilimumab in Renal Cell CarcinomaP1active not recruiting19Patrick Ott, MD, PhDMar 2019
NCT03999749A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaP2active not recruiting71NYU Langone HealthJun 2019
NCT06342037TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialP2recruiting60The Netherlands Cancer InstituteJun 2024
NCT04665206Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsP1/P2recruiting434Vivace Therapeutics, IncMar 2021
NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesP2recruiting60Stanford UniversityAug 2025
NCT04283890CHOPINPHP and Immunotherapy in Metastasized UMP1/P2active not recruiting83Leiden University Medical CenterDec 2019
NCT07401875SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)P1recruiting35M.D. Anderson Cancer CenterMar 2026
NCT04562129IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsP2recruiting29H. Lee Moffitt Cancer Center and Research InstituteSep 2020
NCT07563738TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212P1/P2recruiting229Orion Corporation, Orion PharmaMar 2026
NCT03340129ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)P2recruiting218Melanoma Institute AustraliaAug 2019
NCT03899155Pan Tumor Rollover StudyP2recruiting1,500Bristol-Myers SquibbAug 2019
NCT00586391CRETI-NHCD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLP1active not recruiting14Baylor College of MedicineFeb 2009
NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerP1recruiting60Memorial Sloan Kettering Cancer CenterApr 2026
NCT05148546NESCIONeoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerP2active not recruiting69The Netherlands Cancer InstituteApr 2022
NCT07501117Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaP1not yet recruiting15Inge Marie SvaneMay 2026
NCT07422753A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCP2recruiting36Second Affiliated Hospital, School of Medicine, Zhejiang UniversityMar 2026
NCT05536141ARC-20A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsP1recruiting362Arcus Biosciences, Inc.Oct 2022
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialP3recruiting226NRG OncologyFeb 2026
NCT07233668IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCN/Anot yet recruiting172Seoul National University HospitalDec 2025
NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsP1/P2active not recruiting49Susan Chi, MDAug 2023
NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaP2active not recruiting105Washington University School of MedicineJan 2021
NCT06747845ParpVax2Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyP2recruiting68Abramson Cancer Center at Penn MedicineMay 2025
NCT06250335ICBImpact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsP2active not recruiting4M.D. Anderson Cancer CenterMar 2024
NCT06941857NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerP2recruiting20Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2025
NCT06362369A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyP1/P2recruiting1267 Hills Pharma, LLCAug 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4recruiting776IsalaSep 2023
NCT02693535TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerP2recruiting4,200American Society of Clinical OncologyMar 2016
NCT02374242ABCAnti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesP2active not recruiting76Melanoma Institute AustraliaNov 2014
NCT04949113NADINANeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaP3active not recruiting423The Netherlands Cancer InstituteJul 2021
NCT06708949RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)P2recruiting15M.D. Anderson Cancer CenterMar 2025
NCT06295159Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaP2recruiting90H. Lee Moffitt Cancer Center and Research InstituteMay 2024
NCT06097728eVOLVE-MesoMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaP3active not recruiting861AstraZenecaNov 2023
NCT03907852TC-210Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerP1/P2active not recruiting57TCR2 TherapeuticsApr 2019
NCT06946797CheckMate-1533A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)P2active not recruiting76Bristol-Myers SquibbSep 2025
NCT07227012Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.P1/P2recruiting138PfizerDec 2025
NCT03929029Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaP1active not recruiting11Dana-Farber Cancer InstituteNov 2020
NCT07147101HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironmentrecruiting150Fudan UniversitySep 2025
NCT06490536The Sagittarius TrialP3recruiting700IFOM ETS - The AIRC Institute of Molecular OncologyOct 2024
NCT04840589Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsP1suspended66National Cancer Institute (NCI)Feb 2022
NCT04709276CHAMPA Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerP2active not recruiting41Andrew J. Armstrong, MDJun 2021
NCT07128680EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerP1recruiting33City of Hope Medical CenterMar 2026
NCT07506109A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerP2recruiting49Tianjin Medical University Cancer Institute and HospitalMar 2026
NCT07482059A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaP1/P2recruiting33West China HospitalFeb 2026
NCT06514651MAQ-001 in Patients With Advanced Solid TumorsP1recruiting30MabQuest SAJun 2024
NCT03546686Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerP2active not recruiting51University of Texas Southwestern Medical CenterNov 2019
NCT03918252Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaP2active not recruiting30Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOct 2019
NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsP1/P2recruiting542SanofiNov 2022
NCT05904080Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerP2recruiting50National Cancer Institute (NCI)Feb 2024
NCT05327686SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialP2recruiting240NRG OncologyFeb 2023
NCT03563729MEMBRAINSMelanoma Metastasized to the Brain and SteroidsP2recruiting80Inge Marie SvaneJun 2018
NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaP2recruiting43Tianjin Medical University Cancer Institute and HospitalMar 2026
NCT04730544NIPISAFETwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.P2active not recruiting96GERCOR - Multidisciplinary Oncology Cooperative GroupMay 2021
NCT04141644Osi+IpiSafety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCP1active not recruiting24University of UtahAug 2020
NCT05492123Nivolumab-ipilimumab and Chemoradiation for Cervical CancerP2recruiting112Hospital Israelita Albert EinsteinAug 2022
NCT07422779MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaN/Arecruiting100Institute of Oncology LjubljanaMar 2022
NCT02703623Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerP2active not recruiting196M.D. Anderson Cancer CenterMay 2016
NCT03816345Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOP1recruiting300National Cancer Institute (NCI)Jul 2019
NCT07487662ACTION-001TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskP2not yet recruiting105Sun Yat-sen UniversityMar 2026
NCT07394062ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)recruiting400Gazi UniversityFeb 2026
NCT05428007Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaP2recruiting105NYU Langone HealthFeb 2023
NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyP3active not recruiting1,175National Cancer Institute (NCI)Jun 2019
NCT05987332IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaP2/P3active not recruiting420IDEAYA BiosciencesOct 2023
NCT07134842WinGlio-ipiA Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.P1recruiting16University College, LondonJul 2025
NCT05779423Cryoablation+Ipilimumab+Nivolumab in MelanomaP2recruiting37Massachusetts General HospitalSep 2023
NCT07075120Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerP1recruiting15University of HawaiiApr 2026
NCT07155317Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialP2recruiting99Emory UniversityOct 2025
NCT05048212A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesP2recruiting20M.D. Anderson Cancer CenterSep 2022
NCT04697576Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaP1recruiting36Carlo ContrerasOct 2021
NCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaP2active not recruiting35M.D. Anderson Cancer CenterSep 2021
NCT04013542Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerP1active not recruiting21M.D. Anderson Cancer CenterSep 2019
NCT03646617RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaP2recruiting54Abramson Cancer Center at Penn MedicineNov 2018
NCT03223155COSINRConcurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerP1active not recruiting78University of ChicagoSep 2017
NCT02696993Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerP1/P2active not recruiting80M.D. Anderson Cancer CenterDec 2016
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2recruiting1,550The Netherlands Cancer InstituteAug 2016
NCT05012254NIVIPI-BrainNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesP2active not recruiting71Fundación GECPNov 2021
NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerP1recruiting50Emory UniversityNov 2018
NCT03406247ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaP2recruiting140Gustave Roussy, Cancer Campus, Grand ParisFeb 2018
NCT05928806ARCITECTAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialP2suspended120Michael B. Atkins, MDSep 2023
NCT04863885Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsP1/P2active not recruiting46H. Lee Moffitt Cancer Center and Research InstituteApr 2021
NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryP2active not recruiting32M.D. Anderson Cancer CenterOct 2017
NCT02259621NA_00092076Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCP2active not recruiting39Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2014
NCT04495010CheckMate 7UANeoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsP2withdrawn0Bristol-Myers SquibbMar 2021
NCT06364917DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCP2recruiting24University of Alabama at BirminghamMay 2025
NCT06594991A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaP2recruiting88Memorial Sloan Kettering Cancer CenterSep 2024
NCT05310643NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCP2recruiting30GERCOR - Multidisciplinary Oncology Cooperative GroupMay 2022
NCT03233139Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesP1active not recruiting146Regeneron PharmaceuticalsJun 2017
NCT02530463Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeP2active not recruiting99M.D. Anderson Cancer CenterSep 2015
NCT05200988Indi-BladeCheckpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UCP2active not recruiting50The Netherlands Cancer InstituteMar 2022
NCT05498792Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaEarly P1recruiting12Fox Chase Cancer CenterNov 2022
NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaP2recruiting35University of California, IrvineAug 2020
NCT06377111A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaP1active not recruiting12University Health Network, TorontoJun 2024
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisP1/P2recruiting134Neonc Technologies, Inc.Nov 2023
NCT05361720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyP2recruiting54Vanderbilt-Ingram Cancer CenterDec 2022
NCT04511013A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesP2recruiting112SWOG Cancer Research NetworkJan 2021
NCT03061539Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureP2active not recruiting380University College, LondonFeb 2018
NCT04117087Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerP1active not recruiting27Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2020
NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsP2active not recruiting798National Cancer Institute (NCI)Jan 2017
NCT05384496Axitinib and Nivolumab for the Treatment of Mucosal MelanomaP2recruiting20Memorial Sloan Kettering Cancer CenterMay 2022
NCT05144854A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)P3active not recruiting626Ono Pharmaceutical Co., Ltd.Nov 2021
NCT04317105Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENP1/P2active not recruiting54National Cancer Institute (NCI)Jul 2020
NCT03449108TNBCLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasP2active not recruiting30M.D. Anderson Cancer CenterApr 2018
NCT03104439Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerP2active not recruiting84Massachusetts General HospitalMay 2017
NCT03122522A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyP2active not recruiting70Memorial Sloan Kettering Cancer CenterApr 2017
NCT05715229G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyP2recruiting108Hackensack Meridian HealthSep 2023
NCT02785952Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersP3active not recruiting275SWOG Cancer Research NetworkDec 2015
NCT05141721A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerP2/P3active not recruiting700Seattle Project CorporationFeb 2022
NCT03391869Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerP3active not recruiting339M.D. Anderson Cancer CenterDec 2017
NCT05597800LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeP2not yet recruiting105Universita di VeronaFeb 2023
NCT04996823Axitinib + Ipilimumab in Advanced MelanomaP2recruiting25H. Lee Moffitt Cancer Center and Research InstituteAug 2021
NCT02314169Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerP2active not recruiting143National Cancer Institute (NCI)May 2015
NCT03604978Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaP1/P2active not recruiting38National Cancer Institute (NCI)Jun 2019
NCT01134614Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryP2active not recruiting245National Cancer Institute (NCI)Dec 2010
NCT01708941Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryP2active not recruiting88National Cancer Institute (NCI)Jan 2013
NCT04300244NIPUNivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaP2active not recruiting118Åslaug HellandMay 2020
NCT05289193CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaP2active not recruiting28Memorial Sloan Kettering Cancer CenterMar 2022
NCT03873402A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerP3active not recruiting437Bristol-Myers SquibbJun 2019
NCT04969887MOST-CIRCUITCombination Immunotherapy in Rare Cancers Under InvesTigationP2active not recruiting240Olivia Newton-John Cancer Research InstituteAug 2021
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsP2recruiting314National Cancer Institute (NCI)May 2019
NCT03789110NIMBUSNIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerP2active not recruiting30Dana-Farber Cancer InstituteMar 2019
NCT01274338Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryP3active not recruiting1,673National Cancer Institute (NCI)Jun 2011
NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerP1/P2recruiting25Vanderbilt-Ingram Cancer CenterMay 2023
NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerP1/P2recruiting16National Cancer Institute (NCI)Jul 2024
NCT03816358Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerP1active not recruiting74National Cancer Institute (NCI)Dec 2019
NCT03937219COSMIC-313Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaP3active not recruiting855ExelixisJun 2019
NCT03235245EBINImmunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibP2active not recruiting271European Organisation for Research and Treatment of Cancer - EORTCOct 2018
NCT03520491A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyP2active not recruiting52Memorial Sloan Kettering Cancer CenterApr 2018
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2recruiting720Canadian Cancer Trials GroupMar 2018
NCT02506153Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryP3active not recruiting1,301National Cancer Institute (NCI)Nov 2015
NCT04464759LIMITA Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaP1/P2recruiting94Ravi Amaravadi, MDOct 2020
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerP1recruiting18Emory UniversityDec 2025
NCT06353646XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerN/Arecruiting28Wu WenmingMar 2024
NCT05721846CheckVACNivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerP1active not recruiting20Inna Chen, MDMay 2023
NCT05188118Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell CarcinomaEarly P1recruiting20Icahn School of Medicine at Mount SinaiFeb 2023
NCT04751370Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerP2active not recruiting31National Cancer Institute (NCI)Feb 2022
NCT04606316Surgical Nivolumab And Ipilimumab For Recurrent GBMP1active not recruiting63Patrick Wen, MDFeb 2021
NCT04145115A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenP2active not recruiting37National Cancer Institute (NCI)Dec 2020
NCT04388852DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersP1active not recruiting65M.D. Anderson Cancer CenterAug 2020
NCT04091750Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaP2active not recruiting14Georgetown UniversityMar 2020
NCT04043195NSCLCNivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCP1/P2active not recruiting30Hatim HusainAug 2019
NCT03912064A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTP1active not recruiting25Dana-Farber Cancer InstituteJul 2019
NCT03604991Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgeryP2/P3suspended278National Cancer Institute (NCI)May 2019
NCT03650894HERNivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsP2active not recruiting30Providence Health & ServicesApr 2019
NCT03333616Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsP2active not recruiting100Dana-Farber Cancer InstituteDec 2017
NCT02919683Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityP2active not recruiting30Dana-Farber Cancer InstituteNov 2016
NCT02812524Ipilimumab for Head and Neck Cancer PatientsP1active not recruiting18Providence Health & ServicesNov 2016
NCT02210117Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryEarly P1active not recruiting104M.D. Anderson Cancer CenterNov 2014
NCT01896999Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaP1/P2active not recruiting146National Cancer Institute (NCI)Mar 2014
NCT02068196Ipi4A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.P4active not recruiting150Oslo University HospitalJan 2014
NCT02020070Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyP2active not recruiting16Memorial Sloan Kettering Cancer CenterDec 2013
NCT03776487Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerP2active not recruiting32M.D. Anderson Cancer CenterJan 2019
NCT04413123Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCP2active not recruiting60Bradley A. McGregor, MDNov 2020
NCT02224781Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaP3active not recruiting267National Cancer Institute (NCI)Sep 2015
NCT03914300Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerP2active not recruiting11National Cancer Institute (NCI)Feb 2020
NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaP2recruiting26Alliance for Clinical Trials in OncologyNov 2024
NCT05215470CLARACLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyP2active not recruiting100Hospital das Clínicas de Ribeirão PretoJan 2022
NCT03233152GlitIpNiA Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.P1/P2active not recruiting110Universitair Ziekenhuis BrusselNov 2016
NCT05501054Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.P1/P2active not recruiting50M.D. Anderson Cancer CenterFeb 2023
NCT04361162Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerP2active not recruiting30Massachusetts General HospitalMay 2020
NCT03693014A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsP2active not recruiting69Memorial Sloan Kettering Cancer CenterOct 2018
NCT06399419CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerP1recruiting28Osel, Inc.Jun 2024
NCT04080804Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerP2active not recruiting80Dan ZandbergDec 2019
NCT04933903LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabP2recruiting25Brown UniversityOct 2021
NCT03355976BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasP2active not recruiting46Brown UniversityApr 2018
NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsP1active not recruiting152National Cancer Institute (NCI)Jul 2015
NCT01688492Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate CancerP1/P2active not recruiting54Memorial Sloan Kettering Cancer CenterSep 2012
NCT04003649IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMP1active not recruiting20City of Hope Medical CenterDec 2019
NCT03816332Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersP1active not recruiting12National Cancer Institute (NCI)Nov 2019
NCT03071406Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaP2active not recruiting50H. Lee Moffitt Cancer Center and Research InstituteMar 2017
NCT02453620Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerP1active not recruiting57National Cancer Institute (NCI)Feb 2016
NCT04013854Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabP2active not recruiting67Abramson Cancer Center at Penn MedicineJan 2020
NCT03377023Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerP1/P2active not recruiting66H. Lee Moffitt Cancer Center and Research InstituteFeb 2018
NCT04079712Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsP2active not recruiting17National Cancer Institute (NCI)Aug 2020
NCT02890329Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaP1active not recruiting54National Cancer Institute (NCI)Sep 2017
NCT04938232Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLP2active not recruiting13Dana-Farber Cancer InstituteJun 2021
NCT03463408Immunotherapy + Radiation in Resectable Soft Tissue SarcomaEarly P1active not recruiting14University of RochesterJul 2018
NCT05504642CERAD-IMMUNEChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer PatientsP2withdrawn0Universitätsklinikum KölnNov 2023
NCT03844256CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyP1/P2recruiting50Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Jan 2019
NCT05933265Study of LP-184 in Patients With Advanced Solid TumorsP1/P2active not recruiting64Lantern Pharma Inc.Jun 2023
NCT02879695Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaP1active not recruiting28National Cancer Institute (NCI)Oct 2017
NCT04039607CheckMate 9DWA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaP3active not recruiting732Bristol-Myers SquibbSep 2019
NCT03502733Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaP1active not recruiting64National Cancer Institute (NCI)Aug 2018
NCT05401786RAD-IOAnti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCP2active not recruiting54The Netherlands Cancer InstituteJan 2023
NCT05262556NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasP1active not recruiting15Amr Mohamed MDDec 2022
NCT04416568Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersP2active not recruiting45Dana-Farber Cancer InstituteAug 2020
NCT03443856VESTIGEPostoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceP2active not recruiting197European Organisation for Research and Treatment of Cancer - EORTCJul 2019
NCT03719131Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyP2active not recruiting15Emory UniversityJun 2019
NCT02743819Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaP2active not recruiting70University of ChicagoJun 2016
NCT03203473Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)P2active not recruiting85Toni Choueiri, MDOct 2017
NCT06049576Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaP1active not recruiting31City of Hope Medical CenterOct 2023
NCT04008030CheckMate 8HWA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)P3active not recruiting839Bristol-Myers SquibbAug 2019
NCT04042753Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsP2completed10Memorial Sloan Kettering Cancer CenterJul 2019
NCT03166397Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsP2unknown30Sheba Medical CenterJun 2017
NCT02648997An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaP2active not recruiting40Dana-Farber Cancer InstituteMar 2016
NCT01676649Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV MelanomaP2unknown30Jewish General HospitalNov 2012
NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaP2active not recruiting66National Cancer Institute LAOOct 2023
NCT03036098CheckMate901Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerP3active not recruiting1,314Bristol-Myers SquibbMar 2017
NCT04151563CheckMate 79XA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyP1/P2withdrawn0Bristol-Myers SquibbApr 2021
NCT04090710CYTOSHRINKSBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerP2active not recruiting66Ontario Clinical Oncology Group (OCOG)Jan 2020
NCT03799445Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaP2terminated37M.D. Anderson Cancer CenterJul 2019
NCT04817254ICIAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaP2completed47National Cancer Institute (NCI)Dec 2021
NCT06388369NEPINeoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerP1/P2terminated1University Hospital, EssenAug 2025
NCT04495257RCCA Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)P1completed26Yale UniversitySep 2020
NCT07215962Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%active not recruiting300Bristol-Myers SquibbNov 2024
NCT03645928Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsP2terminated225Iovance Biotherapeutics, Inc.May 2019
NCT05926960PORTSIDEA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaP2terminated38PfizerJun 2023
NCT06163820BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesP1/P2recruiting46Melanoma and Skin Cancer Trials LimitedMay 2025
NCT07526961Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Polandcompleted240Bristol-Myers SquibbDec 2025
NCT03141177CheckMate 9ERA Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaP3active not recruiting701Bristol-Myers SquibbJul 2017
NCT05598853IT-IOIntrathecal Double Checkpoint InhibitionP1active not recruiting26University of ZurichNov 2022
NCT04074967Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabP1/P2active not recruiting70Dan ZandbergJun 2020
NCT03670056Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyP2active not recruiting25Yale UniversityDec 2018
NCT03350126NIPICOLiRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabP2active not recruiting57GERCOR - Multidisciplinary Oncology Cooperative GroupDec 2017
NCT06784648Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaP1/P2active not recruiting35BioInvent International ABDec 2024
NCT03707808myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabP1/P2recruiting18Universitair Ziekenhuis BrusselJan 2018
NCT04396860Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaP2/P3completed159National Cancer Institute (NCI)Sep 2020
NCT04717154INSPIREIpilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerP2completed69Radboud University Medical CenterJan 2021
NCT04362839Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerP1completed39City of Hope Medical CenterMay 2020
NCT03958383IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaP1/P2terminated8University of Wisconsin, MadisonJan 2020
NCT03400332A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersP1/P2completed281Bristol-Myers SquibbFeb 2018
NCT03245892A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerP1completed27Memorial Sloan Kettering Cancer CenterAug 2017
NCT03274258Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaP2terminated10M.D. Anderson Cancer CenterDec 2017
NCT05136677CheckMate 6DWA Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsP2completed102Bristol-Myers SquibbJan 2022
NCT07091695Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumabcompleted100Bristol-Myers SquibbMay 2025
NCT02668770Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesP1terminated28M.D. Anderson Cancer CenterMay 2016
NCT04006262NEONIPIGAPre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.P2active not recruiting32GERCOR - Multidisciplinary Oncology Cooperative GroupOct 2019
NCT03469960DICIPLEDouble Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErP3completed265Intergroupe Francophone de Cancerologie ThoraciqueMay 2018
NCT03520686Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerP3terminated102ImmunityBio, Inc.May 2018
NCT05284214SALIENTSargramostim With Ipilimumab Containing Therapy in Patients With Solid TumorsP2withdrawn0Partner Therapeutics, Inc.Jan 2024
NCT04315155BENEFITEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof MutationP1withdrawn0University of UtahOct 2020
NCT03647163Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsP1/P2active not recruiting33Vyriad, Inc.Apr 2019
NCT04887870Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyP2/P3completed52Mirati Therapeutics Inc.Jun 2021
NCT03070392Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaP2completed378Immunocore LtdOct 2017
NCT06410534A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerP2withdrawn0National Cancer Institute (NCI)Sep 2025
NCT05199285A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabP2terminated15Academic and Community Cancer Research UnitedJan 2023
NCT04741438RAR-ImmuneEfficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeP3unknown96Centre Leon BerardMar 2021
NCT03873818Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainP2completed24M.D. Anderson Cancer CenterFeb 2019
NCT01701674Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsN/Acompleted13H. Lee Moffitt Cancer Center and Research InstituteOct 2012
NCT03146650Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerP2unknown25Northwestern UniversityMay 2017
NCT04787991REVOLUTIONExploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaP1completed45Cancer Insight, LLCAug 2021
NCT03068624Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaP1unknown34M.D. Anderson Cancer CenterSep 2017
NCT04465643Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorP1completed13Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2021
NCT02498600Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerP2completed100National Cancer Institute (NCI)Aug 2015
NCT05407675A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsP1/P2completed68Bristol-Myers SquibbAug 2022
NCT05219435VEXILLUMStudy of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerP2completed25Spanish Oncology Genito-Urinary GroupJul 2022
NCT04107168Microbiome Immunotherapy Toxicity and Response Evaluationunknown1,800CCTU- Cancer ThemeJul 2020
NCT07024862Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapyactive not recruiting100Bristol-Myers SquibbOct 2024
NCT04334759DREAM3RDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaP3completed214PrECOG, LLC.Feb 2021
NCT04591431ROMEThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyP2unknown400Fondazione per la Medicina PersonalizzataOct 2020
NCT02977052OpACIN-neoOptimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabP2unknown186The Netherlands Cancer InstituteNov 2016
NCT02437279OpACINStudy to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsP1unknown20The Netherlands Cancer InstituteNov 2016
NCT05444530A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative NeoplasmsP1completed14Janssen Research & Development, LLCJul 2022
NCT05014776Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerP2completed17Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 2022
NCT05665348TRIPLETStudy Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyP2/P3completed229Federation Francophone de Cancerologie DigestiveMar 2023
NCT03388632Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersP1completed31National Cancer Institute (NCI)Feb 2018
NCT03297593Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaP2completed74Swiss Cancer InstituteDec 2017
NCT04988841PICASSOAssessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaP2completed70Assistance Publique - Hôpitaux de ParisJan 2022
NCT04021043BMS-986156BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersP1/P2completed51M.D. Anderson Cancer CenterAug 2019
NCT07079644Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Databasecompleted678Bristol-Myers SquibbNov 2024
NCT04250246NIBIT-ML1A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1P2unknown184Italian Network for Tumor Biotherapy FoundationMar 2020
NCT02231749Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)P3completed1,096Bristol-Myers SquibbOct 2014
NCT04850755A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid MalignanciesP1completed11National University Hospital, SingaporeMar 2021
NCT04223648MEDI4736Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaEarly P1withdrawn0Yale UniversityAug 2020
NCT04781855Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationP1withdrawn0M.D. Anderson Cancer CenterJul 2022
NCT04966676ATLASStudy of Nivolumab-Ipilimumab and cfDNA in Lung CancerP2terminated5University Health Network, TorontoJan 2022
NCT03459222An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadP1/P2completed229Bristol-Myers SquibbMay 2018
NCT01950390Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryP2completed169National Cancer Institute (NCI)Jan 2014
NCT03117309Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaP2completed164Michael B. Atkins, MDApr 2017
NCT02922764A Study of RGX-104 in Patients With Advanced Lung & Endometrial CancerP1completed146Inspirna, Inc.Nov 2016
NCT03143153CheckMate 648A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinP3completed970Bristol-Myers SquibbJun 2017
NCT04620200MATISSENeo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryP2completed50The Netherlands Cancer InstituteAug 2020
NCT03387761NABUCCONeo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyP1completed54The Netherlands Cancer InstituteJan 2018
NCT02985957CheckMate 650A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)P2completed351Bristol-Myers SquibbMar 2017
NCT05150236ANZUP2001EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCP2unknown93Australian and New Zealand Urogenital and Prostate Cancer Trials GroupApr 2022
NCT06566391Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaP2unknown35European Institute of OncologyMar 2019
NCT03879122A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerP2/P3unknown135Spanish Oncology Genito-Urinary GroupFeb 2019
NCT03472586Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverP2completed14Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityMay 2018
NCT03097939Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaP2unknown113National Cancer Centre, SingaporeMar 2017
NCT03458455TREATMENTImproved Therapy Response Assessment in Metastatic Brain Tumorsunknown200Oslo University HospitalMar 2013
NCT03172624Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerP2completed64Memorial Sloan Kettering Cancer CenterMay 2017
NCT04290546CIML NK Cell in Head & Neck CancerP1completed11Dana-Farber Cancer InstituteJul 2020
NCT03591731NIPINECNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)P2completed185Intergroupe Francophone de Cancerologie ThoraciqueJan 2019
NCT02998528CheckMate 816A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)P3completed505Bristol-Myers SquibbMar 2017
NCT04247165LAPTOPNivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.P1/P2completed55Herlev HospitalJun 2020
NCT03600155Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeP1completed29M.D. Anderson Cancer CenterOct 2018
NCT03442569PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCP2completed56UNC Lineberger Comprehensive Cancer CenterMar 2018
NCT04823403HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaP1recruiting27Gustave Roussy, Cancer Campus, Grand ParisNov 2020
NCT04133948DONIMIMulticenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaP1/P2completed44The Netherlands Cancer InstituteJan 2020
NCT04026412CheckMate73LA Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryP3completed925Bristol-Myers SquibbOct 2019
NCT05921760Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaP1/P2terminated7Servier Bio-Innovation LLCOct 2023
NCT01928394A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsP1/P2completed1,163Bristol-Myers SquibbOct 2013
NCT03158129Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerP2completed101M.D. Anderson Cancer CenterJun 2017
NCT01658878CheckMate040An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerP1/P2completed657Bristol-Myers SquibbOct 2012
NCT05909995Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsP1terminated8Incyte CorporationAug 2023
NCT03508570Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisP1completed26M.D. Anderson Cancer CenterSep 2018
NCT03369223A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsP1/P2completed356Bristol-Myers SquibbDec 2017
NCT03377361CheckMate 9N9An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadP1/P2completed325Bristol-Myers SquibbJan 2018
NCT04480502ENVASARCENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaP2unknown207Tracon Pharmaceuticals Inc.Dec 2020
NCT02477826CheckMate 227An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)P3completed2,747Bristol-Myers SquibbAug 2015
NCT02060188CheckMate142A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadP2completed385Bristol-Myers SquibbMar 2014
NCT03215706CheckMate 9LAA Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCP3completed719Bristol-Myers SquibbAug 2017
NCT02388906CheckMate 238Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaP3completed906Bristol-Myers SquibbMar 2015
NCT03404960ParpvaxNiraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyP1/P2completed104University of PennsylvaniaJan 2018
NCT05144529TOP2101A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCP2terminated19Eziafa Oduah, MD, PhD, MPHMar 2022
NCT02419495KPT-330Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesP1terminated221M.D. Anderson Cancer CenterJun 2015
NCT02408861Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryP1terminated79National Cancer Institute (NCI)Oct 2015
NCT05655715CheckPROCheckpoint Inhibitors and SBRT for MCRPCP2completed90Herlev and Gentofte HospitalNov 2019
NCT05704933Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesEarly P1completed1H. Lee Moffitt Cancer Center and Research InstituteJun 2023
NCT04326257Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyP2completed20Dan ZandbergMay 2020
NCT04256213COLIBRICOL Immunotherapy Before Radiochimio + IpilimumabN/Acompleted40ARCAGY/ GINECO GROUPJul 2020
NCT05220722Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsP1/P2terminated23TriSalus Life Sciences, Inc.Mar 2022
NCT04463368SCANDIUM IIIsolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesP1completed18Vastra Gotaland RegionMar 2021
NCT05200143Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaP2terminated4Providence Health & ServicesJun 2022
NCT03647969Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerP2completed262Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNov 2018
NCT04855929ANV419-001A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.P1completed55Anaveon AGMay 2021
NCT05169957HAMMER IHepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)P1completed2University of Michigan Rogel Cancer CenterAug 2022
NCT04935229PERIOIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaP1terminated67TriSalus Life Sciences, Inc.Aug 2021
NCT01592370An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaP1/P2completed320Bristol-Myers SquibbAug 2012
NCT05088889Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerP1unknown10Sheba Medical CenterJan 2022
NCT03575793A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerP1/P2completed39Salma SabbourSep 2018
NCT04575922Nivolumab+Ipilimumab+RT in MSS mCRCP2unknown32Massachusetts General HospitalOct 2020
NCT02017717CheckMate 143A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsP3completed529Bristol-Myers SquibbFeb 2014
NCT02833233A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerN/Acompleted5Memorial Sloan Kettering Cancer CenterJun 2016
NCT02872116CheckMate649Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerP3completed2,031Bristol-Myers SquibbOct 2016
NCT05341349Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesP1terminated1Emory UniversityOct 2022
NCT03510871HCCNivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)P2completed43National Health Research Institutes, TaiwanFeb 2019
NCT03700905IMSTAR-HNStudy of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant TherapyP3unknown276Universitätsklinikum Hamburg-EppendorfAug 2018
NCT02631447SECOMBITSequential Combo Immuno and Target Therapy (SECOMBIT) StudyP2completed251Fondazione Melanoma OnlusNov 2016
NCT06159101A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsP1unknown304Shanghai Henlius BiotechNov 2023
NCT05116202A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)P1/P2completed110Hoffmann-La RocheFeb 2022
NCT01585194Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaP2completed67M.D. Anderson Cancer CenterNov 2012
NCT02681302CPIT001Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceP1/P2terminated46Hackensack Meridian HealthJun 2016
NCT01919619Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesP2completed41M.D. Anderson Cancer CenterNov 2013
NCT03739710NSCLCPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)P2completed175GlaxoSmithKlineJan 2019
NCT03818685BreastImmune03Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseP2unknown95Centre Leon BerardJul 2019
NCT02553642CA209-260Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)P2completed81Memorial Sloan Kettering Cancer CenterSep 2015
NCT03956680An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersP1completed54Bristol-Myers SquibbMar 2019
NCT01844505Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)P3completed945Bristol-Myers SquibbJun 2013
NCT04967196Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaP1terminated6Mayo ClinicSep 2021
NCT02027935CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaP2completed16M.D. Anderson Cancer CenterJan 2015
NCT04382664UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaP2completed156Ultimovacs ASAMay 2020
NCT06345183Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patientscompleted327Bristol-Myers SquibbFeb 2024
NCT03110107First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsP1/P2terminated376Bristol-Myers SquibbMay 2017
NCT07436390MAKIFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaN/Acompleted132Institute of Oncology LjubljanaMar 2024
NCT03570619IMPACTImmunotherapy in Patients With Metastatic Cancers and CDK12 MutationsP2completed56University of Michigan Rogel Cancer CenterDec 2018
NCT03033576Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaP2completed94National Cancer Institute (NCI)Oct 2017
NCT04124601CHINORECNeoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerP2completed80Johannes Laengle, MD, PhDJun 2020
NCT05302921Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsP2completed5Children's National Research InstituteFeb 2022
NCT04611126T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerP1/P2terminated6Inge Marie SvaneApr 2021
NCT03784040da VINciNivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.P1unknown40National University Hospital, SingaporeFeb 2019
NCT04239040GVAX Plus Checkpoint Blockade in NeuroblastomaP1terminated19Dana-Farber Cancer InstituteJan 2020
NCT03752398DUET-3A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)P1completed198Xencor, Inc.May 2019
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaP2terminated12Roberto PiliJul 2018
NCT03285321NSCLCUnresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)P2completed105Greg Durm, MDSep 2017
NCT03138512CheckMate 914A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyP3completed1,641Bristol-Myers SquibbJul 2017
NCT04429321Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryP1terminated1Abramson Cancer Center at Penn MedicineAug 2020
NCT02913313A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsP1/P2completed101Bristol-Myers SquibbNov 2016
NCT03195478A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsP1/P2completed37Bristol-Myers SquibbAug 2017
NCT04513522CheckMate 7C9A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaP4completed101Bristol-Myers SquibbDec 2020
NCT04571632LuscidClinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsP2unknown36Universitair Ziekenhuis BrusselSep 2020
NCT03161756CHARLIEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaP1/P2unknown72Melanoma and Skin Cancer Trials LimitedDec 2017
NCT02278887TILStudy Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaP3completed168The Netherlands Cancer InstituteSep 2014
NCT04060407CINDICD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)P1/P2withdrawn0Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Jun 2021
NCT02846376CPIT-002Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantP1terminated8Hackensack Meridian HealthMar 2019
NCT03829111CBM588CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerP1completed30City of Hope Medical CenterMay 2019
NCT01738139Ipilimumab and Imatinib Mesylate in Advanced CancerP1completed68M.D. Anderson Cancer CenterFeb 2013
NCT04340193CheckMate 74WA Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerP3completed26Bristol-Myers SquibbSep 2020
NCT02923934A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersP2completed120Olivia Newton-John Cancer Research InstituteAug 2017
NCT03682276PRIME-HCCSafety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaP1/P2unknown32Imperial College LondonMar 2019
NCT03075423Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCP2completed316Goethe UniversityNov 2017
NCT03083691BIOLUMABIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerP2completed90Lung Cancer Group CologneApr 2017
NCT03043599Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerP1/P2completed21H. Lee Moffitt Cancer Center and Research InstituteFeb 2017
NCT06163170A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanomacompleted100Bristol-Myers SquibbAug 2023
NCT03749460Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersP1/P2completed20University of WashingtonJan 2019
NCT04892043Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsP1terminated5SQZ BiotechnologiesAug 2021
NCT03728179RACINRACIN in Patients With Advanced TIL-negative Solid TumorsP1completed40Centre Hospitalier Universitaire VaudoisJan 2019
NCT03425292A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerP1completed49Saint John's Cancer InstituteMar 2018
NCT03126331Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabP2completed26Case Comprehensive Cancer CenterAug 2017
NCT05116917INFLUENCEImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.P2terminated19Herlev HospitalNov 2021
NCT02397720Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaP2completed150M.D. Anderson Cancer CenterApr 2015
NCT03241186Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaP2active not recruiting36Robert R. McWilliams, MDSep 2017
NCT04203901Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaP2terminated16CoImmuneJul 2020
NCT04270864PRIMOIntratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersP1terminated25Gustave Roussy, Cancer Campus, Grand ParisApr 2020
NCT03190265Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerP2completed61Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 2017
NCT03293784TICIMELTNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanomaP1completed33Institut Claudius RegaudOct 2017
NCT03668119CheckMate 848A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)P2completed212Bristol-Myers SquibbOct 2018
NCT03978611A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentP1terminated11Bristol-Myers SquibbDec 2021
NCT04518046Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesP1completed22Mirati Therapeutics Inc.Aug 2020
NCT03651271Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerP2completed100Parker Institute for Cancer ImmunotherapyOct 2018
NCT03528408Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaP2unknown52Suthee RapisuwonJul 2018
NCT02913417Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesP1/P2unknown26David Minor, MDOct 2016
NCT03573947TOP1705Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCP2completed46Jeffrey ClarkeOct 2018
NCT04899921Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsP2terminated1Dana-Farber Cancer InstituteJun 2021
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedP1terminated6Jonsson Comprehensive Cancer CenterJul 2019
NCT05074992NeAT GlioA Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed GlioblastomaP2terminated1University College, LondonAug 2022
NCT02899299CheckMate743Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsP3completed605Bristol-Myers SquibbNov 2016
NCT03001882CheckMate 592An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)P2completed230Bristol-Myers SquibbMar 2017
NCT05041062A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaP2completed2University of ChicagoDec 2021
NCT02500797Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryP2completed164National Cancer Institute (NCI)Aug 2015
NCT02304458Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasP1/P2completed140National Cancer Institute (NCI)Mar 2015
NCT04610658Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCP1terminated9H. Lee Moffitt Cancer Center and Research InstituteNov 2020
NCT04721301Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialP1completed50University Hospital HeidelbergJan 2017
NCT03953235A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensP1/P2completed39Gritstone bio, Inc.Jul 2019
NCT03219775TITAN-TCCTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaP2unknown169AIO-Studien-gGmbHJul 2017
NCT04084951Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsP1completed30SQZ BiotechnologiesJan 2020
NCT04635735Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaP1/P2terminated3Memorial Sloan Kettering Cancer CenterJan 2020
NCT02519322Neoadjuvant and Adjuvant Checkpoint BlockadeP2completed53M.D. Anderson Cancer CenterFeb 2016
NCT03922880Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaP1completed9Memorial Sloan Kettering Cancer CenterApr 2019
NCT04311710CheckMate 76UA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesP1terminated21Bristol-Myers SquibbJun 2020
NCT02403778Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaP2completed10University of Colorado, DenverDec 2015
NCT01176474Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaP1completed73H. Lee Moffitt Cancer Center and Research InstituteAug 2010
NCT04319224JTX-2011Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsP1/P2terminated4Jounce Therapeutics, Inc.Mar 2020
NCT04131621CheCUPNivolumab/Ipilimumab in Second Line CUP-syndromeP2unknown194University Hospital HeidelbergDec 2019
NCT03126461SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsP2withdrawn0University of Texas Southwestern Medical CenterMar 2018
NCT03177239UNISoNPhase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)P2unknown85Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOct 2017
NCT03453892ST-ICIInvestigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibitioncompleted150University of Erlangen-Nürnberg Medical SchoolApr 2017
NCT05005273A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerP2completed1Bristol-Myers SquibbOct 2022
NCT02311920Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaP1completed32National Cancer Institute (NCI)Apr 2015
NCT03468985Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerP2completed3National Cancer Institute (NCI)May 2018
NCT03850691Radiation and Combination Immunotherapy for MelanomaP2completed4Masonic Cancer Center, University of MinnesotaMay 2019
NCT03798639Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerP1completed7Claire VerschraegenJan 2019
NCT02866383CheckPACImmune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsP2completed160Herlev HospitalNov 2016
NCT02829931Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasP1completed33H. Lee Moffitt Cancer Center and Research InstituteAug 2016
NCT03162731Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerEarly P1completed24Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityMay 2017
NCT03639714A Study of a Personalized Neoantigen Cancer VaccineP1/P2completed29Gritstone bio, Inc.Feb 2019
NCT02917772TITAN-RCCTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaP2completed200AIO-Studien-gGmbHOct 2016
NCT02488759CheckMate358An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsP1/P2completed578Bristol-Myers SquibbOct 2015
NCT02864251CheckMate722A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyP3completed367Bristol-Myers SquibbMar 2017
NCT03437200CRUCIALCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerP2terminated8European Organisation for Research and Treatment of Cancer - EORTCJan 2019
NCT02741570CheckMate 651Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP3completed947Bristol-Myers SquibbOct 2016
NCT04655157QUAD01Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaP1/P2terminated2Jason J. Luke, MDMay 2021
NCT03222076Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerP2completed30M.D. Anderson Cancer CenterSep 2017
NCT04894994FLX475 in Combination With Ipilimumab in Advanced MelanomaP2terminated6RAPT Therapeutics, Inc.Sep 2021
NCT03302234NSCLCStudy of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)P3completed568Merck Sharp & Dohme LLCDec 2017
NCT05456165Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerP2withdrawn0Gritstone bio, Inc.May 2022
NCT03219671CKSNivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)P2unknown20Alona ZerApr 2018
NCT02948348Study to Nivolumab Following Preoperative ChemoradiotherapyP1/P2unknown90Takayuki YoshinoOct 2016
NCT04132817A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadP1completed12Bristol-Myers SquibbSep 2020
NCT02880020Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryP2completed36Jonsson Comprehensive Cancer CenterDec 2016
NCT02978443A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabP2terminated14Georgetown UniversityJul 2017
NCT03351361eNERGYNivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsP3completed217Rennes University HospitalFeb 2018
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerP1completed19Washington University School of MedicineSep 2018
NCT03396952Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaP2completed27University of California, San FranciscoApr 2018
NCT04500548Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyP1withdrawn0National Cancer Institute (NCI)May 2021
NCT03620123OPTIMA Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckP2completed54AIO-Studien-gGmbHJul 2018
NCT02977156ISI-JXImmunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.P1completed22Centre Leon BerardJan 2017
NCT03507699Combined Immunotherapy and Radiosurgery for Metastatic Colorectal CancerP1completed19Sheba Medical CenterDec 2018
NCT02857569NIVIPITA Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaP1/P2completed90Gustave Roussy, Cancer Campus, Grand ParisDec 2016
NCT03406715SCLCCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)P2terminated14H. Lee Moffitt Cancer Center and Research InstituteMar 2018
NCT02869789An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersP4completed1,041Bristol-Myers SquibbOct 2016
NCT03409198ICONPhase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast CancerP2completed82Oslo University HospitalJan 2018
NCT02935634FRACTION-GCA Study to Test Combination Treatments in Participants With Advanced Gastric CancerP2completed190Bristol-Myers SquibbNov 2016
NCT04868760A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male VolunteersP1completed148Innovent Biologics (Suzhou) Co. Ltd.May 2021
NCT02970981Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaP2completed18NYU Langone HealthNov 2016
NCT03865082ILLUMINATE-206Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)P2active not recruiting30Idera Pharmaceuticals, Inc.Oct 2019
NCT02983045PIVOT-02A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsP1/P2completed557Nektar TherapeuticsDec 2016
NCT04118166Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaP2completed30Kristen GanjooOct 2019
NCT02823574CheckMate 714Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP2completed425Bristol-Myers SquibbNov 2016
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancercompleted1,864SWOG Cancer Research NetworkJul 2014
NCT03949153CRIRINCryotherapy With in Situ Immunotherapy in Melanoma MetastasisP1/P2completed19University Hospital, Strasbourg, FranceAug 2019
NCT03367715Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaP2completed10NYU Langone HealthFeb 2018
NCT03989362EMERGEVopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerP2completed61Jounce Therapeutics, Inc.Jun 2019
NCT03168464Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)P1/P2terminated15Weill Medical College of Cornell UniversityOct 2017
NCT02659059CheckMate 568Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerP2completed324Bristol-Myers SquibbFeb 2016
NCT03409848INTEGAIpilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaP2completed97AIO-Studien-gGmbHMar 2018
NCT01940809Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryP1terminated15National Cancer Institute (NCI)Aug 2013
NCT03313323ZirconipiUptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic MelanomaP2unknown29Amsterdam UMC, location VUmcFeb 2017
NCT03444753An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedP1terminated82Bristol-Myers SquibbApr 2018
NCT03461952NIMBLeNivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)P2terminated4Canadian Cancer Trials GroupMar 2019
NCT02046733STIMULISmall Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseP2completed222ETOP IBCSG Partners FoundationDec 2015
NCT05714371Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanomacompleted618Novartis PharmaceuticalsOct 2021
NCT03130959CheckMate 908A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesP2completed166Bristol-Myers SquibbJun 2017
NCT03262779Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.P2completed20Yale UniversityJul 2017
NCT04840615Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaP1terminated2National Cancer Institute (NCI)Jun 2021
NCT04134182Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.P2unknown8Kidney Cancer Research BureauOct 2019
NCT03251924A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsP1/P2terminated80Bristol-Myers SquibbSep 2017
NCT05611229Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burdencompleted1,975Novartis PharmaceuticalsJun 2020
NCT03711188A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaP2completed16Immodulon Therapeutics LtdOct 2018
NCT03425331Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCP2terminated5Dana-Farber Cancer InstituteApr 2018
NCT03420521Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsP2terminated9Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2018
NCT01693783Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerP2completed42National Cancer Institute (NCI)Dec 2012
NCT04258150TRIPPLE-RIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerP2terminated26Herlev HospitalApr 2020
NCT02996110FRACTION-RCCA Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaP2completed182Bristol-Myers SquibbFeb 2017
NCT03416244RAMONAA Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerP2completed66AIO-Studien-gGmbHFeb 2018
NCT04088500A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaP2terminated5Bristol-Myers SquibbSep 2020
NCT02538666CheckMate 451An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyP3completed907Bristol-Myers SquibbOct 2015
NCT03126110Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesP1/P2completed145Incyte Biosciences International SàrlApr 2017
NCT03903640Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisP2terminated2Washington University School of MedicineOct 2019
NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerP1completed10Emory UniversityDec 2017
NCT02658890An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadP1/P2completed627Bristol-Myers SquibbApr 2016
NCT03663166NSCLCRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)P1/P2terminated19H. Lee Moffitt Cancer Center and Research InstituteNov 2018
NCT02039674MK-3475A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)P1/P2completed267Merck Sharp & Dohme LLCFeb 2014
NCT02982954CHECKMATE 920A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerP4completed211Bristol-Myers SquibbJan 2017
NCT02601014STARVE-PCBiomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7P2completed32Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2016
NCT03832621MAYANIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerP2completed135Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoMar 2019
NCT06790303NSCLCPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2P2terminated8GlaxoSmithKlineMar 2021
NCT03335540ADVISEAn Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentP1completed20Bristol-Myers SquibbMay 2018
NCT02107755Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaP2completed8Ohio State University Comprehensive Cancer CenterSep 2014
NCT03246958Nivolumab Plus Ipilimumab in Thyroid CancerP2completed53Dana-Farber Cancer InstituteOct 2017
NCT01454102BMS-936558Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)P1completed472Bristol-Myers SquibbDec 2011
NCT02939300Ipilimumab and Nivolumab in Leptomeningeal MetastasesP2completed18Massachusetts General HospitalFeb 2018
NCT02626962GEM1402Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaP2completed52Grupo Español Multidisciplinar de MelanomaApr 2016
NCT03220009Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaP2withdrawn0National Cancer Institute (NCI)Nov 2017
NCT02523313Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDP2completed167Prof. Dr. med. Dirk SchadendorfSep 2015
NCT04434560Neoadjuvant Immunotherapy in Brain MetastasesP2terminated1Sarah Sammons, MDNov 2020
NCT01822509Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantP1completed71National Cancer Institute (NCI)May 2013
NCT03101566Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerP2completed75University of Michigan Rogel Cancer CenterSep 2017
NCT01472081RCCNivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)P1completed194Bristol-Myers SquibbFeb 2012
NCT03445533A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaP3terminated481Idera Pharmaceuticals, Inc.May 2018
NCT02644967A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaP2completed53Idera Pharmaceuticals, Inc.Dec 2015
NCT02714218A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaP3completed387Bristol-Myers SquibbApr 2016
NCT03305445Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLP1completed6Icahn School of Medicine at Mount SinaiMay 2018
NCT02089685MK-3475Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)P1/P2completed295Merck Sharp & Dohme LLCMar 2014
NCT01740297Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaP1/P2completed217AmgenFeb 2013
NCT03693846Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsP2terminated11Abramson Cancer Center at Penn MedicineFeb 2019
NCT03425461Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaP1terminated6Jonsson Comprehensive Cancer CenterJun 2018
NCT04149275Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaP2withdrawn0University of Alabama at BirminghamFeb 2021
NCT03823625SQUINTAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)P2unknown112Fondazione Ricerca TraslazionaleSep 2017
NCT01927419CheckMate 069Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaP2completed142Bristol-Myers SquibbAug 2013
NCT03271047MSSStudy of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationP2completed75PfizerOct 2017
NCT02960906BIONIKKA BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerP2completed200Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieMay 2017
NCT03003637IMCISIONImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaP1/P2completed33The Netherlands Cancer InstituteFeb 2017
NCT03068455CheckMate 915An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaP3completed1,844Bristol-Myers SquibbApr 2017
NCT03347123ECHO-208A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)P1/P2terminated11Incyte CorporationMar 2018
NCT02467361A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersP1completed104Sumitomo Pharma America, Inc.Aug 2015
NCT02428192Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaP2completed20National Cancer Institute (NCI)May 2015
NCT03430791Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaP2terminated5Baptist Health South FloridaDec 2018
NCT02054520Immunotherapy Study for Patients With Stage IV MelanomaP2terminated47NewLink Genetics CorporationJun 2014
NCT03728465Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaP2terminated6University Hospital TuebingenApr 2018
NCT03422094Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaP1terminated3Washington University School of MedicineOct 2018
NCT02982486A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaP2unknown60Assaf-Harofeh Medical CenterDec 2017
NCT03963518SURROGATE-ICIImmune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)completed631Institut BergoniéJan 2017
NCT03878524SMMARTSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialP1terminated2OHSU Knight Cancer InstituteApr 2020
NCT03526185A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesEarly P1terminated6Yale UniversityFeb 2018
NCT03065179RADVAXSBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer PatientsP2completed29University of Texas Southwestern Medical CenterMar 2017
NCT02275416Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaP1/P2completed12Ultimovacs ASAFeb 2015
NCT02737475An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadP1/P2completed166Bristol-Myers SquibbJun 2016
NCT03283046Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaP1withdrawn0M.D. Anderson Cancer CenterOct 2017
NCT03354962BOOSTER MELANOMAInduction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)P1/P2terminated6Institut Claudius RegaudOct 2018
NCT03013491PROCLAIM-CX-072PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasP1/P2terminated196CytomX TherapeuticsJan 2017
NCT01827111Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaP2completed21M.D. Anderson Cancer CenterApr 2013
NCT02320058CheckMate204An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfP2completed119Bristol-Myers SquibbMar 2015
NCT01804465CTLA-4Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerP2completed50University of California, San FranciscoApr 2014
NCT01783938Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)P2completed138Bristol-Myers SquibbApr 2013
NCT03597282NEO-PV-01A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaP1terminated22BioNTech US Inc.Oct 2018
NCT03203876A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsP1completed10Bristol-Myers SquibbJul 2017
NCT02675439ADU-S100Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasP1terminated47Chinook Therapeutics, Inc. (formerly Aduro)Apr 2016
NCT02097732Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic RadiosurgeryP2terminated4University of Michigan Rogel Cancer CenterApr 2014
NCT02659540Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaP1completed20Ludwig Institute for Cancer ResearchOct 2016
NCT01711515Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical CancerP1completed34National Cancer Institute (NCI)Oct 2012
NCT03296137Adoptive Cell Therapy Across Cancer DiagnosesP1/P2completed25Inge Marie SvaneOct 2017
NCT02904226ICONICJTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsP1/P2completed242Jounce Therapeutics, Inc.Aug 2016
NCT03707457Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaP1terminated3Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2019
NCT03287674TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian CancerP1/P2completed7Inge Marie SvaneOct 2017
NCT03724968Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionP2terminated2Elizabeth DavisJan 2019
NCT03993379PROCLAIMPROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsP2terminated3CytomX TherapeuticsNov 2019
NCT02506114Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerP2terminated15Lawrence FongOct 2016
NCT03767439Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeP2withdrawn0Columbia UniversityJul 2019
NCT01840579MK-3475Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)P1completed57Merck Sharp & Dohme LLCApr 2013
NCT03982121ISILIStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyP1withdrawn0Gustave Roussy, Cancer Campus, Grand ParisJun 2019
NCT02599402CheckMate 401Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaP3completed533Bristol-Myers SquibbDec 2015
NCT03297463Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaP1/P2withdrawn0Masonic Cancer Center, University of MinnesotaJan 2018
NCT02460068NIBIT-M2A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisP3unknown168Italian Network for Tumor Biotherapy FoundationDec 2012
NCT02750514FRACTION-LungAn Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerP2terminated295Bristol-Myers SquibbMay 2016
NCT02203604High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryP2terminated9CINJRegulatoryNov 2014
NCT03565406A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaP1terminated11NYU Langone HealthApr 2018
NCT03527251SEQUENCEAnti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCP1unknown10Sun Yat-sen UniversityMay 2018
NCT03048474INITIATEIpilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaP2completed36The Netherlands Cancer InstituteSep 2016
NCT04007588BMS-986205A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaP2withdrawn0Dana-Farber Cancer InstituteSep 2019
NCT01714739A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsP1/P2completed337Bristol-Myers SquibbOct 2012
NCT02174172A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsP1completed158Hoffmann-La RocheAug 2014
NCT03091491Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerP2terminated31National Cancer Centre, SingaporeApr 2017
NCT02307149MITCIIntratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)P1completed50ViralyticsMay 2015
NCT03477864Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerP1withdrawn0Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityDec 2018
NCT02113657T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerEarly P1completed30M.D. Anderson Cancer CenterAug 2014
NCT02158520Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by SurgeryP2completed24Academic and Community Cancer Research UnitedOct 2013
NCT02905266A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaP3completed106Bristol-Myers SquibbOct 2016
NCT02239900SBRTIpilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid TumorsP1completed143M.D. Anderson Cancer CenterAug 2014
NCT03048136CheckMate 955A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerP3withdrawn0Bristol-Myers SquibbMar 2018
NCT02032810HDACPhase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaP1completed17H. Lee Moffitt Cancer Center and Research InstituteJan 2014
NCT02385669Mel62; 6PACA Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaP1/P2terminated3Craig L Slingluff, JrApr 2015
NCT03241173A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesP1/P2completed52Incyte Biosciences International SàrlOct 2017
NCT03256136Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCP2completed9Massachusetts General HospitalNov 2017
NCT02423928CryoITPhase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerP1completed18Alden Cancer Therapy IIMay 2015
NCT03026166A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerP1/P2terminated42AbbVieMar 2017
NCT02073123Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaP1/P2completed131NewLink Genetics CorporationJul 2014
NCT01611558Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerP2completed40Bristol-Myers SquibbAug 2012
NCT03509584Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsP1terminated6Assistance Publique Hopitaux De MarseilleJun 2018
NCT02716272MAPS2Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsP2completed125Intergroupe Francophone de Cancerologie ThoraciqueMar 2016
NCT01970527Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV MelanomaP2terminated23University of WashingtonMar 2014
NCT03525795ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid TumorsP1completed24Constellation PharmaceuticalsDec 2017
NCT01866319MK-3475Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)P3completed834Merck Sharp & Dohme LLCAug 2013
NCT03342417Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsP2terminated5ExcellaBio LLCFeb 2018
NCT03408587CLEVERCAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)P1completed11ViralyticsJan 2018
NCT01896869FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerP2completed83Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2013
NCT03098160Immunotherapy Study of Evofosfamide in Combination With IpilimumabP1unknown69Threshold PharmaceuticalsMay 2017
NCT02545075A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineP3completed182Bristol-Myers SquibbOct 2015
NCT01024231MDX-1106Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaP1completed127Bristol-Myers SquibbDec 2009
NCT03203304SBRTStereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerP1terminated14University of ChicagoAug 2017
NCT01750983Ipilimumab and Lenalidomide in Advanced CancerP1completed101M.D. Anderson Cancer CenterMar 2013
NCT02731729Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyP2completed20Parker Institute for Cancer ImmunotherapyJun 2016
NCT02892734Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerP2terminated3Northwestern UniversitySep 2017
NCT02941744ipnivA Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesP1/P2completed56Universitair Ziekenhuis BrusselMar 2016
NCT01498978Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerP2completed10OHSU Knight Cancer InstituteFeb 2012
NCT02452281HSPPC-96Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaP1/P2withdrawn0Rabih SaidDec 2015
NCT01530984Ipilimumab and GMCSF Immunotherapy for Prostate CancerP2withdrawn0Lawrence FongJun 2015
NCT01524991First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaP2completed36Hoosier Cancer Research NetworkJan 2012
NCT03153085HF10A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaP2completed28Takara Bio Inc.May 2017
NCT02117362GR-MD-02Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic MelanomaP1completed8Providence Health & ServicesMay 2014
NCT00636168Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III MelanomaP3completed1,211Bristol-Myers SquibbJun 2008
NCT02608437NIBIT-M4A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma PatientsP1unknown19Italian Network for Tumor Biotherapy FoundationOct 2015
NCT01988077Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma PatientsP2terminated2Sheba Medical CenterOct 2013
NCT01621490PD-1PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaP1completed170Bristol-Myers SquibbSep 2012
NCT02381314MGA271Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerP1completed24MacroGenicsMar 2015
NCT02516527A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsP1completed25Bristol-Myers SquibbOct 2015
NCT02272855A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaP2completed46Takara Bio Inc.Apr 2014
NCT01986426LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabP1completed80Lytix Biopharma ASNov 2013
NCT02115139GRAY-BGEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain MetastasesP2completed58Grupo Español Multidisciplinar de MelanomaApr 2014
NCT02259231RTA 408 Capsules in Patients With Melanoma - REVEALP1/P2completed41BiogenOct 2014
NCT01935921Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerP1completed19National Cancer Institute (NCI)Apr 2013
NCT00790010Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaP1completed46Dana-Farber Cancer InstituteFeb 2009
NCT02723006Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaP1terminated22Millennium Pharmaceuticals, Inc.Jun 2016
NCT01473940Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by SurgeryP1completed21Northwestern UniversityJun 2012
NCT02279732Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinP3completed342Bristol-Myers SquibbOct 2014
NCT01820754TOP1201 IPIEvaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)P2completed24Duke UniversityMar 2013
NCT03326258Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryP1/P2withdrawn0National Cancer Institute (NCI)Apr 2018
NCT01703507Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for MelanomaP1completed17Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNov 2012
NCT03149159Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabP2withdrawn0Medical University of South CarolinaApr 2018
NCT01729806Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaP1completed32National Cancer Institute (NCI)Nov 2012
NCT01998126Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerP1completed14University of UtahDec 2013
NCT03460782An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomasno longer available0Center Trials & Treatment
NCT01565837SARTConcurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable MelanomaP2unknown50Wolfram SamlowskiAug 2012
NCT01715077Study of Ipilimumab in the Immune SystemN/Acompleted4University Health Network, TorontoOct 2012
NCT03165409Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spreadcompleted1,828Bristol-Myers SquibbFeb 2017
NCT00972933Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for MelanomaEarly P1completed59Diwakar DavarDec 2009
NCT03009058MODULATEStudy of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerP1/P2terminated2Immodulon Therapeutics LtdMay 2017
NCT01285609Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinP3completed1,289Bristol-Myers SquibbJan 2011
NCT01515189Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabP3completed831Bristol-Myers SquibbFeb 2012
NCT01323517MDX-010Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityP2completed26Memorial Sloan Kettering Cancer CenterFeb 2011
NCT01450761ED-SCLCTrial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneP3completed1,351Bristol-Myers SquibbDec 2011
NCT02935790Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabP1completed1CelgeneSep 2016
NCT01377389Ipilimumab + Androgen Depravation Therapy in Prostate CancerP2terminated30M.D. Anderson Cancer CenterJun 2011
NCT02739386Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseasescompleted370Bristol-Myers SquibbFeb 2016
NCT01608594Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for MelanomaP1completed30Diwakar DavarMay 2013
NCT02736123Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneP1/P2withdrawn0University of PittsburghOct 2016
NCT01302496TriMix-IpiAutologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV MelanomaP2completed39Bart NeynsFeb 2011
NCT02254772A Phase I/II Study of Intratumoral Injection of SD-101P1/P2completed9Robert LowskySep 2014
NCT02200562Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaP1terminated6University of UtahDec 2014
NCT01604889A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaP1/P2terminated50Incyte CorporationMar 2012
NCT02210104Adoptive Therapy Using Antigen-Specific CD4 T-CellsP1withdrawn0M.D. Anderson Cancer CenterDec 2016
NCT02279862Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy NaiveP2completed82Bristol-Myers SquibbDec 2014
NCT01449279Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation TherapyP2completed22Stanford UniversityOct 2011
NCT02009397A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma PatientsP1/P2completed27University of LouisvilleFeb 2012
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaP1/P2terminated9Celldex TherapeuticsApr 2015
NCT02406183Trial of SBRT With Concurrent Ipilimumab in Metastatic MelanomaP1completed13RadiotherapieMar 2015
NCT01216696CTLA4 NY-ESO-1Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1P2completed25National Center for Tumor Diseases, HeidelbergNov 2010
NCT01119508Ipilimumab + Temozolomide in Metastatic MelanomaP2completed64M.D. Anderson Cancer CenterMay 2010
NCT01696045Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaP2terminated14Bristol-Myers SquibbNov 2012
NCT01643278Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticP1completed29National Cancer Institute (NCI)Jul 2012
NCT01409174IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaP1terminated19M.D. Anderson Cancer CenterFeb 2013
NCT01810016NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic MelanomaP1terminated8Ludwig Institute for Cancer ResearchJan 2014
NCT01984255A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma PatientsP1terminated3University of Texas Southwestern Medical CenterApr 2014
NCT01557114Mel-Ipi-RxStudy of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant MelanomaP1terminated19Gustave Roussy, Cancer Campus, Grand ParisMar 2011
NCT02094391ILP+/-IPITrial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases MelanomaP2completed4Gustave Roussy, Cancer Campus, Grand ParisMar 2014
NCT01832870Sipuleucel-T and Ipilimumab for Advanced Prostate CancerP1completed9Prostate Oncology Specialists, Inc.Apr 2013
NCT01730157Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver MetastasesEarly P1terminated6Case Comprehensive Cancer CenterDec 2012
NCT02662725IPI+RTSIpilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain MetastasesP2completed73University Hospital, LilleSep 2012
NCT02115243Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity MelanomaP1completed4Duke UniversityMay 2014
NCT02224768YERVOY® Risk Minimization Tool Effectiveness Evaluation Surveycompleted158Bristol-Myers SquibbJul 2015
NCT01445379Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant CancerP1completed33National Cancer Institute (NCI)Oct 2007
NCT01194271Neoadjuvant Ipilimumab in Prostate CancerP2completed19M.D. Anderson Cancer CenterSep 2010
NCT02221739NSCLCStudy of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)P1/P2completed39NYU Langone HealthJul 2014
NCT01497808RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMAP1/P2completed22Abramson Cancer Center at Penn MedicineNov 2011
NCT01767454Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaP1completed38GlaxoSmithKlineFeb 2013
NCT00861614Study of Immunotherapy to Treat Advanced Prostate CancerP3completed988Bristol-Myers SquibbMay 2009
NCT01838200BCGPhase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic MelanomaP1terminated5Ludwig Institute for Cancer ResearchMar 2014
NCT01856023PROCLIVITY02HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaP4terminated29Clinigen, Inc.May 2013
NCT01590082Doxycycline, Temozolomide and Ipilimumab in MelanomaP1/P2terminated12M.D. Anderson Cancer CenterNov 2012
NCT01057810Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerP3completed837Bristol-Myers SquibbJul 2010
NCT01769222Ipilimumab and Local Radiation for Selected Solid TumorsP1terminated3Stanford UniversityFeb 2013
NCT01480323A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2P2completed15University Hospital TuebingenFeb 2012
NCT01331525ICEThe Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung CancerP2completed42University Hospital Southampton NHS Foundation TrustJun 2011
NCT01363206GIPIGranulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in MelanomaP2completed29Lynn E. Spitler, MDMay 2011
NCT01673854Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaP2completed70Bristol-Myers SquibbSep 2012
NCT01750580Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorP1completed22Bristol-Myers SquibbDec 2012
NCT01585987An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line ChemotherapyP2completed143Bristol-Myers SquibbJul 2012
NCT01689974Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic MelanomaP2terminated10NYU Langone HealthJan 2013
NCT02050594Ipilimumab 12-month Intensive Pharmacovigilance Protocolcompleted6Bristol-Myers SquibbFeb 2014
NCT01990859Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsP2completed20Bristol-Myers SquibbDec 2013
NCT01502592Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast CancerP1completed19Memorial Sloan Kettering Cancer CenterDec 2011
NCT02009384Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin DiftitoxP2terminated2University of LouisvilleJan 2012
NCT01654692NIBIT-M1A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic MelanomaP2completed86Italian Network for Tumor BiotherapyJun 2010
NCT01689870Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic MelanomaP1/P2withdrawn0Ludwig Institute for Cancer ResearchMar 2014
NCT01672450A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV MelanomaP1completed12University of UtahSep 2012
NCT01709162Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaP2terminated31Bristol-Myers SquibbMar 2013
NCT02186249CheckMate218Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanomano longer available0Bristol-Myers Squibb
NCT01489059Safety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaP1completed42Bristol-Myers SquibbDec 2011
NCT01681212Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaP2completed21Bristol-Myers SquibbOct 2012
NCT00162123A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesP2completed248Bristol-Myers SquibbMay 2006
NCT01913691Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaP2withdrawn0National Cancer Institute (NCI)Jul 2013
NCT01400451BRAFPh I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)P1terminated18Bristol-Myers SquibbNov 2011
NCT00871481Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic MelanomaP1/P2completed10Fred Hutchinson Cancer CenterFeb 2009
NCT00324155Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaP3completed681Bristol-Myers SquibbAug 2006
NCT01950195SRS (Stereotactic Radiosurgery) Plus IpilimumabP1terminated4Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2013
NCT01355120DeCOGTHE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseP2completed171Prof. Dr. med. Dirk SchadendorfOct 2011
NCT01165216Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerP1completed15Bristol-Myers SquibbSep 2010
NCT00170157Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerP2completed112Mayo ClinicJun 2004
NCT01743157BBIBiochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic MelanomaP1/P2completed24California Pacific Medical Center Research InstituteDec 2010
NCT01471197Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerP2terminated9Bristol-Myers SquibbJul 2012
NCT00803374Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaP1withdrawn0Bristol-Myers SquibbNov 2010
NCT01757639Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaP1completed42National Cancer Institute (NCI)Dec 2012
NCT01245556Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaP1completed8Bristol-Myers SquibbJan 2011
NCT00920907Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced MelanomaP1completed99Bristol-Myers SquibbAug 2009
NCT00796991Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineP1completed72Bristol-Myers SquibbFeb 2009
NCT00623766Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesP2completed99Bristol-Myers SquibbJul 2008
NCT00064129Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerP1completed42National Cancer Institute (NCI)May 2003
NCT00836407Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic CancerP1completed30Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFeb 2009
NCT00527735NSCLCPhase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)P2completed334Bristol-Myers SquibbFeb 2008
NCT01510288Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate CancerP1terminated28Amsterdam UMC, location VUmcNov 2004
NCT01409187IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic MelanomaP1/P2withdrawn0M.D. Anderson Cancer CenterOct 2011
NCT00732186Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaP1withdrawn0Bristol-Myers SquibbAug 2009
NCT00047164Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine TherapyP1completed89National Institutes of Health Clinical Center (CC)Sep 2002
NCT00362713Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionP1completed12Bristol-Myers SquibbMar 2007
NCT00089076MDX-010 in Treating Patients With Recurrent or Refractory LymphomaP1/P2terminated18National Cancer Institute (NCI)Jun 2004
NCT00084656Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaP2completed77Bristol-Myers SquibbMay 2004
NCT00112580MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryP2completed27Bristol-Myers SquibbJul 2005
NCT00077532Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaP2completed179National Institutes of Health Clinical Center (CC)Mar 2004
NCT00057889Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell CancerP2completed0National Institutes of Health Clinical Center (CC)Feb 2003
NCT00039091Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerP1terminated26National Cancer Institute (NCI)Mar 2002
NCT00261365MDX-010Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)P1/P2completed80Bristol-Myers SquibbNov 2005
NCT00289640MDX-010Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaP2completed210Bristol-Myers SquibbApr 2006
NCT00289627A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaP2completed155Bristol-Myers SquibbApr 2006
NCT00135408BMS-734016A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideP2completed115Bristol-Myers SquibbDec 2005
NCT00495066Compassionate Use Trial for Unresectable Melanoma With Ipilimumabno longer available0Bristol-Myers Squibb
NCT00140855A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial SarcomaP2terminated6Ludwig Institute for Cancer ResearchJun 2005
NCT00058279Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaP1/P2completed0National Cancer Institute (NCI)Feb 2003
NCT00032045Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaP2completed0National Cancer Institute (NCI)Jan 2002
NCT00357461Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaP2withdrawn0Bristol-Myers SquibbMay 2006
NCT00025181Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During SurgeryP1completed19University of Southern CaliforniaOct 2001
NCT00060372Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerP1completed21National Cancer Institute (NCI)Apr 2003

Ipilimumab clinical trials: frequently asked questions

How many Ipilimumab clinical trials are there?
791 Ipilimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 108 are actively recruiting participants. 340 are marked completed.
Are Ipilimumab clinical trials recruiting in 2026?
Yes — 108 Ipilimumab trials are actively recruiting in 2026, with 1761 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ipilimumab being studied for?
Ipilimumab is being studied for Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Unresectable Melanoma, Non Small Cell Lung Cancer and 1352 more. The trials are grouped by indication on this page.
What phase is Ipilimumab in?
Ipilimumab clinical trials span 7 Phase 4, 64 Phase 3, 344 Phase 2, 198 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ipilimumab clinical trials?
The lead sponsor across the most Ipilimumab trials is Bristol-Myers Squibb, with 280 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ipilimumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: